Tumor markers in ovarian cancer

ABSTRACT

The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

[0001] This invention was made with intramural support from the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

[0002] This invention relates generally to the identification of ovarian tumor markers and diagnostic, prognostic, and therapeutic methods for their use, as well as kits for use in the aforementioned methods.

BACKGROUND OF THE INVENTION

[0003] Ovarian cancer is one of the most common forms of neoplasia in women. Early diagnosis and treatment of any cancer ordinarily improves the likelihood of survival. However, ovarian cancer is difficult to detect in its early stages, and remains the leading cause of death among women with cancer of the female reproductive tract.

[0004] The low survival rate of ovarian cancer patients is in part due to the lack of good diagnostic markers for the detection of early stage neoplasms, and in part due to a deficit in the general understanding of ovarian cancer biology, which would facilitate the development of effective anti-tumor therapies. The present invention overcomes these shortcomings by providing much-needed improvements for the diagnosis, treatment, and prevention ovarian tumors, based on the identification of a series of ovarian tumor marker genes that are highly expressed in ovarian epithelial tumor cells and are minimally expressed in normal ovarian epithelial cells. Over 75% of all ovarian tumors, and about 95% of all malignant ovarian tumors, arise from the ovarian surface epithelium (OSE). Because the tumor marker genes are broadly expressed in various types of ovarian epithelial tumors, the present invention should greatly improve the diagnosis and treatment of most ovarian cancers.

SUMMARY OF THE INVENTION

[0005] In a first aspect, the invention features a method of detecting an ovarian tumor in a subject. The method includes the step of measuring the expression level of an ovarian tumor marker gene in the subject, wherein an increase in the expression level of the ovarian tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in a reference subject not having an ovarian tumor, detects an ovarian tumor in the subject.

[0006] In a second aspect, the invention features a method of identifying a subject at increased risk for developing ovarian cancer. The method includes the step of measuring the expression level of an ovarian tumor marker gene in the subject, wherein an increase in the expression level of the ovarian tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in a reference subject not at increased risk for developing ovarian cancer, identifies an individual at increased risk for developing ovarian cancer.

[0007] In a preferred embodiment of the second aspect of the invention, the expression level of the ovarian tumor marker gene in the subject is compared to the expression level of the tumor marker gene in a reference subject that is identified as having an increased risk for developing ovarian cancer.

[0008] In a third aspect, the invention features a method of determining the effectiveness of an ovarian cancer treatment in a subject. The method includes the step of measuring the expression level of an ovarian tumor marker gene in the subject after treatment of the subject, wherein a modulation in the expression level of the ovarian tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in the subject prior to treatment, indicates an effective ovarian cancer treatment in the subject.

[0009] In a preferred embodiment of the first three aspects of the invention, the expression level of the ovarian tumor marker gene is determined in the subject by measuring the expression level of the tumor marker gene in a sample from the subject. The sample may be, for example, a tissue biopsy, ovarian epithelial cell scrapings, peritoneal fluid, blood, urine, or serum. In another preferred embodiment of the first three aspects of the invention, the expression level of the tumor marker gene is measured in vivo in the subject.

[0010] In yet another preferred embodiment of the first three aspects of the invention, the expression level of more than one ovarian tumor marker gene is measured. For example, the expression level of two, three, four, five, or more tumor marker genes may be measured.

[0011] In various other embodiments of the first three aspects of the invention, the expression level of the tumor marker gene may be determined by measuring the level of ovarian tumor marker mRNA. For example, the level of ovarian tumor marker mRNA may be measured using RT-PCR, Northern hybridization, dot-blotting, or in situ hybridization. In addition, or alternatively, the expression level of the ovarian tumor marker gene may be determined by measuring the level of ovarian tumor marker polypeptide encoded by the ovarian tumor marker gene. For example, the level of ovarian tumor marker polypeptide may be measured by ELISA, immunoblotting, or immunohistochemistry. The level of ovarian tumor marker polypeptide may also be measured in vivo in the subject using an antibody that specifically binds an ovarian tumor marker polypeptide, coupled to a paramagnetic label or other label used for in vivo imaging, and visualizing the distribution of the labeled antibody within the subject using an appropriate in vivo imaging method, such as magnetic resonance imaging.

[0012] In still another embodiment of the first three aspects of the invention, the expression level of the tumor marker gene may be compared to the expression level of the tumor marker gene in a reference subject diagnosed with ovarian cancer.

[0013] In a fourth aspect, the invention features a method of identifying a tumor as an ovarian tumor. The method includes the step of measuring the expression level of an ovarian tumor marker gene in a tumor cell from the tumor, wherein an increase in the expression level of the ovarian tumor marker gene in the tumor cell, relative to the expression level of the ovarian tumor marker gene in a noncancerous ovarian cell, identifies the tumor as an ovarian tumor.

[0014] In a fifth aspect, the invention features a method of treating or preventing an ovarian tumor in a subject. The method includes the step of modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in an ovarian epithelial cell in the subject.

[0015] In a sixth aspect, the invention features a method of inhibiting the growth or metastasis of an ovarian tumor cell in a subject. The method includes the step of modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in the ovarian tumor cell in the subject.

[0016] In a seventh aspect, the invention features a method of inhibiting the growth or metastasis of an ovarian tumor in a subject. The method includes the step of contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide encoded by an ovarian tumor marker gene, wherein the binding of the antibody to the ovarian tumor marker polypeptide inhibits the growth or metastasis of the ovarian tumor in the subject.

[0017] In various preferred embodiments of the seventh aspect of the invention, the ovarian tumor marker polypeptide may be on the surface of the ovarian tumor cell, and the antibody may be coupled to a radioisotope or to a toxic compound.

[0018] In an eighth aspect, the invention features a kit including an antibody for measuring the expression level of an ovarian tumor marker gene in a subject.

[0019] In a ninth aspect, the invention features a kit including a nucleic acid for measuring the expression level of an ovarian tumor marker gene in a subject.

[0020] In a tenth aspect, the invention features a method of diagnosing ovarian cancer in a subject. The method includes the step of measuring the amount of an ovarian tumor marker polypeptide in the subject, wherein an amount of ovarian tumor marker polypeptide that is greater than the amount of ovarian tumor marker polypeptide measured in a subject not haying ovarian cancer diagnoses an ovarian cancer in the subject.

[0021] In various embodiments of the tenth aspect of the invention, the ovarian tumor marker polypeptide can be present at the surface of a cell (e.g., a cell-surface-localized polypeptide such as a cell adhesion molecule), or the ovarian tumor marker polypeptide may be in soluble form (e.g., secreted from a cell, released from a lysed cell, or otherwise detectable in a fluid-based assay).

[0022] In a preferred embodiment of all of the above aspects of the invention, the ovarian tumor may be an epithelial ovarian tumor. The epithelial ovarian tumor may be, for example, a serous cystadenoma, a borderline serous tumor, a serous cystadenocarcinoma, a mucinous cystadenoma, a borderline mucinous tumor, a mucinous cystadenocarcinoma, an endometrioid carcinoma, an undifferentiated carcinoma, a cystadenofibroma, an adenofibroma, or a Brenner tumor. The epithelial ovarian tumor may also be a clear cell adenocarcinoma.

[0023] In preferred embodiments of all of the above aspects of the invention, the ovarian tumor marker gene can be, but is not limited to, alpha prothymosin; beta polypeptide 2-like G protein subunit 1; tumor rejection antigen-1 (gp96)1; HSP90; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p⁶7. The ovarian tumor marker gene may also be HSP60 or Lutheran blood group (3-CAM). In other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene may also be HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase), glutathione perroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLI4303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apoplipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

[0024] The ovarian tumor marker gene may also be HOST-3 (Claudin-16) (e.g., Genbank Accession No. XM_(—)003150; SEQ ID NOs: 141 and 142); HOST-4 (e.g., a gene that comprises SEQ ID NO: 144); or HOST-5 (sodium dependent transporter isoform NaPi-Iib) (e.g., Genbank Accession No. AF146796; SEQ ID NOs: 146 and 147).

[0025] In other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

[0026] In still other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

[0027] In yet other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.

[0028] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The low survival rate of ovarian cancer patients is in part due to the lack of good diagnostic markers allowing early detection of the disease. Further compounding this difficulty in early diagnosis is the lack of effective treatments for ovarian cancer, development of which has been impeded by a deficit in the general understanding of ovarian cancer biology. The present invention overcomes these deficits in the art by providing ovarian tumor markers that are expressed at elevated levels in ovarian epithelial tumor cells, relative to their expression in normal ovarian epithelial cells.

[0030] To identify marker genes that are up-regulated in ovarian tumor cells, SAGE (Serial Analysis of Gene Expression; Velculescu et al., Science 270:484-487, 1995) was employed to obtain global gene expression profiles of three ovarian tumors, five ovarian tumor cell lines of various histological types, a pool of ten ovarian tumor cell lines of various histological types, and normal human ovarian surface epithelium (HOSE). The expression patterns were generated by acquiring thousands of short sequence tags that contain sufficient information to uniquely identify transcripts due to the unique position of each tag within the transcript. Comparing the SAGE-generated expression profiles between ovarian cancer and HOSE revealed an abundance of genes that are expressed at elevated levels in ovarian tumor cells, relative to their expression in normal HOSE.

[0031] Selected SAGE results were further validated through immunohistochemical analysis of archival ovarian serous carcinoma samples. Ovarian tumor marker genes implicated in immune response pathways, regulation of cell proliferation, and protein folding were identified, many of which are membrane-localized or secreted. The ovarian tumor marker genes identified from these SAGE profiles are useful both as diagnostic and prognostic markers to detect and monitor a broad variety of ovarian cancers, and as therapeutic targets for the treatment of such ovarian cancers.

[0032] Definitions

[0033] In this specification and in the claims that follow, reference is made to a number of terms that shall be defined to have the following meanings.

[0034] As used in the specification and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. For example, “a cell” can mean a single cell or more than one cell.

[0035] By “ovarian cell” is meant a cell that is of ovarian origin or that is a descendent of a cell of ovarian origin (e.g., a metastatic tumor cell in the liver that is derived from a tumor originating in the ovary), irrespective of whether the cell is physically within the ovary at the time at which it is subjected to a diagnostic test or an anti-tumor treatment. For example, the ovarian cell may be a normal ovarian cell or an ovarian tumor cell, either within the ovary or at another location within the body. The ovarian cell may also be outside the body (for example, in a tissue biopsy). A preferred ovarian cell is an ovarian cell of epithelial origin.

[0036] By “ovarian tumor marker gene” is meant a gene of the invention, for which expression is increased (as described below) in ovarian tumor cells relative to normal ovarian cells. Preferably, an ovarian tumor marker gene has been observed to display increased expression in at least two ovarian tumor SAGE libraries (relative to a HOSE library), more preferably in at least three SAGE libraries, and most preferably in at least four SAGE libraries (relative to a HOSE library). Examples of ovarian tumor marker genes are provided in Tables 2 and 4 hereinbelow.

[0037] By “ovarian tumor marker polypeptide” is meant a polypeptide that is encoded by an ovarian tumor marker gene and is produced at an increased level in an ovarian tumor cell due to the increased expression of the ovarian tumor marker gene that encodes the polypeptide.

[0038] By “sample” is meant any body fluid (e.g., but not limited to, blood, serum, urine, cerebrospinal fluid, semen, sputum, saliva, tears, joint fluids, body cavity fluids (e.g., peritoneal fluid), or washings), tissue, or organ obtained from a subject; a cell (either within a subject, taken directly from a subject, or a cell maintained in culture or from a cultured cell line); a lysate (or lysate fraction) or extract derived from a cell; or a molecule derived from a cell or cellular material.

[0039] By “modulate” is meant to alter, by increase or decrease.

[0040] By “increase in gene expression level,” “expressed at an increased level,” “increased expression,” and similar phrases is meant a rise in the relative amount of mRNA or protein, e.g., on account of an increase in transcription, translation, mRNA stability, or protein stability, such that the overall amount of a product of the gene, i.e., an mRNA or polypeptide, is augmented. Preferably the increase is by at least about 3-fold, more preferably, by at least about: 4-fold, 5-fold, 7-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 70-fold, or more. For example, as described herein, the expression level of the ovarian tumor marker genes of the invention is generally increased by at least 3-fold in ovarian tumor cells, relative to normal ovarian surface epithelial cells.

[0041] By “decrease in gene expression level” is meant a reduction in the relative amount of mRNA or protein transcription, translation, mRNA stability, or protein stability, such that the overall amount of a product of the gene, i.e., an mRNA or polypeptide, is reduced. Preferably the decrease is by at least about 20%-25%, more preferably by at least about 26%-50%, still more preferably by at least about 51%-75%, even more preferably by at least about 76%-95%, and most preferably, by about 96%-100%.

[0042] By “about” is meant +10% of a recited value.

[0043] By “modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene” is meant to increase or decrease gene expression level, as described above, or to stimulate or inhibit the ability of an ovarian tumor marker polypeptide to perform its intrinsic biological function (examples of such functions include, but are not limited to, enzymatic activity, e.g., kinase activity or GTPase activity; cell-signaling activity, e.g., activation of a growth factor receptor; or cell adhesion activity. The modulation may be an increase in the amount of the polypeptide produced or an increase in the activity of the polypeptide, of at least about: 2-fold, 4-fold, 6-fold, or 10-fold, or the modulation may be a decrease in the amount of the polypeptide produced or a decrease in the activity of the polypeptide, of at least about: 20%-25%, 26%-50%, 51%-75%, 76%-95%, or 96%-100%. These increases and/or decreases are compared with the amount of production and/or activity in a normal cell, sample, or subject.

[0044] By “effective amount” of a compound as provided herein is meant a nontoxic but sufficient amount of the compound to provide the desired effect, e.g., modulation of ovarian tumor marker gene expression or modulation of ovarian tumor marker polypeptide activity. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity and type of disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.

[0045] By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with a molecule or compound of the invention (e.g., an antibody or nucleic acid molecule) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

[0046] By “having an increased risk” is meant a subject that is identified as having a higher than normal chance of developing an ovarian tumor, compared to the general population. Such subjects include, for example, women that have a hereditary disposition to develop ovarian cancer, for example, those identified as harboring one or more genetic mutations (e.g., a mutation in the BRCA-1 gene) that are known indicators of a greater than normal chance of developing ovarian cancer, or who have a familial history of ovarian cancer. In addition, a subject who has had, or who currently has, an ovarian tumor is a subject who has an increased risk for developing an ovarian tumor, as such a subject may continue to develop new tumors. Subjects who currently have, or who have had, an ovarian tumor also have an increased risk for ovarian tumor metastases.

[0047] By “treat” is meant to administer a compound or molecule of the invention to a subject in order to: eliminate an ovarian tumor or reduce the size of an ovarian tumor or the number of ovarian tumors in a subject; arrest or slow the growth of an ovarian tumor in a subject; inhibit or slow the development of a new ovarian tumor or an ovarian tumor metastasis in a subject; or decrease the frequency or severity of symptoms and/or recurrences in a subject who currently has or who previously has had an ovarian tumor.

[0048] By “prevent” is meant to minimize the chance that a subject will develop an ovarian tumor or to delay the development of an ovarian tumor. For example, a woman at increased risk for an ovarian tumor, as described above, would be a candidate for therapy to prevent an ovarian tumor.

[0049] By “specifically binds” is meant that an antibody recognizes and physically interacts with its cognate antigen and does not significantly recognize and interact with other antigens.

[0050] By “probe,” “primer,” or “oligonucleotide” is meant a single-stranded DNA or RNA molecule of defined sequence that can base-pair to a second DNA or RNA molecule that contains a complementary sequence (the “target”). The stability of the resulting hybrid depends upon the extent of the base-pairing that occurs. The extent of base-pairing is affected by parameters such as the degree of complementarity between the probe and target molecules, and the degree of stringency of the hybridization conditions. The degree of hybridization stringency is affected by parameters such as temperature, salt concentration, and the concentration of organic molecules such as formamide, and is determined by methods known to one skilled in the art. Probes or primers specific for ovarian tumor marker nucleic acids (e.g., genes and/or mRNAs) preferably have at least 50%-55% sequence complementarity, more preferably at least 60%-75% sequence complementarity, even more preferably at least 80%-90% sequence complementarity, yet more preferably at least 91%-99% sequence complementarity, and most preferably 100% sequence complementarity to the ovarian tumor marker nucleic acid to be detected. Probes, primers, and oligonucleotides may be detectably-labeled, either radioactively, or non-radioactively, by methods well-known to those skilled in the art. Probes, primers, and oligonucleotides are used for methods involving nucleic acid hybridization, such as: nucleic acid sequencing, reverse transcription and/or nucleic acid amplification by the polymerase chain reaction, single stranded conformational polymorphism (SSCP) analysis, restriction fragment polymorphism (RFLP) analysis, Southern hybridization, Northern hybridization, in situ hybridization, electrophoretic mobility shift assay (EMSA).

[0051] By “specifically hybridizes” is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (i.e., base-pairs) with a substantially complementary nucleic acid (e.g., an ovarian tumor marker mRNA of the invention) under high stringency conditions, and does not substantially base pair with other nucleic acids.

[0052] By “high stringency conditions” is meant conditions that allow hybridization comparable with the hybridization that occurs using a DNA probe of at least 500 nucleotides in length, in a buffer containing 0.5 M NaHPO₄, pH 7.2, 7% SDS, 1 mM EDTA, and 1% BSA (fraction V), at a temperature of 65° C., or a buffer containing 48% formamide, 4.8×SSC, 0.2 M Tris-Cl, pH 7.6, 1× Denhardt's solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42° C. (these are typical conditions for high stringency Northern or Southern hybridizations). High stringency hybridization is relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and in situ hybridization. In contrast to Northern and Southern hybridizations, these techniques are usually performed with relatively short probes (e.g., usually 16 nucleotides or longer for PCR or sequencing, and 40 nucleotides or longer for in situ hybridization). The high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology, and may be found, for example, in F. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1997, herein incorporated by reference.

[0053] Examples of Ovarian Tumor Marker Genes

[0054] Examples of ovarian tumor marker genes of the invention include alpha prothymosin (e.g., Genbank Accession No. M14483; SEQ ID NOs: 1 and 2); beta polypeptide 2-like G protein subunit 1 (e.g., Genbank Accession No. M24194; SEQ ID NOs: 3 and 4); tumor rejection antigen-1 (gp96)1 (e.g., Genbank Accession No. NM_(—)003299; SEQ ID NOs: 7 and 8); HSP90 (e.g., Genbank Accession No. AA071048; SEQ ID NOs: 9 and 10); Hepatoma-Derived Growth Factor (HGDF) (e.g., Genbank Accession No. D16431; SEQ ID NOs: 13 and 14); DKFZp5860031 (e.g., Genbank Accession No. AL117237; SEQ ID NOs: 15 and 16); CD63 antigen (melanoma 1 antigen) (e.g., Genbank Accession No. AA041408; SEQ ID NOs: 17 and 18); protein kinase C substrate 80K-H (e.g., Genbank Accession No. J03075; SEQ ID NOs: 19 and 20); Polymerase II cofactor 4 (PC4) (e.g., Genbank Accession No. X79805; SEQ ID NOs: 21 and 22); mitochondrial Tu translation elongation factor (e.g., Genbank Accession No. L38995; SEQ ID NOs: 23 and 24); hNRP H1 (e.g., Genbank Accession No. L22009; SEQ ID NOs: 25 and 26); Solute carrier family 2 (e.g., Genbank Accession No. AF070544; SEQ ID NOs: 27 and 28); KIAA0591 protein (e.g., Genbank Accession No. AB011163; SEQ ID NOs: 29 and 30); X-ray repair protein (e.g., Genbank Accession No. AF035587; SEQ ID NOs: 31 and 32); DKFZP564M2423 protein (e.g., Genbank Accession No. BC003049; SEQ ID NOs: 35 and 139); growth factor-regulated tyrosine kinase substrate (e.g., Genbank Accession No. D84064; SEQ ID NOs: 36 and 37); and/or eIF-2-associated p67 (e.g., Genbank Accession No. U29607; SEQ ID NOs: 38 and 39). The ovarian tumor marker gene may also be HSP60 (e.g., Genbank Accession No. M22382; SEQ ID NOs: 11 and 12) and Lutheran blood group protein (B-CAM) (e.g., Genbank Accession No. NM_(—)005581; SEQ ID NOs: 5 and 6).

[0055] Other examples of ovarian tumor marker genes of the invention include HLA-DR alpha chain (e.g., Genbank Accession No. K01171; SEQ ID NOs: 40 and 41); cysteine-rich protein 1 (e.g., Genbank Accession No. NM_(—)001311; SEQ ID NOs: 42 and 43); claudin 4 (e.g., Genbank Accession No. NM_(—)001305; SEQ ID NOs: 44 and 45); HOST-2 (e.g., SEQ ID NO: 46); claudin 3 (e.g., Genbank Accession No. NM_(—)001306; SEQ ID NOs: 47 and 48); ceruloplasmin (ferroxidase) (e.g., Genbank Accession No. M13699; SEQ ID NOs: 49 and 50); glutathione perroxidase 3 (e.g., Genbank Accession No. D00632; SEQ ID NOs: 51 and 52); secretory leukocyte protease inhibitor (e.g., Genbank Accession No. AF114471; SEQ ID NOs: 53 and 54); HOST-1 (FLJ14303 fis) (e.g., Genbank Accession No. AK024365; SEQ ID NOs: 55 and 56); interferon-induced transmembrane protein 1 (e.g., Genbank Accession No. J04164; SEQ ID NOs: 57 and 58); apolipoprotein J/clusterin (e.g., Genbank Accession No. J02908; SEQ ID NOs: 59 and 60); serine protease inhibitor, Kunitz type 2 (e.g., Genbank Accession No. AF027205; SEQ ID NOs: 61 and 62); apoplipoprotein E (e.g., Genbank Accession No. BC003557; SEQ ID NOs: 63 and 64); complement component 1, r subcomponent (e.g., Genbank Accession No. M14058; SEQ ID NOs: 65 and 66); G1P3/IFI-6-16 (e.g., Genbank Accession No. X02492; SEQ ID NOs: 67 and 68); Lutheran blood group (BCAM) (e.g., Genbank Accession No. X83425; SEQ ID NOs: 69 and 70); collagen type III, alpha-1 (e.g., Genbank Accession No. X14420; SEQ ID NOs: 71 and 72); Mal (T cell differentiation protein) (e.g., Genbank Accession No. M15800; SEQ ID NOs: 73 and 74); collagen type I, alpha-2 (e.g., Genbank Accession No. J03464; SEQ ID NOs: 75 and 76); HLA-DPB1 (e.g., Genbank Accession No. J03041; SEQ ID NOs: 77 and 78); bone marrow stroma antigen 2 (13ST-2) (e.g., Genbank Accession No. D28137; SEQ ID NOs: 79 and 80); and HLA-Cw (e.g., Genbank Accession No. X17093; SEQ ID NOs: 81 and 82).

[0056] Still other examples of ovarian tumor marker genes of the invention include HOST-3 (Claudin-16) (e.g., Genbank Accession No. XM_(—)003150; SEQ ID NOs: 141 and 142); HOST-4 (e.g., a gene that comprises SEQ ID NO: 144); or HOST-5 (sodium dependent transporter isoform NaPi-Iib) (e.g., Genbank Accession No. AF146796; SEQ ID NOs: 146 and 147).

[0057] Ovarian tumor marker genes of the invention may also be described by SAGE tags, as disclosed herein. For example, an ovarian tumor marker genes of the invention can include a nucleotide sequence set forth in one of SEQ ID NOs: 84-102; 103-129; or 141, 143, or 145.

[0058] Diagnostic Uses of Ovarian Tumor Marker Genes and Polypeptides

[0059] The ovarian tumor marker genes of the invention are overexpressed in a broad variety of ovarian epithelial tumor cells, relative to normal ovarian epithelial cells. This differential expression can be exploited in diagnostic tests for ovarian cancer, in prognostic tests for assessing the relative severity of ovarian cancer, in tests for monitoring a subject in remission from ovarian cancer, and in tests for monitoring disease status in a subject being treated for ovarian cancer. Increased expression of an ovarian tumor marker gene, i.e., detection of elevated levels of ovarian tumor marker mRNA and/or protein in a subject or in a sample from a subject (i.e., levels at least three-fold higher than in a normal subject or in an equivalent sample, e.g., blood, cells, or tissue from a normal subject) is diagnostic of ovarian cancer.

[0060] One of ordinary skill in the art will understand that in some instances, higher expression of a given ovarian tumor marker gene will indicate a worse prognosis for a subject having ovarian cancer. For example, relatively higher levels of ovarian tumor marker gene expression may indicate a relative large primary tumor, a higher tumor burden (e.g., more metastases), or a relatively more malignant tumor phenotype.

[0061] The diagnostic and prognostic methods of the invention involve using known methods, e.g., antibody-based methods to detect ovarian tumor marker polypeptides and nucleic acid hybridization- and/or amplification-based methods to detect ovarian tumor marker mRNA. One of ordinary skill in the art will understand how to choose the most appropriate method for measuring ovarian tumor marker expression, based upon the combination of the particular ovarian tumor marker to be measured, the information desired, and the particular type of diagnostic test to be used. For example, immunological tests such as enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and Western blots may be used to measure the level of an ovarian tumor marker polypeptide in a body fluid sample (such as blood, serum, sputum, urine, or peritoneal fluid). Biopsies, tissue samples, and cell samples (such as ovaries, lymph nodes, ovarian surface epithelial cell scrapings, lung biopsies, liver biopsies, and any fluid sample containing cells (such as peritoneal fluid, sputum, and pleural effusions) may be tested by disaggregating and/or solubilizing the tissue or cell sample and subjecting it to an immunoassay for polypeptide detection, such as ELISA, RIA, or Western blotting. Such cell or tissue samples may also be analyzed by nucleic acid-based methods, e.g., reverse transcription-polymerase chain reaction (RT-PCR) amplification, Northern hybridization, or slot- or dot-blotting. To visualize the three-dimensional distribution of tumor cells within a tissue sample, diagnostic tests that preserve the tissue structure of a sample, e.g., immunohistological staining, in situ RNA hybridization, or in situ RT-PCR may be employed to detect ovarian tumor marker polypeptide or mRNA, respectively. For in vivo localization of tumor masses, imaging tests such as magnetic resonance imaging (MRI) may be employed by introducing into the subject an antibody that specifically binds an ovarian tumor marker polypeptide (particularly a cell surface-localized polypeptide), wherein the antibody is conjugated or otherwise coupled to a paramagnetic tracer (or other appropriate detectable moiety, depending upon the imaging method used); alternatively, localization of an unlabeled tumor marker-specific antibody may be detected using a secondary antibody coupled to a detectable moiety.

[0062] The skilled artisan will understand that selection of a particular ovarian tumor marker polypeptide as the target for detection in any diagnostic test and selection of the particular test to be employed will depend upon the type of sample to be tested. For example, measurement of ovarian tumor marker polypeptides that are secreted from a cell (e.g., HDGF) may be preferred for serological tests. Moreover, ovarian tumor marker polypeptides that are not normally actively secreted from cells (e.g., intracellular or membrane-associated polypeptides), but that are found in blood and other fluid samples (e.g., peritoneal fluid or washings) at detectable levels in subjects having tumors (e.g., due to tumor cell lysis) are considered to be soluble ovarian tumor marker polypeptides that may be used in serological and other diagnostic assays of body fluids.

[0063] A fluid sample (such as blood, peritoneal fluid, sputum, or pleural effusions) from a subject with ovarian cancer, particularly metastatic cancer, may contain one or more ovarian tumor cells or ovarian tumor cell fragments. The presence of such cells or fragments allows detection of a tumor mRNA using an RT-PCR assay, e.g., but not limited to, real-time quantitative RT-PCR using the Taqman method (Heid and Stevens, Genome Res. 6:986-94, 1996).

[0064] In addition, since rapid tumor cell destruction often results in autoantibody generation, the ovarian tumor markers of the invention may be used in serological assays (e.g., an ELISA test of a subject's serum) to detect autoantibodies against ovarian tumor markers in a subject. Ovarian tumor marker polypeptide-specific autoantibody levels that are at least about 3-fold higher (and preferably at least 5-fold or 7-fold higher, most preferably at least 10-fold or 20-fold higher) than in a control sample are indicative of ovarian cancer.

[0065] Cell-surface localized, intracellular, and secreted ovarian tumor marker polypeptides may all be employed for analysis of biopsies, e.g., tissue or cell samples (including cells obtained from liquid samples such as peritoneal cavity fluid) to identify a tissue or cell biopsy as containing ovarian tumor cells. A biopsy may be analyzed as an intact tissue or as a whole-cell sample, or the tissue or cell sample may be disaggregated and/or solubilized as necessary for the particular type of diagnostic test to be used. For example, biopsies or samples may be subjected to whole-tissue or whole-cell analysis of ovarian tumor marker polypeptide or mRNA levels in situ, e.g., using immunohistochemistry, in situ mRNA hybridization, or in situ RT-PCR. The skilled artisan will know how to process tissues or cells for analysis of polypeptide or mRNA levels using immunological methods such as ELISA, immunoblotting, or equivalent methods, or analysis of mRNA levels by nucleic acid-based analytical methods such as RT-PCR, Northern hybridization, or slot- or dot-blotting.

[0066] All of the above methods are well-known in the art. For example, generation of antibodies against a given protein, ELISA, immunoblotting, selection of nucleic acid primers for PCR, RT-PCR, Northern hybridization, in situ hybridization, in situ RT-PCR, and slot- or dot-blotting are all well-described in Current Protocols in Molecular Biology (Ausubel et al., eds.), John Wiley and Sons, Inc., 1996.

[0067] Kits for Measuring Expression Levels of Ovarian Tumor Marker Genes

[0068] The present invention provides kits for detecting an increased expression level of an ovarian tumor marker gene in a subject. A kit for detecting ovarian tumor marker polypeptide will contain an antibody that specifically binds a chosen ovarian tumor marker polypeptide. A kit for detecting ovarian tumor marker mRNA will contain one or more nucleic acids (e.g., one or more oligonucleotide primers or probes, DNA probes, RNA probes, or templates for generating RNA probes) that specifically hybridize with a chosen ovarian tumor marker mRNA.

[0069] Particularly, the antibody-based kit can be used to detect the presence of, and/or measure the level of, an ovarian tumor marker polypeptide that is specifically bound by the antibody or an immunoreactive fragment thereof. The kit can include an antibody reactive with the antigen and a reagent for detecting a reaction of the antibody with the antigen. Such a kit can be an ELISA kit and can contain a control (e.g., a specified amount of a particular ovarian tumor marker polypeptide), primary and secondary antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates and color reagents as described above. The diagnostic kit can, alternatively, be an immunoblot kit generally comprising the components and reagents described herein.

[0070] A nucleic acid-based kit can be used to detect and/or measure the expression level of an ovarian tumor marker gene by detecting and/or measuring the amount of ovarian tumor marker mRNA in a sample, such as a tissue or cell biopsy (e.g., an ovary, ovarian cell scrapings, a bone marrow biopsy, a lung biopsy or lung aspiration, etc.). For example, an RT-PCR kit for detection of elevated expression of an ovarian tumor marker gene will contain oligonucleotide primers sufficient to perform reverse transcription of ovarian tumor marker mRNA to cDNA and PCR amplification of ovarian tumor marker cDNA, and will preferably also contain control PCR template molecules and primers to perform appropriate negative and positive controls, and internal controls for quantitation. One of ordinary skill in the art will understand how to select the appropriate primers to perform the reverse transcription and PCR reactions, and the appropriate control reactions to be performed Such guidance is found, for example, in F. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1997. Numerous variations of RT-PCR are known in the art. One example of a quantitative RT-PCR assay is the real-time quantitative RT-PCR assay described by Heid and Stevens (Genome Res. 6:986-94, 1996), in which the primers are labeled by a fluorescent tag, and the amount of amplification product may be measured in a Taqman apparatus (Perkin-Elmer; Norwal, Conn.).

[0071] Targeted Delivery of Immunotoxins to Ovarian Tumor Cells

[0072] The tumor marker genes of the invention can be employed as therapeutic targets for the treatment or prevention of ovarian cancer. For example, an antibody molecule that specifically binds a cell surface-localized ovarian tumor marker polypeptide can be conjugated to a radioisotope or other toxic compound. Antibody conjugates are administered to the subject such that the binding of the antibody to its cognate ovarian tumor marker polypeptide results in the targeted delivery of the therapeutic compound to ovarian tumor cells, thereby treating an ovarian cancer.

[0073] The therapeutic moiety can be a toxin, radioisotope, drug, chemical, or a protein (see, e.g., Bera et al. “Pharmacokinetics and antitumor activity of a bivalent disultide-stabilized Fv immunotoxin with improved antigen binding to erbB2” Cancer Res. 59:4018-4022 (1999)). For example, the antibody can be linked or conjugated to a bacterial toxin (e.g., diptheria toxin, pseudomonas exotoxin A, cholera toxin) or plant toxin (e.g., ricin toxin) for targeted delivery of the toxin to a cell expressing the ovarian tumor marker. This immunotoxin can be delivered to a cell and upon binding the cell surface-localized ovarian tumor marker polypeptide, the toxin conjugated to the ovarian tumor marker-specific antibody will be delivered to the cell.

[0074] In addition, for any ovarian tumor polypeptide for which there is a specific ligand (e.g., a ligand that binds a cell surface-localized protein), the ligand can be used in place of an antibody to target a toxic compound to an ovarian tumor cell, as described above.

[0075] Antibodies That Specifically Bind Ovarian Tumor Marker Polypeptides

[0076] The term “antibodies” is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term “antibodies” are fragments or polymers of those immunoglobulin molecules and humanized versions of immunoglobulin molecules, so long as they exhibit any of the desired properties (e.g., specific binding of an ovarian tumor marker polypeptide, delivery of a toxin to an ovarian tumor cell expressing an ovarian tumor marker gene at an increased level, and/or inhibiting the activity of an ovarian tumor marker polypeptide) described herein.

[0077] Whenever possible, the antibodies of the invention may be purchased from commercial sources. The antibodies of the invention may also be generated using well-known methods. The skilled artisan will understand that either full length ovarian tumor marker polypeptides or fragments thereof may be used to generate the antibodies of the invention. A polypeptide to be used for generating an antibody of the invention may be partially or fully purified from a natural source, or may be produced using recombinant DNA techniques. For example, a cDNA encoding an ovarian tumor marker polypeptide, or a fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect, or mammalian cells), after which the recombinant protein can be purified and used to generate a monoclonal or polyclonal antibody preparation that specifically bind the ovarian tumor marker polypeptide used to generate the antibody.

[0078] In addition, one of skill in the art will know how to choose an antigenic peptide for the generation of monoclonal or polyclonal antibodies that specifically bind ovarian tumor antigen polypeptides. Antigenic peptides for use in generating the antibodies of the invention are chosen from non-helical regions of the protein that are hydrophilic. The PredictProtein Server (http://www.embl-heidelberg.de/predictprotein/subunit_def.html) or an analogous program may be used to select antigenic peptides to generate the antibodies of the invention. In one example, a peptide of about fifteen amino acids may be chosen and a peptide-antibody package may be obtained from a commercial source such as Anaspec (San Jose, Calif.). One of skill in the art will know that the generation of two or more different sets of monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an antibody with the specificity and affinity required for its intended use (e.g., ELISA, immunohistochemistry, in vivo imaging, immunotoxin therapy). The antibodies are tested for their desired activity by known methods, in accordance with the purpose for which the antibodies are to be used (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the generation and testing of antibodies, see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988). For example, the antibodies may be tested in ELISA assays, Western blots, immunohistochemical staining of formalin-fixed ovarian cancers or frozen tissue sections. After their initial in vitro characterization, antibodies intended for therapeutic or in vivo diagnostic use are tested according to known clinical testing methods.

[0079] The term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e.; the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0080] Monoclonal antibodies of the invention may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro.

[0081] The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).

[0082] In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fe fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross-linking antigen.

[0083] The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody fragment. (Zoller, M. J. Curr. Opin. Biotechnol. 3:348-354, 1992).

[0084] The antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature, 321:522-525 (1986), Reichmann et al., Nature, 332:323-327 (1988), and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

[0085] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986), Riechmann et al., Nature, 332:323-327 (1988), Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such “humanized” antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0086] Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immuno., 7:33 (1993)). Human antibodies can also be produced in phage display libraries (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). The techniques of Cote et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)].

[0087] Administration of Therapeutic and Diagnostic Antibodies

[0088] Antibodies of the invention are preferably administered to a subject in a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

[0089] The antibodies can be administered to the subject, patient, or cell by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. The antibodies may also be administered by intratumoral or peritumoral routes, to exert local as well as systemic therapeutic effects. Local or intravenous injection is preferred.

[0090] Effective dosages and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. Guidance in selecting appropriate doses for antibodies is found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antibody used alone might range from about 1 μg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

[0091] Following administration of an antibody for treating ovarian cancer, the efficacy of the therapeutic antibody can be assessed in various ways well known to the skilled practitioner. For instance, the size, number, and/or distribution of ovarian tumors in a subject receiving treatment may be monitored using standard tumor imaging techniques. A therapeutically-administered antibody that arrests tumor growth, results in tumor shrinkage, and/or prevents the development of new tumors, compared to the disease course that would occurs in the absence of antibody administration, is an efficacious antibody for treatment of ovarian cancer.

[0092] Antisense and Gene Therapy Approaches for Inhibiting Ovarian Tumor Marker Gene Function

[0093] Because the ovarian tumor marker genes of the invention are highly expressed in ovarian tumor cells and are expressed at extremely low levels in normal ovarian cells, inhibition of ovarian tumor marker expression or polypeptide activity may be integrated into any therapeutic strategy for treating or preventing ovarian cancer.

[0094] The principle of antisense therapy is based on the hypothesis that sequence-specific suppression of gene expression (via transcription or translation) may be achieved by intracellular hybridization between genomic DNA or mRNA and a complementary antisense species. The formation of such a hybrid nucleic acid duplex interferes with transcription of the target tumor antigen-encoding genomic DNA, or processing/transport/translation and/or stability of the target tumor antigen mRNA.

[0095] Antisense nucleic acids can be delivered by a variety of approaches. For example, antisense oligonucleotides or antisense RNA can be directly administered (e.g., by intravenous injection) to a subject in a form that allows uptake into tumor cells. Alternatively, viral or plasmid vectors that encode antisense RNA (or RNA fragments) can be introduced into cells in vivo. Antisense effects can also be induced by sense sequences; however, the extent of phenotypic changes are highly variable. Phenotypic changes induced by effective antisense therapy are assessed according to changes in, e.g., target mRNA levels, target protein levels, and/or target protein activity levels. In a specific example, inhibition of ovarian tumor marker function by antisense gene therapy may be accomplished by direct administration of antisense ovarian tumor marker RNA to a subject. The antisense tumor marker RNA may be produced and isolated by any standard technique, but is most readily produced by in vitro transcription using an antisense tumor marker cDNA under the control of a high efficiency promoter (e.g., the T7 promoter). Administration of antisense tumor marker RNA to cells can be carried out by any of the methods for direct nucleic acid administration described below.

[0096] An alternative strategy for inhibiting ovarian tumor marker polypeptide function using gene therapy involves intracellular expression of an anti-ovarian tumor marker antibody or a portion of an anti-ovarian tumor marker antibody. For example, the gene (or gene fragment) encoding a monoclonal antibody that specifically binds to an ovarian tumor marker polypeptide and inhibits its biological activity is placed under the transcriptional control of a specific (e.g., tissue- or tumor-specific) gene regulatory sequence, within a nucleic acid expression vector. The vector is then administered to the subject such that it is taken up by ovarian tumor cells or other cells, which then secrete the anti-ovarian tumor marker antibody and thereby block biological activity of the ovarian tumor marker polypeptide. Preferably, the ovarian tumor marker polypeptide is present at the extracellular surface of ovarian tumor cells.

[0097] Nucleic Acid Delivery

[0098] In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the nucleic acids of the present invention can be in the form of naked DNA or the nucleic acids can be in a vector for delivering the nucleic acids to the cells for inhibition of ovarian tumor marker protein expression. The vector can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCOBRL, Inc., Gaithersburg, Md.), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, Wis.), as well as other liposomes developed according to procedures standard in the art. In addition, the nucleic acid or vector of this invention can be delivered in vivo by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, Calif.) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, Ariz.).

[0099] As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., Proc. Natl. Acad. Sci. U.S.A. 85:4486, 1988; Miller et al., Mol. Cell. Biol. 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells antisense nucleic acid that inhibits expression of an ovarian tumor marker gene. The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of adenoviral vectors (Mitani et al., Hum. Gene Ther. 5:941-948, 1994), adeno-associated viral (AAV) vectors (Goodman et al., Blood 84:1492-1500, 1994), lentiviral vectors (Naidini et al., Science 272:263-267, 1996), pseudotyped retroviral vectors (Agrawal et al., Exper. Hematol. 24:738-747, 1996). Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzenberger et al., Blood 87:472-478, 1996). This invention can be used in conjunction with any of these or other commonly used gene transfer methods.

[0100] As one example, if the antisense nucleic acid of this invention is delivered to the cells of a subject in an adenovirus vector, the dosage for administration of adenovirus to humans can range from about 10⁷ to 10⁹ plaque forming units (pfu) per injection but can be as high as 10¹² pfu per injection (Crystal, Hum. Gene Ther. 8:985-1001, 1997; Alvarez and Curiel, Hum. Gene Ther. 8:597-613, 1997). Ideally, a subject will receive a single injection. If additional injections are necessary, they can be repeated at six month intervals for an indefinite period and/or until the efficacy of the treatment has been established.

[0101] Parenteral administration of the nucleic acid or vector of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein. For additional discussion of suitable formulations and various routes of administration of therapeutic compounds, see, e.g., Remington: The Science and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995.

EXAMPLE I Identification of Ovarian Tumor Marker Genes Using SAGE

[0102] Serial Analysis of Gene Expression is a method that enables the global analysis of gene expression from a tissue of interest (Velculescu et al., Science 270:484487, 1995; Zhang et al., Science 276:1268-72, 1997). The advantages of SAGE over cDNA arrays, another method for the global analysis of gene expression, include: 1) the possibility of identifying novel genes, 2) determination of absolute levels of gene expression, which is difficult in hybridization-based techniques, and, 3) examination of gene expression as a whole instead of as a subset of genes.

[0103] Construction and Screening of SAGE Libraries

[0104] The SAGE technique has been described in detail (Velculescu et al., Science 270:484487, 1995). The SAGE libraries disclosed herein were made as described by Velculescu, supra. First, total RNA was purified from the cells. Poly A+ RNA was then isolated and reverse transcription was performed using a biotinylated poly dT primer for first strand synthesis. The cDNA mixture was cut with NlaIII and the biotinylated 3′ fragments were collected using streptavidin beads. The beads were divided into two aliquots (A and B) and linkers containing PCR primer sites and a site for class II restriction enzyme BsmFI were ligated to the DNA fragments attached to the beads from samples A and B. The mixture was treated with the restriction enzyme BsmFI, which recognizes the site in the linker but cuts 14 bp downstream. The resulting fragments contained the linker and 10 bp of “cDNA sequence” that is referred to as “tag”. The tags from samples A and B were ligated together to form ditags, which were then amplified by PCR. Any repeated ditag (tags containing the same two individual tags) are an indication of PCR bias and were eliminated by the SAGE software (Velculescu et al., Science 270:484-487, 1995; Zhang et al., Science 276:1268-72, 1997). The tags were concatemerized and cloned into a sequencing vector. Sequencing revealed the identity and frequency of the different tags. As described above, the 10 bp tag is sufficient to identify cDNA and the frequency of a particular tag represents the frequency of a particular message in the population. The SAGE software developed in the laboratories of Bert Vogelstein and Kenneth Kinzler at Johns Hopkins extracts the tags from the raw sequencing data, matches the tags to the corresponding genes (present in Genbank) and makes frequency comparisons between the tags from an individual library or other libraries.

[0105] Verification of Ovarian Tumor Marker Genes Identified by SAGE

[0106] The most promising candidates are selected and verified by any expression analysis method, e.g., Northern analysis or reverse transcription-polymerase chain reaction (RT-PCR). For Northern analysis, radioactive probes are generated from expressed sequence tags (ESTs) corresponding to the candidate genes and are used to hybridize to membranes containing total RNA from various ovarian cancers and controls. The candidates may also be verified by real-time PCR using the Taqman method (Heid and Stevens, Genome Res. 6:986-94, 1996). Amplification primers and fluorescent probes are synthesized according to instructions from the manufacturer (Perkin-Elmer; Norwalk, Conn.). Quantitative PCR is performed using a PE 5700 apparatus or an analogous instrument.

[0107] Sources of RNA for SAGE Library Construction

[0108] Eleven SAGE libraries were constructed, as shown in Table 1. The human ovarian surface epithelial cell (HOSE) library was constructed using RNA from HOSE cells that were obtained by gently scraping the ovarian surface from a hysterectomy patient followed by short-term in vitro culture (three passages) of the cells. Three of the ovarian tumor libraries (designated OVT6, OVT7, and OVT8) were constructed using RNA from one of three primary high grade serous adenocarcinomas libraries from individual ovarian tumor cell lines were generated using RNA from OV1063 (derived from an ovarian papillary adenocarcinoma; obtained from the American Type Culture Collection (ATCC; Manassas, Va.; CRL-2183)); ES-2 (derived from a clear cell adenocarcinoma; from the ATCC; CRL-1978); A2780 (derived from an ovarian cancer; obtained from Dr. Vilhelm Bohr, Baltimore, Md.); OVCA432 (derived from an ovarian serous cystadenocarcinoma; Bast et al., J. Clin. Invest. 68:1331-1337, 1981); ML10 (derived from an ovarian cystadenoma; Luo et al. Gyn. Oncol., 67:277-284, 1997); or IOSE29 (simian virus 40-immortalized OSE cells; Auersperg et al., Proc. Natl. Acad. Sci. USA 96:6249-6254, 1999).

[0109] The pooled library was generated using RNA from a pool of 10 cell lines: A2780; BG-1 (poorly differentiated ovarian cancer; obtained from Dr. Carl Barrett, Durham, N.C.); ES-2; OVCA432; MDAH 2774 (endometrioid adenocarcinoma; obtained from the ATCC); and five cell lines obtained from Dr. Michael Birrer (Rockville, Md.): AD10 (an adriamycin-resistant derivative of A2780); A222 (ovarian carcinoma); UCI101 (papillary ovarian adenocarcinoma); UCI107 (papillary ovarian adenocarcinoma); and A224 (ovarian carcinoma). TABLE 1 Library Seq Tags (raw) Tags Genes At least 2 HOSE 2,290 49,394 47,881 16,034 4,532 OVT6 2,104 43,891 41,620 18,476 4,799 OVT7 2,089 57,725 53,898 19,523 5,669 OVT8 2,076 36,813 32,494 16,363 3,815 OV1063 2,146 41,131 37,862 15,231 4,746 ES-2 1,775 36,430 35,352 14,739 3,952 A2780** 475 9,269 8,246 5,179 1,021 OVCA432 384 3,011 2,824 1,940 310 Pool 2,201 10,952 10,554 5,956 1,627 ML10 1,935 61,083 55,700 18,727 6,637 IOSE29 * * * * * TOTAL 17,475 349,699 326,431 75,056 25,071

[0110] Results of SAGE

[0111] Eleven ovarian SAGE libraries were constructed, ten of which have been sequenced to date. The overall data are summarized in Table 1 above. For each SAGE library, Table 1 shows the number of SAGE library clones sequenced, the number of raw tags sequenced, the number of tags obtained after correction for PCR bias, the total number of genes that are represented by the corrected pool of tags, and the number of genes that were represented at least twice in the corrected pool of tags. For most libraries, 35,000-61,000 tags were obtained, yielding anywhere from 14,000-20,000 genes. In total, 75,056 genes were identified.

[0112] In order to identify genes that are up-regulated in ovarian tumors and that may serve as diagnostic markers and therapeutic targets, we compared gene expression between the normal ovarian cells (HOSE) and the cancer cells (OVT6, OVT7, OVT8, OV1063, ES2, A2780, Pool). OVCA432 was not included in this analysis because of the poor number of tags obtained from this library. We looked for genes for which expression was absent or low (frequency smaller or equal to 2 tags per 100,000) in HOSE and at least 7- to 10-fold up-regulated in the majority of the tumor libraries, and detected a number of genes matching these criteria. Table 2 shows the libraries that were screened, the SAGE tags that were identified in the library screens, along with their corresponding genes and Genbank accession numbers, and the relative expression of each gene in each library. Any one of these ovarian tumor marker genes may be used in the diagnostic and/or therapeutic methods of the invention. TABLE 2 SEQ. ID NO. (Tag) Tag OVT8 OVT7 OVT6 A2780 OV1063 ES2 Pool HOSE Gene Product Genbank 83 TCAGACGCAG 52 149 91 97 49 214 82 2 Prothymosin, alpha M14483 84 TTATGGGATC 57 80 57 140 83 126 274 2 G protein, beta polypeptide M24194 2-like 1 85 CCCGCCCCCG 136 166 52 22 7 0 146 2 Lutheran blood group NM_005581 (B-CAM) 86 GAGGAAGAAG 14 38 57 76 53 80 100 2 Tumor rejection antigen-1 NM_003299 (gp96) 1 87 GAAGCTTTGC 27 43 43 22 27 66 73 2 HSP90 AA071048 88 TACCAGTGTA 30 16 14 140 22 30 100 2 HSP60 M22382 89 TCTTCTCCCT 8 42 32 22 27 25 46 2 Hepatoma-Derived Growth D16431 Factor (HDGF) 90 TTGGCTTTTC 14 12 71 32 10 22 18 0 DKFZp5860031 AL117237 91 GGAAGGGAGG 30 14 16 11 12 44 55 2 CD63 antigen (melanoma 1 AA041408 antigen) 92 AAGCCAGCCC 19 17 36 22 17 27 18 2 Protein kinase C substrate J03075 80K-H 93 TTTCAGATTG 16 26 25 32 22 19 18 0 Polymerase II cofactor 4 X79805 (PC4) 94 GCATAGGCTG 11 24 25 22 12 27 9 2 Tu translation elong. factor L38995 (mitochondrial) 95 TTTGTTAATT 30 16 16 43 17 19 18 2 hNRP H1 L22009 96 GAGACTCCTG 11 23 23 22 12 3 64 2 Solute carrier family 2 AF070544 97 CCTGTAATTC 19 10 27 32 15 8 27 2 KIAA0591 protein AB011163 98 GTGGTGCGTG 16 10 21 11 15 19 27 2 X-ray repair protein AF035587 99 TTGGACCTGG 11 19 9 11 27 16 18 2 ATP synthase AA524164 (delta subunit) 100 CTTAAGGATT 11 12 18 11 15 27 9 0 DKFZP564M2423 protein BC003049 101 GTCTGTGAGA 8 17 9 22 12 22 18 0 Growth factor-regul. tyr D84064 kinase substrate 102 GAAACTGAAC 16 10 14 32 12 3 9 2 eIF-2-associated p67 U29607

EXAMPLE II Identification of Additional Ovarian Tumor Marker Genes Using SAGE

[0113] Serial Analysis of Gene Expression (SAGE) was used to generate global gene expression profiles from various ovarian cell lines and tissues, including primary cancers, ovarian surface epithelial (OSE) cells and cystadenoma cells. The profiles were used to compare overall patterns of gene expression and identify differentially expressed genes. We have sequenced a total of 385,000 tags, yielding over 56,000 genes expressed in ten different libraries derived from ovarian tissues.

[0114] In general, ovarian cancer cell lines showed relatively high levels of similarity to libraries from other cancer cell lines, regardless of the tissue of origin (ovarian or colon), indicating that these lines had lost many of their tissue specific expression patterns. In contrast, immortalized OSE (IOSE) and ovarian cystadenoma cells showed much higher similarity to primary ovarian carcinomas as compared to primary colon carcinomas. Primary tissue specimens therefore appeared to be a better model for gene expression analyses. Using the expression profiles described above and stringent selection criteria, we have identified a number of genes highly differentially expressed between non-transformed ovarian epithelia and ovarian carcinomas. Some of the genes identified are already known to be overexpressed in ovarian cancer but several represent novel candidates. Many of the genes up-regulated in ovarian cancer represent surface or secreted proteins such as Claudin-3 and -4, HE4, Mucin-1, Ep-CAM and Mesothelin. The genes encoding apolipoprotein E (ApoE) and apolipoprotein J (ApoJ), two proteins involved in lipid homeostasis are among the genes highly up-regulated in ovarian cancer. Selected SAGE results were further validated through immunohistochemical analysis of ApoJ, Claudin-3, Claudin-4 and Ep-CAM in archival material. These experiments provided additional evidence of the relevance of our findings in vivo.

[0115] A) Methods

[0116] Cell Culture and Tissue Samples

[0117] Ovarian cancer cell lines OV1063, ES2, and MDAH 2774 were obtained from the American Type Culture Collection (Manassas, Va.). Cell lines A222, AD10, UCI101 and UCI107 were obtained from Dr. Michael Birrer (Rockville, Md.). Cell line A2780 was obtained from Dr. Vilhelm Bohr (Baltimore, Md.). The SV40-immortalized cell lines IOSE29 (Auersperg, N., et al. Proc. Natl Acad. Sci. USA, 96:6249-6254, 1999) and ML10 (Luo, M. P., et al. Gynecol. Oncol. 67:277-284, 1997) were kindly provided by Dr. Nelly Auersperg (British Columbia, Canada) and Dr. Louis Dubeau (Los Angeles, Calif.), respectively. Except for IOSE29, ML-10 and HOSE-4, all cell lines were cultured in McCoy's 5A growth medium (Life Technologies, Inc, Gaithersburg, Md.) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml of Penicillin and 100 ug/ml Streptomycin). IOSE29 was cultivated in Medium 199 (Life Technologies, Inc, Gaithersburg, Md.) supplemented with 5% newborn calf serum (NCS). ML10 was cultivated in MEM (Life Technologies, Inc, Gaithersburg, Md.) supplemented with 10% FBS and antibiotics as above.

[0118] Three high-grade serous ovarian cancer specimens, OVT6, OVT7, and OVT8, composed of at least 80% tumor cells as determined by histopathology, were chosen for SAGE. The ovarian tumor samples were frozen immediately after surgical resection and were obtained form the Johns Hopkins gynecological tumor bank in accordance with institutional guidelines on the use of human tissue. Normal human ovarian surface epithelial (HOSE-4) cells were cultured from the right ovary of a patient undergoing hysterectomy and bilateral salpingo-oophorectomy for benign disease. The OSE cells were obtained by gently scraping the surface of the ovary with a cytobrush and grown for 2 passages in RPMI 1640 medium supplemented with 10% FBS and 10 ug/ml insulin-like growth factor (IGF).

[0119] Serial Analysis of Gene Expression (SAGE)

[0120] Total RNA was obtained from guanidinium isothiocyanate cell lysates by centrifugation on CsCl. Polyadenylated mRNA was purified from total RNA using the Messagemaker kit (Life Technologies, Gaithersburg, Md.) and the cDNA generated using the cDNA Synthesis System (Life Technologies, Gaithersburg, Md.). For the “Pool” library, 100 ug of total RNA from each of 10 ovarian cancer cell lines (A222, A2780, AD10, BG-1, ES-2, MDAH 2774, OVCA432, OV1063, UCI10 and UCI107) were combined and mRNA purified. SAGE was performed essentially as described (Velculescu, V. E., et al. Science 270:484487, 1995) for all the libraries except HOSE. To create the HOSE library, MicroSAGE, a modified SAGE technique developed for limited sample sizes (Datson, N. A., et al. Nucleic Acids Res. 27:1300-1307, 1999), was used. Approximately 1×10⁶ OSE cells in short-term culture were lysed and the mRNA purified directly using Oligo (dT)₂₅ Dynabeads (Dynal, Norway). As part of the Cancer Genome Anatomy Project (CGAP) SAGE consortium, the SAGE libraries were arrayed at the Lawrence Livermore National Laboratories and sequenced at the Washington University Human Genome Center or NISC (NIH, Bethesda, Mich.). The data has been posted on the CGAP website (http://www.ncbi.nlm.nih.gov/SAGE/) as part of the SAGEmap database (Lal, A., et al. Cancer Res. 59:5403-5407, 1999.).

[0121] Sequence data from each library were analyzed by the SAGE software (Velculescu, V. E., et al. Science 270:484-487, 1995.) to quantify tags and identify their corresponding transcripts. The data for the colon libraries NC1, NC2, Tu98, Tu102, HCT116 and SW837 were obtained from the SAGEmap database and analyzed in the same way. Because the different libraries contained various numbers of total tags, normalization (to 100,000 tags) was performed to allow meaningful comparisons. The 10,000 most highly expressed genes in each of the 16 SAGE libraries of interest were formatted in a Microsoft Excel spreadsheet and Pearson correlation coefficients were calculated for each pair-wise comparison using normalized tag values for each library. The value for the Pearson correlation coefficient (r) represents the degree of similarity (the strength of the relationship) between two libraries and is calculated using the following equation: $r = \frac{{n\left( {\Sigma \quad x\quad y} \right)} - {\left( {\Sigma \quad x} \right)\left( {\Sigma \quad y} \right)}}{\sqrt{\left\lbrack {{n\quad \Sigma \quad x^{2}} - \left( {\Sigma \quad x} \right)^{2}} \right\rbrack\left\lbrack {{n\quad \Sigma \quad y^{2}} - ({\Sigma y})^{2}} \right.}}$

[0122] where, x_(i)=number of tags per 100,000 for tag i in the first library and y_(i)=number of tags per 100,000 for tag i in the second library. For our purposes n equals 10,000 since 10,000 tags are compared. A dendrogram representing the hierarchical relationships between samples was then generated using hierarchical cluster analysis as described risen, M. B., et al. Proc. Natl Acad. Sci. USA 95:14863-14868, 1998). In addition, the identification of differentially expressed genes was also done using this subset of the SAGE data.

[0123] Immunohistochemistry

[0124] Deparafinized 5-um sections of formalin-fixed ovarian cancer specimens were submitted to heat-induced antigen retrieval and processed using the LSAB2 system (DAKO, Carpinteria, Calif.) with 3,3′-diaminobenzidine as the chromatogen and a hematoxylin counterstain. Monoclonal antibody against ApoJ/Clusterin (Clone CLI-9) was obtained from Alexis Corporation (San Diego, Calif.) and used at a 1:500 Dilution. Monoclonal antibody against Ep-CAM (Clone 323/A3) from NeoMarkers (Fremont, Calif.) was used at a 1:500 dilution. Polyclonal antibodies against Claudin-3 and 4 were a generous gift from Drs. M. Furuse and S. Tsukita (Kyoto, Japan) and were used at a dilution of 1:1000.

[0125] B) Results

[0126] Ovarian SAGE Library Construction and Analysis

[0127] Gene expression alterations that arise during malignant transformation can be identified a number of ways. We chose the unbiased, comprehensive method SAGE to create global gene expression profiles from ten different ovarian sources. The expression patterns are generated by sequencing thousands of short sequence tags that contain sufficient information to uniquely identify the corresponding transcripts (Velculescu, V. E., et al. Science 270:484487, 1995). Ten different SAGE libraries were constructed and sequenced for this study (Table 3). Our libraries included two derived from OSE cells (IOSE29 and HOSE-4), one derived from immortalized cystadenoma cells (ML-10), three primary tumors (OVT-6, -7, -8) and four libraries derived from ovarian cancer cell lines (OV-1063, ES-2, A2780 and a pool of cell lines). Almost 20,000 sequencing reactions were performed yielding a total of 384,497 tags, of which, 82,533 were unique. Accounting for a SAGE tag error rate of 6.8% (due to sequencing errors; see Zhang, L., et al., Science 276:1268-1272, 1997), we estimate that we have identified a total of 56,387 genes expressed in ovarian tissues. Except for the A2780 cell line and the pooled lines (POOL) samples, a minimum of 12,000 genes were obtained from every library. Typically, for each library, 10% of the genes were expressed at levels of at least 0.01% and, collectively, these genes accounted for more than 50% of all the tags sequenced. Among the tags that appeared more than once, up to 95% matched to known sequences in the current Genbank nr database. For example, of the 6637 tags that appeared more than once in ML10, only 311 had no matches in the current database, excluding the EST databases. TABLE 3 Summary of SAGE library analyses Library^(a) Sequence Tags^(b) Unique tags^(c) Genes^(d) ≧2 tags^(e) HOSE 2,290 47,881 16,034 12,778 4,532 IOSE 1,912 47,549 18,004 14,771 5,681 ML10 1,935 55,700 18,727 14,939 6,637 OVT6 2,104 41,620 18,476 15,646 4,799 OVT7 2,089 53,898 19,523 15,858 5,669 OVT8 2,076 32,494 16,363 14,153 3,815 OV1063 2,146 37,862 15,231 12,656 4,746 A2780 1,332 21,587 10,717 9,249 2,761 ES2 1,775 35,352 14,739 12,335 3,952 POOL 2,201 10,554 5,956 5,238 1,627 TOTAL 19,860 384,497 82,533 56,387 28,219

[0128] Comparisons of Global Gene Expression Between Ovarian Tissue Samples

[0129] Although progression to malignancy requires a number of gene expression changes, the transcript levels from the vast majority of genes remain unaltered (Zhang, L., et al., Science 276:1268-1272, 1997; and Alon, U., et al., Proc. Natl Acad. Sci. USA 96:6745-6750, 1999). Similarities between the global expression profiles of two given samples can be readily visualized using scatterplots and quantitated through the calculation of Pearson correlation coefficients. Scatterplots of global gene expression analysis in IOSE (ovarian) vs. ML10 (ovarian), OVT6 (ovarian), or Tu98 (colon) cells were generated using the Spotfire Pro 4.0 software (Cambridge, Mass.) and the Pearson correlation coefficients for each pair-wise comparison of the 16 ovarian and colon SAGE libraries were calculated.

[0130] As expected, the immortalized IOSE29 and ovarian cystadenoma strain ML10 are much more similar to ovarian tumors than to colon tumors (average correlation coefficients of 0.70 vs. 0.51, respectively). In addition, IOSE29 and ML10 are very similar to each other, with a correlation coefficient of 0.82. The primary culture of OSE cells (HOSE-4) exhibited higher similarities to the ovarian tumors than to the colon tumors, although the similarity levels were much lower than those observed for IOSE29. Interestingly, HOSE-4 and IOSE29 appear to be much more distantly related than expected considering the fact that they were both derived from “normal” OSE cells. The differences in gene expression between these cells may be due to a number of factors. The age of the patient, the pathological state of the ovaries, the presence of non-epithelial cells in the culture and the fact that IOSE29 is SV40-immortalized may all contribute to the gene expression differences observed. However, it is unlikely that the main differences are due to SV40-immortalization since IOSE29 is much more similar to normal colon (a non SV40-immortalized epithelium) than HOSE-4. It is, of course, possible that the lower degree of similarity between HOSE-4 and the ovarian tumors compared to IOSE29 and ML-10 reflects the fact that HOSE-4 represents a better approximation of the normal in vivo OSE cell.

[0131] Three dendrograms were created from hierarchical cluster analysis of all colon and ovarian SAGE libraries, ovarian samples only, and non-malignant ovarian and colon epithelia as well as ovarian and colon primary tumors, using Cluster software (Eisen, M. B., et al. Proc. Natl. Acad. Sci USA 95:14863-14868, 1998). When all the samples were included in the hierarchical clustering analysis, the primary colon tumors clustered with the normal colon epithelium, but colon cell lines clustered with the ovarian specimens. Clearly, the tissue clustering that was readily apparent when comparing primary tissues or immortalized lines was lost when including carcinoma cell lines. For example, A2780, a widely used ovarian cancer cell line was just as similar to colon cancer cell lines as it was to ovarian cancer cell lines. This observation supports the idea that in the process of establishment, cell lines may lose many of the gene expression characteristics of their tissue of origin, although tissue specific expression is clearly not completely lost in cancer cell lines (Ross, D. T., et al. Nat. Genet. 24:227-235,2000).

[0132] It is widely believed that epithelial ovarian cancer and benign ovarian cysts, while not necessarily part of a progression sequence toward malignancy, are both derived from the ovarian surface epithelium (Scully, R. E. J. Cell Biochem. 23, Suppl.: 208-218, 1995). OSE cells themselves are mesodermal in origin and are believed to undergo metaplasia before progressing to neoplasia (Scully, R. E. J. Cell Biochem. 23 Suppl.: 208-218, 1995; and Maines-Bandiera, S. L. and Auersperg, N. Int. J. Gynecol. Pathol. 16:250-255, 1997). On the other hand, it has also been argued that ovarian cancers are not derived from OSE but rather from the secondary Mullerian system, structures lined by Mullerian epithelium but located outside the uterus, cervix and fallopian tubes (Schink, J. C. Semin. Oncol. 26 Suppl. 1: 2-7, 1999). This hypothesis would explain some of the shortcomings of the OSE model, such as the requirement for metaplasia and the lack of well-defined precursors in the ovary. While not wishing to be bound by theory, our results are consistent with the widely accepted dogma of the OSE origin of ovarian cancer. Indeed, IOSE29 showed high degrees of similarity to the ovarian tumors and both IOSE29 and HOSE were much more closely related to ovarian than colon primary cancers.

[0133] E-cadherin expression has been proposed to be a major determinant in the formation of metaplastic OSE (Auersperg, N., et al. Proc. Natl Acad. Sci. USA, 96:6249-6254, 1999; and Maines-Bandiera, S. L. and Auersperg, N. Int. J. Gynecol. Pathol. 16:250-255, 1997). Consistent with this hypothesis, E-cadherin was absent in IOSE29, HOSE and ML10 but was expressed in all three ovarian tumors (Table 4). Other cadherins are also shown for comparison. Interestingly, VE-cadherin is absent in most libraries except in two of the pre-neoplastic ovarian samples, again suggesting metaplasia As expected, LI-Cadherin was expressed exclusively in the colon-derived libraries. Interestingly, vimentin, a mesenchymal marker, was present in essentially all the ovarian libraries but very low in the colon specimens. Although the specificity of vimentin as a mesenchymal marker has been questioned, this suggests that OSE may retain some of their mesenchymal characteristics, even after turning on the expression of E-cadherin.

[0134] The cytokeratins (CKs) and carcinoembryonic antigen (CEA) have been used to differentiate between colon cancer and ovarian cancer (Lagendijk, J. H., et al. Hum. Pathol. 29:491-497, 1998; and Berezowski, K., et al. Mod. Pathol. 9:426-429, 1996). Typically, colon cancer expresses CK20 and CEA while ovarian cancer expresses CK7. The expression patterns in our libraries were consistent with previously reported observations: CK20 and CEA were found in normal colon and colon tumors but absent from all of our ovarian samples (Table 4). Conversely, CK7 was expressed in all three primary ovarian tumors and, while not absent, was much lower in the colon samples. Examination of the differential expression patterns of a variety of established ovarian cancer markers thus provided validation of the SAGE database and cluster analysis.

[0135] Differential Gene Expression

[0136] The ultimate goal of comparing SAGE libraries is to identify differentially expressed genes. Criteria for differential expression can be determined for each comparison and transcripts within the determined range selected for study. We found a large number of genes that were up-regulated in only one or two of the three tumors on which SAGE was performed. For example, a total of 444 genes were up-regulated more than 10-fold in at least one of the three ovarian primary cancers compared to IOSE29. However, only 45 genes were overexpressed more than 10-fold in all three ovarian tumors analyzed compared to IOSE29.

[0137] Our analysis of three different primary ovarian cancers allowed us to reduce the number of candidates by looking for consistency between samples. In order to identify genes that are very likely to be frequently up-regulated during ovarian tumorigenesis we set the following conservative criteria for our analysis. First, the fold induction was calculated by adding the number of normalized tags from the three primary tumors and dividing this number by the total normalized tags in the three non-malignant specimens. Cell lines were not included here for reasons described above. In addition, although HOSE-4 appeared more distantly related to the other non-transformed specimens, we believe that the inclusion of HOSE-4, while possibly eliminating real candidates makes our analysis more conservative and more likely to identify truly overexpressed genes in ovarian cancer. Second, all three primary tumors were required to consistently show elevated levels (>12 tags/100,000) of the gene in question. This eliminated genes that may be very highly overexpressed in one tumor but not in others. Finally, the candidate genes were required to be expressed in at least one ovarian cell line at a level greater than 3 tags/100,000. This last criterion was used to reduce the possibility of identifying genes because of their high level of expression in inflammatory cells or in the stroma of the primary tumors. Using these criteria, the genes that exhibited more than 10-fold overexpression were identified and are shown in Table 4.

[0138] Two members of the Claudin family of tight junction proteins, Claudin-3 and 4 were found among the top six differentially expressed genes and likely represent transmembrane receptors. In addition, Apolipoprotein J (ApoJ) and Apolipoprotein E (ApoE) were both overexpressed in ovarian cancer.

[0139] Of the 27 overexpressed genes shown in Table 4, ten were relatively specific for the ovary (HLA-DR, two different ESTs, GA733-1, ceruloplasmin, glutathione peroxidase-3, the secretory leukocyte protease inhibitor, ApoJ, ApoE and mesothelin) while the others were also expressed in colon tissues. In any event, it is significant that MUC1, HE4, Ep-CAM and mesothelin, four genes already known to be up-regulated in epithelial ovarian cancer, were identified in this study. This fact validates our approach as well as our set of criteria used to determine the genes differentially expressed.

[0140] Similarly, stringent criteria were used to identify genes down-regulated in ovarian tumors compared to IOSE29, HOSE-4 and ML10. Again, the fold difference was calculated by adding tag frequency for all three “normal” specimens and dividing by the total number of tags in the three ovarian tumors. A candidate was required to be expressed at a level of 12 tags/100,000 or greater in all three normal samples. The genes found elevated more than ten-fold in normal tissue compared to tumors are shown in Table 4. TABLE 4 A subset of genes differentially expressed in ovarian tumors compared to non-malignant ovarian samples EXPRESSION^(c) SEQ ID OSE Ovarian Colon Colon NO. (TAG) TAG GENE Fold ML10 Tumors Epithelium Tumors FUNCTION up-regulated^(a) 103 GGGCATCTCT HLA-DR α chain 289 − ++ − − Major histocompatibility complex, class II/antigen presentation 104 TTTGGGCCTA Cysteine-rich protein 1 123 − ++ + − LIM/double zinc finger 105 ATCGTGGCGG Claudin 4 109 − + ++ + Tight junction barrier function 106 TATTATGGTA ESTs (HOST-2) 101 − + − − Unknown 107 GCCTACCCGA Surface marker 93 − + − − Tumor Ag/Ca²⁺ signal transducer 1/GA733-1/TROP2 108 CTCGCGCTGG Claudin 3 83 − + ++ + Tight junction barrier function 109 TTGCTTGCCA Ceruloplasmin (ferroxidase) 79 − + − − Secreted metalloprotein/antioxidant 110 CCTGCTTGTC HE4 72 − ++ + − Secreted protease inhibitor 111 AGGGAGGGGC Glutathione peroxidase 3 69 − + − − Secreted selenoprotein/peroxidase (plasma) 112 TGTGGGAAAT Secretory leukocyte 60 − ++ − − Secreted serine protease inhibitor protease inhibitor 113 CCTGATCTGC ESTs (HOST-1) 56 − + − − Unknown 114 ACCATTGGAT Interferon-induced 49 − ++ − + Receptor for interferon signaling transmembrane protein 1 115 AGTTTGTTAG Ep-CAM/EGP2/ 48 − + ++ + Tumor Ag/Ca²⁺-independant CAM/proliferation TROP1/GA733-2 116 CCTGGGAAGT Mucin 1 43 − ++ + + Tumor Ag/Type-I membrane glycoprotein 117 CAACTAATTC Apolipoprotein J/clusterin 39 − ++ − − Secreted chaperone/cytoprotection 118 GCCTGCAGTC Serine protease inhibitor, 34 − ++ ++ + Transmembrane/protease inhibitor Kunitz type, 2 119 CGACCCCACG Apolipoprotein E 34 − ++ − − Lipoprotein particle binding, internalization and catabolism 120 TTCTGTGCTG Complement component 1, 24 − + − − Serine protease of complement system/autoimmune diseases r subcomponent 121 CGCCGACGAT G1P3/IFI-6-16 24 − ++ + + Interferon primary response/ α IFN-inducible 122 CCCGCCCCCG Lutheran blood group 17 − ++ − − Possible cell surface receptor/ protein/BCAM immunoglobulin superfamily 123 GATCAGGCCA Collagen Type III, alpha-1 16 − ++ − + Unknown 124 GTGGAAGACG Mal (T cell differentiation 16 − + − − Trans-Golgi membrane protein (epithelial cells)/T-cell differentiation protein) 124 GATGAGGAGA ESTs (Collagen Type I, 13 + ++ − + Unknown alpha-2 126 TTCCCTTCTT HLA-DPB1 13 − + − − Major histocompatibility complex, class II/antigen presentation 127 CCCCCTGCAG Mesothelin 12 − ++ − − GPI-anchored/mesothelioma and ovarian cancer antigen/ cell adhesion 128 TGCTGCCTGT Bone marrow stroma 12 − ++ − + Type II transmembrane protein/pre-B-cell growth antigen 2/BST-2 129 TGCAGCACGA HLA-Cw 10 − ++ ++ + Major histocompatibility complex, class I/antigen presentation down-regulated^(b) 130 GGTTATTTTG Unknown 99 + − − − Unknown 131 TGTCATCACA Lysyl oxidase-like 2 73 + − − − Secreted/collagen and elastin crosslinker 132 AAAATAAACA Chloride intracellular 29 + − − − Ion transport channel 4 like 133 TAAAAATGTT Plasminogen activator 26 ++ − − − Serine protease inhibitor inhibitor, type 1 family/tPA inhibitor 134 GAGCTTTTGA EST 14 + − − − Unknown 135 GGCTGATGTG Glycine-t-RNA synthetase 13 + − − − Protein synthesis 136 CGACGAGGAG Epithelial membrane protein-3 13 + − − − Proliferation, differentiation, and apoptosis 137 GCCCCCAATA Galectin-1 10 ++ + − − β-galactoside binding lectin/ ECM interaction and proliferation 138 GCAACTTGGA Vinexin β 10 + − − − Cell-adhesion and cytoarchitecture

[0141] In order to validate the candidates identified by SAGE, we performed immunohistochemical analysis of thirteen cases of serous cancer of the ovary using antibodies against four of the genes identified as up-regulated in ovarian cancer (Table 5). This was particularly important since the SAGE analysis was initially performed from primary ovarian cancers, which contain a mixture of cell types. Ep-CAM exhibited diffuse, strong staining of tumor cell membranes in all thirteen tumors, without blood cell or stromal staining. Importantly, only one of six samples of the ovarian surface epithelium present in the cases showed weak focal staining, and the rest were negative. The strong immunoreactivity of all thirteen ovarian tumors confirms the validity of our approach to identify genes highly and consistently up-regulated in ovarian cancer. Similarly, ApoJ was found to be expressed in ovarian cancer cells and absent from the surface epithelium. While some expression was detected in non-tumor stroma and inflammatory cells, most of the immuno-reactivity was in tumor cells, and a majority (nine out of thirteen) of the cases showed staining. This observation represents the first report of ApoJ expression in ovarian cancer and provides a novel target for diagnosis or therapy. Claudin-3 and -4 also exhibited staining limited to the tumor component of the specimens. Most tumor cells showed strong membrane staining with weak cytoplasmic reactivity. Some tumors specimens showed decreased membrane staining with strong cytoplasmic reactivity. The normal surface epithelial component (or mesothelial cells) examined did not stain or only stained weakly with the Claudin-4 antibody, while the determination of Claudin-3 levels in normal epithelium was complicated by a low background reactivity with this antibody.

[0142] Incorporation by Reference

[0143] Throughout this application, various publications, patents, and/or patent applications are referenced in order to more fully describe the state of the art to which this invention pertains. The disclosures of these publications, patents, and/or patent applications are herein incorporated by reference in their entireties to the same extent as if each independent publication, patent, and/or patent application was specifically and individually indicated to be incorporated by reference.

[0144] Other Embodiments

[0145] It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

1 147 1 490 DNA Homo sapiens 1 tccttgcccg ccgcagtcgc ctccgccgcg cgcctcctcc gccgccgcgg actccggcag 60 ctttatcgcc agagtccctg aactctcgct ttctttttaa tcccctgcat cggatcaccg 120 gcgtgcccca ccatgtcaga cgcagccgta gacaccagct ccgaaatcac caccaaggac 180 ttaaaggaga agaaggaagt tgtggaagag gcagaaaatg gaagagacgc ccctgctaac 240 gggaatgcta atgaggaaaa cggggagcag gaggctgaca atgaggtaga cgaagaagag 300 gaagaaggtg gggaggaaga ggaggaggaa gaagaaggtg atggtgagga agaggatgga 360 gatgaagatg aggaagctga gtcagctacg ggcaagcggg cagctgaaga tgatgaggat 420 gacgatgtcg ataccaagaa gcagaagacc gacgaggatg actagacagc aaaaaaggaa 480 aagttaaact 490 2 110 PRT Homo sapiens 2 Met Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys Asp 1 5 10 15 Leu Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn Gly Arg Asp 20 25 30 Ala Pro Ala Asn Gly Asn Ala Asn Glu Glu Asn Gly Glu Gln Glu Ala 35 40 45 Asp Asn Glu Val Asp Glu Glu Glu Glu Glu Gly Gly Glu Glu Glu Glu 50 55 60 Glu Glu Glu Glu Gly Asp Gly Glu Glu Glu Asp Gly Asp Glu Asp Glu 65 70 75 80 Glu Ala Glu Ser Ala Thr Gly Lys Arg Ala Ala Glu Asp Asp Glu Asp 85 90 95 Asp Asp Val Asp Thr Lys Lys Gln Lys Thr Asp Glu Asp Asp 100 105 110 3 1093 DNA Homo sapiens 3 ctgcaaggcg gcggcaggag aggttgtggt gctagtttct ctaagccatc cagtgccatc 60 ctcgtcgctg cagcgacacc gctctcgccg ccgccatgac tgagcagatg acccttcgtg 120 gcaccctcaa gggccacaac ggctgggtaa cccagatcgc tactaccccg cagttcccgg 180 acatgatcct ctccgcctct cgagataaga ccatcatcat gtggaaactg accagggatg 240 agaccaacta tggaattcca cagcgtgctc tgcggggtca ctcccacttt gttagtgatg 300 tggttatctc ctcagatggc cagtttgccc tctcaggctc ctgggatgga accctgcgcc 360 tctgggatct cacaacgggc accaccacga ggcgatttgt gggccatacc aaggatgtgc 420 tgagtgtggc cttctcctct gacaaccggc agattgtctc tggatctcga gataaaacca 480 tcaagctatg gaataccctg ggtgtgtgca aatacactgt ccaggatgag agccactcag 540 agtgggtgtc ttgtgtccgc ttctcgccca acagcagcaa ccctatcatc gtctcctgtg 600 gctgggacaa gctggtcaag gtatggaacc tggctaactg caagctgaag accaaccaca 660 ttggccacac aggctatctg aacacggtga ctgtctctcc agatggatcc ctctgtgctt 720 ctggaggcaa ggatggccag gccatgttat gggatctcaa cgaaggcaaa cacctttaca 780 cgctagatgg tggggacatc atcaacgccc tgtgcttcag ccctaaccgc tactggctgt 840 gtgctgccac aggccccagc atcaagatct gggatttaga gggaaagatc attgtagatg 900 aactgaagca agaagttatc agtaccagca gcaaggcaga accaccccag tgcacttccc 960 tggcctggtc tgctgatggc cagactctgt ttgctggcta cacggacaac ctggtgcgag 1020 tgtggcaggt gaccattggc acacgctaga agtttatggc agagctttac aaataaaaaa 1080 aaaatggctt ttc 1093 4 317 PRT Homo sapiens 4 Met Thr Glu Gln Met Thr Leu Arg Gly Thr Leu Lys Gly His Asn Gly 1 5 10 15 Trp Val Thr Gln Ile Ala Thr Thr Pro Gln Phe Pro Asp Met Ile Leu 20 25 30 Ser Ala Ser Arg Asp Lys Thr Ile Ile Met Trp Lys Leu Thr Arg Asp 35 40 45 Glu Thr Asn Tyr Gly Ile Pro Gln Arg Ala Leu Arg Gly His Ser His 50 55 60 Phe Val Ser Asp Val Val Ile Ser Ser Asp Gly Gln Phe Ala Leu Ser 65 70 75 80 Gly Ser Trp Asp Gly Thr Leu Arg Leu Trp Asp Leu Thr Thr Gly Thr 85 90 95 Thr Thr Arg Arg Phe Val Gly His Thr Lys Asp Val Leu Ser Val Ala 100 105 110 Phe Ser Ser Asp Asn Arg Gln Ile Val Ser Gly Ser Arg Asp Lys Thr 115 120 125 Ile Lys Leu Trp Asn Thr Leu Gly Val Cys Lys Tyr Thr Val Gln Asp 130 135 140 Glu Ser His Ser Glu Trp Val Ser Cys Val Arg Phe Ser Pro Asn Ser 145 150 155 160 Ser Asn Pro Ile Ile Val Ser Cys Gly Trp Asp Lys Leu Val Lys Val 165 170 175 Trp Asn Leu Ala Asn Cys Lys Leu Lys Thr Asn His Ile Gly His Thr 180 185 190 Gly Tyr Leu Asn Thr Val Thr Val Ser Pro Asp Gly Ser Leu Cys Ala 195 200 205 Ser Gly Gly Lys Asp Gly Gln Ala Met Leu Trp Asp Leu Asn Glu Gly 210 215 220 Lys His Leu Tyr Thr Leu Asp Gly Gly Asp Ile Ile Asn Ala Leu Cys 225 230 235 240 Phe Ser Pro Asn Arg Tyr Trp Leu Cys Ala Ala Thr Gly Pro Ser Ile 245 250 255 Lys Ile Trp Asp Leu Glu Gly Lys Ile Ile Val Asp Glu Leu Lys Gln 260 265 270 Glu Val Ile Ser Thr Ser Ser Lys Ala Glu Pro Pro Gln Cys Thr Ser 275 280 285 Leu Ala Trp Ser Ala Asp Gly Gln Thr Leu Phe Ala Gly Tyr Thr Asp 290 295 300 Asn Leu Val Arg Val Trp Gln Val Thr Ile Gly Thr Arg 305 310 315 5 2402 DNA Homo sapiens 5 agtctccgcc gccgccgtga acatggagcc cccggacgca ccggcccagg cgcgcggggc 60 cccgcggctg ctgttgctcg cagtcctgct ggcggcgcac ccagatgccc aggcggaggt 120 gcgcttgtct gtacccccgc tggtggaggt gatgcgagga aagtctgtca ttctggactg 180 cacccctacg ggaacccacg accattatat gctggaatgg ttccttaccg accgctcggg 240 agctcgcccc cgcctagcct cggctgagat gcagggctct gagctccagg tcacaatgca 300 cgacacccgg ggccgcagtc ccccatacca gctggactcc caggggcgcc tggtgctggc 360 tgaggcccag gtgggcgacg agcgagacta cgtgtgcgtg gtgagggcag gggcggcagg 420 cactgctgag gccactgcgc ggctcaacgt gtttgcaaag ccagaggcca ctgaggtctc 480 ccccaacaaa gggacactgt ctgtgatgga ggactctgcc caggagatcg ccacctgcaa 540 cagccggaac gggaacccgg cccccaagat cacgtggtat cgcaacgggc agcgcctgga 600 ggtgcccgta gagatgaacc cagagggcta catgaccagc cgcacggtcc gggaggcctc 660 gggcctgctc tccctcacca gcaccctcta cctgcggctc cgcaaggatg accgagacgc 720 cagcttccac tgcgccgccc actacagcct gcccgagggc cgccacggcc gcctggacag 780 ccccaccttc cacctcaccc tgcactatcc cacggagcac gtgcagttct gggtgggcag 840 cccgtccacc ccagcaggct gggtacgcga gggtgacact gtccagctgc tctgccgggg 900 ggacggcagc cccagcccgg agtatacgct tttccgcctt caggatgagc aggaggaagt 960 gctgaatgtg aatctcgagg ggaacttgac cctggaggga gtgacccggg gccagagcgg 1020 gacctatggc tgcagagtgg aggattacga cgcggcagat gacgtgcagc tctccaagac 1080 gctggagctg cgcgtggcct atctggaccc cctggagctc agcgagggga aggtgctttc 1140 cttacctcta aacagcagtg cagtcgtgaa ctgctccgtg cacggcctgc ccacccctgc 1200 cctacgctgg accaaggact ccactcccct gggcgatggc cccatgctgt cgctcagttc 1260 tatcaccttc gattccaatg gcacctacgt atgtgaggcc tccctgccca cagtcccggt 1320 cctcagccgc acccagaact tcacgctgct ggtccaaggc tcgccagagc taaagacagc 1380 ggaaatagag cccaaggcag atggcagctg gagggaagga gacgaagtca cactcatctg 1440 ctctgcccgc ggccatccag accccaaact cagctggagc caattggggg gcagccccgc 1500 agagccaatc cccggacggc agggttgggt gagcagctct ctgaccctga aagtgaccag 1560 cgccctgagc cgcgatggca tctcctgtga agcctccaac ccccacggga acaagcgcca 1620 tgtcttccac ttcggcgccg tgagccccca gacctcccag gctggagtgg ccgtcatggc 1680 cgtggccgtc agcgtgggcc tcctgctcct cgtcgttgct gtcttctact gcgtgagacg 1740 caaagggggc ccctgctgcc gccagcggcg ggagaagggg gctccgccgc caggggagcc 1800 agggctgagc cactcggggt cggagcaacc agagcagacc ggccttctca tgggaggtgc 1860 ctccggagga gccaggggtg gcagcggggg cttcggagac gagtgctgag ccaagaacct 1920 cctagaggct gtccctggac ctggagctgc aggcatcaga gaaccagccc tgctcacgcc 1980 atgcccgccc ccgccttccc tcttccctct tccctctccc tgcccagccc tcccttcctt 2040 cctctgccgg caaggcaggg acccacagtg gctgcctgcc tccgggaggg aaggagaggg 2100 agggtgggtg ggtgggaggg ggccttcctc cagggaatgt gactctccca ggccccagaa 2160 tagctcctgg acccaagccc aaggcccagc ctgggacaag gctccgaggg tcggctggcc 2220 ggagctattt ttacctcccg cctcccctgc tggtcccccc acctgacgtc ttgctgcaga 2280 gtctgacact ggattccccc ccctcacccc gcccctggtc ccactcctgc ccccgcccta 2340 cctccgcccc accccatcat ctgtggacac tggagtctgg aataaatgct gtttgtcaca 2400 tc 2402 6 628 PRT Homo sapiens 6 Met Glu Pro Pro Asp Ala Pro Ala Gln Ala Arg Gly Ala Pro Arg Leu 1 5 10 15 Leu Leu Leu Ala Val Leu Leu Ala Ala His Pro Asp Ala Gln Ala Glu 20 25 30 Val Arg Leu Ser Val Pro Pro Leu Val Glu Val Met Arg Gly Lys Ser 35 40 45 Val Ile Leu Asp Cys Thr Pro Thr Gly Thr His Asp His Tyr Met Leu 50 55 60 Glu Trp Phe Leu Thr Asp Arg Ser Gly Ala Arg Pro Arg Leu Ala Ser 65 70 75 80 Ala Glu Met Gln Gly Ser Glu Leu Gln Val Thr Met His Asp Thr Arg 85 90 95 Gly Arg Ser Pro Pro Tyr Gln Leu Asp Ser Gln Gly Arg Leu Val Leu 100 105 110 Ala Glu Ala Gln Val Gly Asp Glu Arg Asp Tyr Val Cys Val Val Arg 115 120 125 Ala Gly Ala Ala Gly Thr Ala Glu Ala Thr Ala Arg Leu Asn Val Phe 130 135 140 Ala Lys Pro Glu Ala Thr Glu Val Ser Pro Asn Lys Gly Thr Leu Ser 145 150 155 160 Val Met Glu Asp Ser Ala Gln Glu Ile Ala Thr Cys Asn Ser Arg Asn 165 170 175 Gly Asn Pro Ala Pro Lys Ile Thr Trp Tyr Arg Asn Gly Gln Arg Leu 180 185 190 Glu Val Pro Val Glu Met Asn Pro Glu Gly Tyr Met Thr Ser Arg Thr 195 200 205 Val Arg Glu Ala Ser Gly Leu Leu Ser Leu Thr Ser Thr Leu Tyr Leu 210 215 220 Arg Leu Arg Lys Asp Asp Arg Asp Ala Ser Phe His Cys Ala Ala His 225 230 235 240 Tyr Ser Leu Pro Glu Gly Arg His Gly Arg Leu Asp Ser Pro Thr Phe 245 250 255 His Leu Thr Leu His Tyr Pro Thr Glu His Val Gln Phe Trp Val Gly 260 265 270 Ser Pro Ser Thr Pro Ala Gly Trp Val Arg Glu Gly Asp Thr Val Gln 275 280 285 Leu Leu Cys Arg Gly Asp Gly Ser Pro Ser Pro Glu Tyr Thr Leu Phe 290 295 300 Arg Leu Gln Asp Glu Gln Glu Glu Val Leu Asn Val Asn Leu Glu Gly 305 310 315 320 Asn Leu Thr Leu Glu Gly Val Thr Arg Gly Gln Ser Gly Thr Tyr Gly 325 330 335 Cys Arg Val Glu Asp Tyr Asp Ala Ala Asp Asp Val Gln Leu Ser Lys 340 345 350 Thr Leu Glu Leu Arg Val Ala Tyr Leu Asp Pro Leu Glu Leu Ser Glu 355 360 365 Gly Lys Val Leu Ser Leu Pro Leu Asn Ser Ser Ala Val Val Asn Cys 370 375 380 Ser Val His Gly Leu Pro Thr Pro Ala Leu Arg Trp Thr Lys Asp Ser 385 390 395 400 Thr Pro Leu Gly Asp Gly Pro Met Leu Ser Leu Ser Ser Ile Thr Phe 405 410 415 Asp Ser Asn Gly Thr Tyr Val Cys Glu Ala Ser Leu Pro Thr Val Pro 420 425 430 Val Leu Ser Arg Thr Gln Asn Phe Thr Leu Leu Val Gln Gly Ser Pro 435 440 445 Glu Leu Lys Thr Ala Glu Ile Glu Pro Lys Ala Asp Gly Ser Trp Arg 450 455 460 Glu Gly Asp Glu Val Thr Leu Ile Cys Ser Ala Arg Gly His Pro Asp 465 470 475 480 Pro Lys Leu Ser Trp Ser Gln Leu Gly Gly Ser Pro Ala Glu Pro Ile 485 490 495 Pro Gly Arg Gln Gly Trp Val Ser Ser Ser Leu Thr Leu Lys Val Thr 500 505 510 Ser Ala Leu Ser Arg Asp Gly Ile Ser Cys Glu Ala Ser Asn Pro His 515 520 525 Gly Asn Lys Arg His Val Phe His Phe Gly Ala Val Ser Pro Gln Thr 530 535 540 Ser Gln Ala Gly Val Ala Val Met Ala Val Ala Val Ser Val Gly Leu 545 550 555 560 Leu Leu Leu Val Val Ala Val Phe Tyr Cys Val Arg Arg Lys Gly Gly 565 570 575 Pro Cys Cys Arg Gln Arg Arg Glu Lys Gly Ala Pro Pro Pro Gly Glu 580 585 590 Pro Gly Leu Ser His Ser Gly Ser Glu Gln Pro Glu Gln Thr Gly Leu 595 600 605 Leu Met Gly Gly Ala Ser Gly Gly Ala Arg Gly Gly Ser Gly Gly Phe 610 615 620 Gly Asp Glu Cys 625 7 2780 DNA Homo sapiens 7 gtgggcggac cgcgcggctg gaggtgtgag gatccgaacc caggggtggg gggtggaggc 60 ggctcctgcg atcgaagggg acttgagact caccggccgc acgccatgag ggccctgtgg 120 gtgctgggcc tctgctgcgt cctgctgacc ttcgggtcgg tcagagctga cgatgaagtt 180 gatgtggatg gtacagtaga agaggatctg ggtaaaagta gagaaggatc aaggacggat 240 gatgaagtag tacagagaga ggaagaagct attcagttgg atggattaaa tgcatcacaa 300 ataagagaac ttagagagaa gtcggaaaag tttgccttcc aagccgaagt taacagaatg 360 atgaaactta tcatcaattc attgtataaa aataaagaga ttttcctgag agaactgatt 420 tcaaatgctt ctgatgcttt agataagata aggctaatat cactgactga tgaaaatgct 480 ctttctggaa atgaggaact aacagtcaaa attaagtgtg ataaggagaa gaacctgctg 540 catgtcacag acaccggtgt aggaatgacc agagaagagt tggttaaaaa ccttggtacc 600 atagccaaat ctgggacaag cgagttttta aacaaaatga ctgaagcaca ggaagatggc 660 cagtcaactt ctgaattgat tggccagttt ggtgtcggtt tctattccgc cttccttgta 720 gcagataagg ttattgtcac ttcaaaacac aacaacgata cccagcacat ctgggagtct 780 gactccaatg aattttctgt aattgctgac ccaagaggaa acactctagg acggggaacg 840 acaattaccc ttgtcttaaa agaagaagca tctgattacc ttgaattgga tacaattaaa 900 aatctcgtca aaaaatattc acagttcata aactttccta tttatgtatg gagcagcaag 960 actgaaactg ttgaggagcc catggaggaa gaagaagcag ccaaagaaga gaaagaagaa 1020 tctgatgatg aagctgcagt agaggaagaa gaagaagaaa agaaaccaaa gactaaaaaa 1080 gttgaaaaaa ctgtctggga ctgggaactt atgaatgata tcaaaccaat atggcagaga 1140 ccatcaaaag aagtagaaga agatgaatac aaagctttct acaaatcatt ttcaaaggaa 1200 agtgatgacc ccatggctta tattcacttt actgctgaag gggaagttac cttcaaatca 1260 attttatttg tacccacatc tgctccacgt ggtctgtttg acgaatatgg atctaaaaag 1320 agcgattaca ttaagctcta tgtgcgccgt gtattcatca cagacgactt ccatgatatg 1380 atgcctaaat acctcaattt tgtcaagggt gtggtggact cagatgatct ccccttgaat 1440 gtttcccgcg agactcttca gcaacataaa ctgcttaagg tgattaggaa gaagcttgtt 1500 cgtaaaacgc tggacatgat caagaagatt gctgatgata aatacaatga tactttttgg 1560 aaagaatttg gtaccaacat caagcttggt gtgattgaag accactcgaa tcgaacacgt 1620 cttgctaaac ttcttaggtt ccagtcttct catcatccaa ctgacattac tagcctagac 1680 cagtatgtgg aaagaatgaa ggaaaaacaa gacaaaatct acttcatggc tgggtccagc 1740 agaaaagagg ctgaatcttc tccatttgtt gagcgacttc tgaaaaaggg ctatgaagtt 1800 atttacctca cagaacctgt ggatgaatac tgtattcagg cccttcccga atttgatggg 1860 aagaggttcc agaatgttgc caaggaagga gtgaagttcg atgaaagtga gaaaactaag 1920 gagagtcgtg aagcagttga gaaagaattt gagcctctgc tgaattggat gaaagataaa 1980 gcccttaagg acaagattga aaaggctgtg gtgtctcagc gcctgacaga atctccgtgt 2040 gctttggtgg ccagccagta cggatggtct ggcaacatgg agagaatcat gaaagcacaa 2100 gcgtaccaaa cgggcaagga catctctaca aattactatg cgagtcagaa gaaaacattt 2160 gaaattaatc ccagacaccc gctgatcaga gacatgcttc gacgaattaa ggaagatgaa 2220 gatgataaaa cagttttgga tcttgctgtg gttttgtttg aaacagcaac gcttcggtca 2280 gggtatcttt taccagacac taaagcatat ggagatagaa tagaaagaat gcttcgcctc 2340 agtttgaaca ttgaccctga tgcaaaggtg gaagaagagc ccgaagaaga acctgaagag 2400 acagcagaag acacaacaga agacacagag caagacgaag atgaagaaat ggatgtggga 2460 acagatgaag aagaagaaac agcaaaggaa tctacagctg aaaaagatga attgtaaatt 2520 atactctcac catttggatc ctgtgtggag agggaatgtg aaatttacat catttctttt 2580 tgggagagac ttgttttgga tgccccctaa tccccttctc ccctgcactg taaaatgtgg 2640 gattatgggt cacaggaaaa agtgggtttt ttagttgaat tttttttaac attcctcatg 2700 aatgtaaatt tgtactattt aactgactat tcttgatgta aaatcttgtc atgtgtataa 2760 aaataaaaaa gatcccaaat 2780 8 838 PRT Homo sapiens 8 Val Gly Gly Pro Arg Gly Trp Arg Cys Glu Asp Pro Asn Pro Gly Val 1 5 10 15 Gly Gly Gly Gly Gly Ser Cys Asp Arg Arg Gly Leu Glu Thr His Arg 20 25 30 Pro His Ala Met Arg Ala Leu Trp Val Leu Gly Leu Cys Cys Val Leu 35 40 45 Leu Thr Phe Gly Ser Val Arg Ala Asp Asp Glu Val Asp Val Asp Gly 50 55 60 Thr Val Glu Glu Asp Leu Gly Lys Ser Arg Glu Gly Ser Arg Thr Asp 65 70 75 80 Asp Glu Val Val Gln Arg Glu Glu Glu Ala Ile Gln Leu Asp Gly Leu 85 90 95 Asn Ala Ser Gln Ile Arg Glu Leu Arg Glu Lys Ser Glu Lys Phe Ala 100 105 110 Phe Gln Ala Glu Val Asn Arg Met Met Lys Leu Ile Ile Asn Ser Leu 115 120 125 Tyr Lys Asn Lys Glu Ile Phe Leu Arg Glu Leu Ile Ser Asn Ala Ser 130 135 140 Asp Ala Leu Asp Lys Ile Arg Leu Ile Ser Leu Thr Asp Glu Asn Ala 145 150 155 160 Leu Ser Gly Asn Glu Glu Leu Thr Val Lys Ile Lys Cys Asp Lys Glu 165 170 175 Lys Asn Leu Leu His Val Thr Asp Thr Gly Val Gly Met Thr Arg Glu 180 185 190 Glu Leu Val Lys Asn Leu Gly Thr Ile Ala Lys Ser Gly Thr Ser Glu 195 200 205 Phe Leu Asn Lys Met Thr Glu Ala Gln Glu Asp Gly Gln Ser Thr Ser 210 215 220 Glu Leu Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Phe Leu Val 225 230 235 240 Ala Asp Lys Val Ile Val Thr Ser Lys His Asn Asn Asp Thr Gln His 245 250 255 Ile Trp Glu Ser Asp Ser Asn Glu Phe Ser Val Ile Ala Asp Pro Arg 260 265 270 Gly Asn Thr Leu Gly Arg Gly Thr Thr Ile Thr Leu Val Leu Lys Glu 275 280 285 Glu Ala Ser Asp Tyr Leu Glu Leu Asp Thr Ile Lys Asn Leu Val Lys 290 295 300 Lys Tyr Ser Gln Phe Ile Asn Phe Pro Ile Tyr Val Trp Ser Ser Lys 305 310 315 320 Thr Glu Thr Val Glu Glu Pro Met Glu Glu Glu Glu Ala Ala Lys Glu 325 330 335 Glu Lys Glu Glu Ser Asp Asp Glu Ala Ala Val Glu Glu Glu Glu Glu 340 345 350 Glu Lys Lys Pro Lys Thr Lys Lys Val Glu Lys Thr Val Trp Asp Trp 355 360 365 Glu Leu Met Asn Asp Ile Lys Pro Ile Trp Gln Arg Pro Ser Lys Glu 370 375 380 Val Glu Glu Asp Glu Tyr Lys Ala Phe Tyr Lys Ser Phe Ser Lys Glu 385 390 395 400 Ser Asp Asp Pro Met Ala Tyr Ile His Phe Thr Ala Glu Gly Glu Val 405 410 415 Thr Phe Lys Ser Ile Leu Phe Val Pro Thr Ser Ala Pro Arg Gly Leu 420 425 430 Phe Asp Glu Tyr Gly Ser Lys Lys Ser Asp Tyr Ile Lys Leu Tyr Val 435 440 445 Arg Arg Val Phe Ile Thr Asp Asp Phe His Asp Met Met Pro Lys Tyr 450 455 460 Leu Asn Phe Val Lys Gly Val Val Asp Ser Asp Asp Leu Pro Leu Asn 465 470 475 480 Val Ser Arg Glu Thr Leu Gln Gln His Lys Leu Leu Lys Val Ile Arg 485 490 495 Lys Lys Leu Val Arg Lys Thr Leu Asp Met Ile Lys Lys Ile Ala Asp 500 505 510 Asp Lys Tyr Asn Asp Thr Phe Trp Lys Glu Phe Gly Thr Asn Ile Lys 515 520 525 Leu Gly Val Ile Glu Asp His Ser Asn Arg Thr Arg Leu Ala Lys Leu 530 535 540 Leu Arg Phe Gln Ser Ser His His Pro Thr Asp Ile Thr Ser Leu Asp 545 550 555 560 Gln Tyr Val Glu Arg Met Lys Glu Lys Gln Asp Lys Ile Tyr Phe Met 565 570 575 Ala Gly Ser Ser Arg Lys Glu Ala Glu Ser Ser Pro Phe Val Glu Arg 580 585 590 Leu Leu Lys Lys Gly Tyr Glu Val Ile Tyr Leu Thr Glu Pro Val Asp 595 600 605 Glu Tyr Cys Ile Gln Ala Leu Pro Glu Phe Asp Gly Lys Arg Phe Gln 610 615 620 Asn Val Ala Lys Glu Gly Val Lys Phe Asp Glu Ser Glu Lys Thr Lys 625 630 635 640 Glu Ser Arg Glu Ala Val Glu Lys Glu Phe Glu Pro Leu Leu Asn Trp 645 650 655 Met Lys Asp Lys Ala Leu Lys Asp Lys Ile Glu Lys Ala Val Val Ser 660 665 670 Gln Arg Leu Thr Glu Ser Pro Cys Ala Leu Val Ala Ser Gln Tyr Gly 675 680 685 Trp Ser Gly Asn Met Glu Arg Ile Met Lys Ala Gln Ala Tyr Gln Thr 690 695 700 Gly Lys Asp Ile Ser Thr Asn Tyr Tyr Ala Ser Gln Lys Lys Thr Phe 705 710 715 720 Glu Ile Asn Pro Arg His Pro Leu Ile Arg Asp Met Leu Arg Arg Ile 725 730 735 Lys Glu Asp Glu Asp Asp Lys Thr Val Leu Asp Leu Ala Val Val Leu 740 745 750 Phe Glu Thr Ala Thr Leu Arg Ser Gly Tyr Leu Leu Pro Asp Thr Lys 755 760 765 Ala Tyr Gly Asp Arg Ile Glu Arg Met Leu Arg Leu Ser Leu Asn Ile 770 775 780 Asp Pro Asp Ala Lys Val Glu Glu Glu Pro Glu Glu Glu Pro Glu Glu 785 790 795 800 Thr Ala Glu Asp Thr Thr Glu Asp Thr Glu Gln Asp Glu Asp Glu Glu 805 810 815 Met Asp Val Gly Thr Asp Glu Glu Glu Glu Thr Ala Lys Glu Ser Thr 820 825 830 Ala Glu Lys Asp Glu Leu 835 9 2912 DNA Homo sapiens 9 cagttgcttc agcgtcccgg tgtggctgtg ccgttggtcc tgtgcggtca cttagccaag 60 atgcctgagg aaacccagac ccaagaccaa ccgatggagg aggaggaggt tgagacgttc 120 gcctttcagg cagaaattgc ccagttgatg tcattgatca tcaatacttt ctactcgaac 180 aaagagatct ttctgagaga gctcatttca aattcatcag atgcattgga caaaatccgg 240 tatgaaactt tgacagatcc cagtaaatta gactctggga aagagctgca tattaacctt 300 ataccgaaca aacaagatcg aactctcact attgtggata ctggaattgg aatgaccaag 360 gctgacttga tcaataacct tggtactatc gccaagtctg ggaccaaagc gttcatggaa 420 gctttgcagg ctggtgcaga tatctctatg attggccagt tcggtgttgg tttttattct 480 gcttatttgg ttgctgagaa agtaactgtg atcaccaaac ataacgatga tgagcagtac 540 gcttgggagt cctcagcagg gggatcattc acagtgagga cagacacagg tgaacctatg 600 ggtcgtggaa caaaagttat cctacacctg aaagaagacc aaactgagta cttggaggaa 660 cgaagaataa aggagattgt gaagaaacat tctcagttta ttggatatcc cattactctt 720 tttgtggaga aggaacgtga taaagaagta agcgatgatg aggctgaaga aaaggaagac 780 aaagaagaag aaaaagaaaa agaagagaaa gagtcggaag acaaacctga aattgaagat 840 gttggttctg atgaggaaga agaaaagaag gatggtgaca agaagaagaa gaagaagatt 900 aaggaaaagt acatcgatca agaagagctc aacaaaacaa agcccatctg gaccagaaat 960 cccgacgata ttactaatga ggagtacgga gaattctata agagcttgac caatgactgg 1020 gaagatcact tggcagtgaa gcatttttca gttgaaggac agttggaatt cagagccctt 1080 ctatttgtcc cacgacgtgc tccttttgat ctgtttgaaa acagaaagaa aaagaacaat 1140 atcaaattgt atgtacgcag agttttcatc atggataact gtgaggagct aatccctgaa 1200 tatctgaact tcattagagg ggtggtagac tcggaggatc tccctctaaa catatcccgt 1260 gagatgttgc aacaaagcaa aattttgaaa gttatcagga agaatttggt caaaaaatgc 1320 ttagaactct ttactgaact ggcggaagat aaagagaact acaagaaatt ctatgagcag 1380 ttctctaaaa acataaagct tggaatacac gaagactctc aaaatcggaa gaagctttca 1440 gagctgttaa ggtactacac atctgcctct ggtgatgaga tggtttctct caaggactac 1500 tgcaccagaa tgaaggagaa ccagaaacat atctattata tcacaggtga gaccaaggac 1560 caggtagcta actcagcctt tgtggaacgt cttcggaaac atggcttaga agtgatctat 1620 atgattgagc ccattgatga gtactgtgtc caacagctga aggaatttga ggggaagact 1680 ttagtgtcag tcaccaaaga aggcctggaa cttccagagg atgaagaaga gaaaaagaag 1740 caggaagaga aaaaaacaaa gtttgagaac ctctgcaaaa tcatgaaaga catattggag 1800 aaaaaagttg aaaaggtggt tgtgtcaaac cgattggtga catctccatg ctgtattgtc 1860 acaagcacat atggctggac agcaaacatg gagagaatca tgaaagctca agccctaaga 1920 gacaactcaa caatgggtta catggcagca aagaaacacc tggagataaa ccctgaccat 1980 tccattattg agaccttaag gcaaaaggca gaggctgata agaacgacaa gtctgtgaag 2040 gatctggtca tcttgcttta tgaaactgcg ctcctgtctt ctggcttcag tctggaagat 2100 ccccagacac atgctaacag gatctacagg atgatcaaac ttggtctggg tattgatgaa 2160 gatgacccta ctgctgatga taccagtgct gctgtaactg aagaaatgcc accccttgaa 2220 ggagatgacg acacatcacg catggaagaa gtagactaat ctctggctga gggatgactt 2280 acctgttcag tactctacaa ttcctctgat aatatatttt caaggatgtt tttctttatt 2340 tttgttaata ttaaaaagtc tgtatggcat gacaactact ttaaggggaa gataagattt 2400 ctgtctacta agtgatgctg tgatacctta ggcactaaag cagagctagt aatgcttttt 2460 gagtttcatg ttggttcttt cacagatggg gtaacgtgca ctgtaagacg tatgtaacat 2520 gatgttaact ttgtgtggtc taaagtgttt agctgtcaag ccggatgcct aagtagacca 2580 aatcttgtta ttgaagtgtt ctgagctgta tcttgatgtt tagaaaagta ttcgttacat 2640 cttgtaggat ctactttttg aacttttcat tccctgtagt tgacaattct gcatgtacta 2700 gtcctctaga aataggttaa actgaagcaa cttgatggaa ggatctctcc acagggcttg 2760 ttttccaaag aaaagtattg tttggaggag caaagttaaa agcctaccta agcatatcgt 2820 aaagctgttc aaatactcga gcccagtctt gtggatggaa atgtagtgct cgagtcacat 2880 tctgcttaaa gttgtaacaa atacagatga gt 2912 10 732 PRT Homo sapiens 10 Met Pro Glu Glu Thr Gln Thr Gln Asp Gln Pro Met Glu Glu Glu Glu 1 5 10 15 Val Glu Thr Phe Ala Phe Gln Ala Glu Ile Ala Gln Leu Met Ser Leu 20 25 30 Ile Ile Asn Thr Phe Tyr Ser Asn Lys Glu Ile Phe Leu Arg Glu Leu 35 40 45 Ile Ser Asn Ser Ser Asp Ala Leu Asp Lys Ile Arg Tyr Glu Thr Leu 50 55 60 Thr Asp Pro Ser Lys Leu Asp Ser Gly Lys Glu Leu His Ile Asn Leu 65 70 75 80 Ile Pro Asn Lys Gln Asp Arg Thr Leu Thr Ile Val Asp Thr Gly Ile 85 90 95 Gly Met Thr Lys Ala Asp Leu Ile Asn Asn Leu Gly Thr Ile Ala Lys 100 105 110 Ser Gly Thr Lys Ala Phe Met Glu Ala Leu Gln Ala Gly Ala Asp Ile 115 120 125 Ser Met Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Tyr Leu Val 130 135 140 Ala Glu Lys Val Thr Val Ile Thr Lys His Asn Asp Asp Glu Gln Tyr 145 150 155 160 Ala Trp Glu Ser Ser Ala Gly Gly Ser Phe Thr Val Arg Thr Asp Thr 165 170 175 Gly Glu Pro Met Gly Arg Gly Thr Lys Val Ile Leu His Leu Lys Glu 180 185 190 Asp Gln Thr Glu Tyr Leu Glu Glu Arg Arg Ile Lys Glu Ile Val Lys 195 200 205 Lys His Ser Gln Phe Ile Gly Tyr Pro Ile Thr Leu Phe Val Glu Lys 210 215 220 Glu Arg Asp Lys Glu Val Ser Asp Asp Glu Ala Glu Glu Lys Glu Asp 225 230 235 240 Lys Glu Glu Glu Lys Glu Lys Glu Glu Lys Glu Ser Glu Asp Lys Pro 245 250 255 Glu Ile Glu Asp Val Gly Ser Asp Glu Glu Glu Glu Lys Lys Asp Gly 260 265 270 Asp Lys Lys Lys Lys Lys Lys Ile Lys Glu Lys Tyr Ile Asp Gln Glu 275 280 285 Glu Leu Asn Lys Thr Lys Pro Ile Trp Thr Arg Asn Pro Asp Asp Ile 290 295 300 Thr Asn Glu Glu Tyr Gly Glu Phe Tyr Lys Ser Leu Thr Asn Asp Trp 305 310 315 320 Glu Asp His Leu Ala Val Lys His Phe Ser Val Glu Gly Gln Leu Glu 325 330 335 Phe Arg Ala Leu Leu Phe Val Pro Arg Arg Ala Pro Phe Asp Leu Phe 340 345 350 Glu Asn Arg Lys Lys Lys Asn Asn Ile Lys Leu Tyr Val Arg Arg Val 355 360 365 Phe Ile Met Asp Asn Cys Glu Glu Leu Ile Pro Glu Tyr Leu Asn Phe 370 375 380 Ile Arg Gly Val Val Asp Ser Glu Asp Leu Pro Leu Asn Ile Ser Arg 385 390 395 400 Glu Met Leu Gln Gln Ser Lys Ile Leu Lys Val Ile Arg Lys Asn Leu 405 410 415 Val Lys Lys Cys Leu Glu Leu Phe Thr Glu Leu Ala Glu Asp Lys Glu 420 425 430 Asn Tyr Lys Lys Phe Tyr Glu Gln Phe Ser Lys Asn Ile Lys Leu Gly 435 440 445 Ile His Glu Asp Ser Gln Asn Arg Lys Lys Leu Ser Glu Leu Leu Arg 450 455 460 Tyr Tyr Thr Ser Ala Ser Gly Asp Glu Met Val Ser Leu Lys Asp Tyr 465 470 475 480 Cys Thr Arg Met Lys Glu Asn Gln Lys His Ile Tyr Tyr Ile Thr Gly 485 490 495 Glu Thr Lys Asp Gln Val Ala Asn Ser Ala Phe Val Glu Arg Leu Arg 500 505 510 Lys His Gly Leu Glu Val Ile Tyr Met Ile Glu Pro Ile Asp Glu Tyr 515 520 525 Cys Val Gln Gln Leu Lys Glu Phe Glu Gly Lys Thr Leu Val Ser Val 530 535 540 Thr Lys Glu Gly Leu Glu Leu Pro Glu Asp Glu Glu Glu Lys Lys Lys 545 550 555 560 Gln Glu Glu Lys Lys Thr Lys Phe Glu Asn Leu Cys Lys Ile Met Lys 565 570 575 Asp Ile Leu Glu Lys Lys Val Glu Lys Val Val Val Ser Asn Arg Leu 580 585 590 Val Thr Ser Pro Cys Cys Ile Val Thr Ser Thr Tyr Gly Trp Thr Ala 595 600 605 Asn Met Glu Arg Ile Met Lys Ala Gln Ala Leu Arg Asp Asn Ser Thr 610 615 620 Met Gly Tyr Met Ala Ala Lys Lys His Leu Glu Ile Asn Pro Asp His 625 630 635 640 Ser Ile Ile Glu Thr Leu Arg Gln Lys Ala Glu Ala Asp Lys Asn Asp 645 650 655 Lys Ser Val Lys Asp Leu Val Ile Leu Leu Tyr Glu Thr Ala Leu Leu 660 665 670 Ser Ser Gly Phe Ser Leu Glu Asp Pro Gln Thr His Ala Asn Arg Ile 675 680 685 Tyr Arg Met Ile Lys Leu Gly Leu Gly Ile Asp Glu Asp Asp Pro Thr 690 695 700 Ala Asp Asp Thr Ser Ala Ala Val Thr Glu Glu Met Pro Pro Leu Glu 705 710 715 720 Gly Asp Asp Asp Thr Ser Arg Met Glu Glu Val Asp 725 730 11 2227 DNA Homo sapiens 11 gacgacctgt ctcgccgagc gcacgcttgc cgccgccccg cagaaatgct tcggttaccc 60 acagtctttc gccagatgag accggtgtcc agggtactgg ctcctcatct cactcgggct 120 tatgccaaag atgtaaaatt tggtgcagat gcccgagcct taatgcttca aggtgtagac 180 cttttagccg atgctgtggc cgttacaatg gggccaaagg gaagaacagt gattattgag 240 cagagttggg gaagtcccaa agtaacaaaa gatggtgtga ctgttgcaaa gtcaattgac 300 ttaaaagata aatacaagaa cattggagct aaacttgttc aagatgttgc caataacaca 360 aatgaagaag ctggggatgg cactaccact gctactgtac tggcacgctc tatagccaag 420 gaaggcttcg agaagattag caaaggtgct aatccagtgg aaatcaggag aggtgtgatg 480 ttagctgttg atgctgtaat tgctgaactt aaaaagcagt ctaaacctgt gaccacccct 540 gaagaaattg cacaggttgc tacgatttct gcaaacggag acaaagaaat tggcaatatc 600 atctctgatg caatgaaaaa agttggaaga aagggtgtca tcacagtaaa ggatggaaaa 660 acactgaatg atgaattaga aattattgaa ggcatgaagt ttgatcgagg ctatatttct 720 ccatacttta ttaatacatc aaaaggtcag aaatgtgaat tccaggatgc ctatgttctg 780 ttgagtgaaa agaaaatttc tagtatccag tccattgtac ctgctcttga aattgccaat 840 gctcaccgta agcctttggt cataatcgct gaagatgttg atggagaagc tctaagtaca 900 ctcgtcttga ataggctaaa ggttggtctt caggttgtgg cagtcaaggc tccagggttt 960 ggtgacaata gaaagaacca gcttaaagat atggctattg ctactggtgg tgcagtgttt 1020 ggagaagagg gattgaccct gaatcttgaa gacgttcagc ctcatgactt aggaaaagtt 1080 ggagaggtca ttgtgaccaa agacgatgcc atgctcttaa aaggaaaagg tgacaaggct 1140 caaattgaaa aacgtattca agaaatcatt gagcagttag atgtcacaac tagtgaatat 1200 gaaaaggaaa aactgaatga acggcttgca aaactttcag atggagtggc tgtgctgaag 1260 gttggtggga caagtgatgt tgaagtgaat gaaaagaaag acagagttac agatgccctt 1320 aatgctacaa gagctgctgt tgaagaaggc attgttttgg gagggggttg tgccctcctt 1380 cgatgcattc cagccttgga ctcattgact ccagctaatg aagatcaaaa aattggtata 1440 gaaattatta aaagaacact caaaattcca gcaatgacca ttgctaagaa tgcaggtgtt 1500 gaaggatctt tgatagttga gaaaattatg caaagttcct cagaagttgg ttatgatgct 1560 atggctggag attttgtgaa tatggtggaa aaaggaatca ttgacccaac aaaggttgtg 1620 agaactgctt tattggatgc tgctggtgtg gcctctctgt taactacagc agaagttgta 1680 gtcacagaaa ttcctaaaga agagaaggac cctggaatgg gtgcaatggg tggaatggga 1740 ggtggtatgg gaggtggcat gttctaactc ctagactagt gctttacctt tattaatgaa 1800 ctgtgacagg aagcccaagg cagtgttcct caccaataac ttcagagaag tcagttggag 1860 aaaatgaaga aaaaggctgg ctgaaaatca ctataaccat cagttactgg tttcagttga 1920 caaaatatat aatggtttac tgctgtcatt gtccatgcct acagataatt tattttgtat 1980 ttttgaataa aaaacatttg tacattcctg atactgggta caagagccat gtaccagtgt 2040 actgctttca acttaaatca ctgaggcatt tttactacta ttctgttaaa atcaggattt 2100 tagtgcttgc caccaccaga tgagaagtta agcagccttt ctgtggagag tgagaataat 2160 tgtgtacaaa gtagagaagt atccaattat gtgacaacct ttgtgtaata aaaatttgtt 2220 taaagtt 2227 12 573 PRT Homo sapiens 12 Met Leu Arg Leu Pro Thr Val Phe Arg Gln Met Arg Pro Val Ser Arg 1 5 10 15 Val Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe 20 25 30 Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala 35 40 45 Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile 50 55 60 Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val 65 70 75 80 Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys 85 90 95 Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly 100 105 110 Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe 115 120 125 Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val 130 135 140 Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys 145 150 155 160 Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala 165 170 175 Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys 180 185 190 Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn 195 200 205 Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile 210 215 220 Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln 225 230 235 240 Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser 245 250 255 Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val 260 265 270 Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu 275 280 285 Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly 290 295 300 Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr 305 310 315 320 Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp 325 330 335 Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys 340 345 350 Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu 355 360 365 Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu 370 375 380 Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly 385 390 395 400 Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu 405 410 415 Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val 420 425 430 Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile 435 440 445 Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly 450 455 460 Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala 465 470 475 480 Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln 485 490 495 Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn 500 505 510 Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala 515 520 525 Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Val 530 535 540 Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala 545 550 555 560 Met Gly Gly Met Gly Gly Gly Met Gly Gly Gly Met Phe 565 570 13 2376 DNA Homo sapiens 13 gaggaggagt ggggaccggg cggggggtgg aggaagaggc ctcgcgcaga ggagggagca 60 attgaatttc aaacacaaac aactcgacga gcgcgcaccc accgcgccgg agccttgccc 120 cgatccgcgc ccgccccgtc cgtgcggcgc gcgggcggag acgccgtggc cgcgccggag 180 ctcgggccgg gggccaccat cgaggcgggg gccgcgcgag ggccggagcg gagcggcgcc 240 gccaccgccg cacgcgcaaa cttgggctcg cgcttcccgg cccggcgcgg agcccggggc 300 gcccggagcc ccgccatgtc gcgatccaac cggcagaagg agtacaaatg cggggacctg 360 gtgttcgcca agatgaaggg ctacccacac tggccggccc ggattgacga gatgcctgag 420 gctgccgtga aatcaacagc caacaaatac caagtctttt ttttcgggac ccacgagacg 480 gcattcctgg gccccaaaga cctcttccct tacgaggaat ccaaggagaa gtttggcaag 540 cccaacaaga ggaaagggtt cagcgagggg ctgtgggaga tcgagaacaa ccctactgtc 600 aaggcttccg gctatcagtc ctcccagaaa aagagctgtg tggaagagcc tgaaccagag 660 cccgaagctg cagagggtga cggtgataag aaggggaatg cagagggcag cagcgacgag 720 gaagggaagc tggtcattga tgagccagcc aaggagaaga acgagaaagg agcgttgaag 780 aggagagcag gggacttgct ggaggactct cctaaacgtc ccaaggaggc agaaaaccct 840 gaaggagagg agaaggaggc agccaccttg gaggttgaga ggccccttcc tatggaggtg 900 gaaaagaata gcaccccctc tgagcccggc tctggccggg ggcctcccca agaggaagaa 960 gaagaggagg atgaagagga agaggctacc aaggaagatg ctgaggcccc aggcatcaga 1020 gatcatgaga gcctgtagcc accaatgttt caagaggagc ccccaccctg ttcctgctgc 1080 tgtctgggtg ctactgggga aactggccat ggcctgcaaa ctgggaaccc ctttcccacc 1140 ccaacctgct ctcctcttct actcactttt cccactccaa gcccagccca tggagattga 1200 cctggatggg gcaggccacc tggctctcac ctctaggtcc ccatactcct atgatctgag 1260 tcagagccat gtcttctccc tggaatgagt tgaggccact gtgttccttc cgcttggagc 1320 tattttccag gcttctgctg gggcctggga caactgctcc cacctcctga cacccttctc 1380 ccactctcct aggcattctg gacctctggg ttgggatcag gggtaggaat ggaaggatgg 1440 agcatcaaca gcagggtggg cttgtggggc ctgggagggg caatcctcaa atgcggggtg 1500 ggggcagcac aggagggcgg cctccttctg agctcctgtc ccctgctaca cctattatcc 1560 cagctgccta gattcaggga aagtgggaca gcttgtaggg gaggggctcc tttccataaa 1620 tccttgatga ttgacaacac ccatttttcc ttttgccgac cccaagagtt ttgggagttg 1680 tagttaatca tcaagagaat ttggggcttc caagttgttc gggccaagga cctgagacct 1740 gaagggttga ctttacccat ttgggtggga gtgttgagca tctgtccccc tttagatctc 1800 tgaagccaca aataggatgc ttgggaagac tcctagctgt cctttttcct ctccacacag 1860 tgctcaaggc cagcttatag tcatatatat cacccagaca taaaggaaaa gacacatttt 1920 ttaggaaatg tttttaataa aagaaaatta caaaaaaaaa ttttaaagac ccctaaccct 1980 ttgtgtgctc tccattctgc tccttcccca tcgttgcccc catttctgag gtgcactggg 2040 aggctcccct tctatttggg gcttgatgac tttctttttg tagctggggc tttgatgttc 2100 cttccagtgt catttctcat ccacataccc tgacctggcc ccctcagtgt tgtcaccaga 2160 tctgatttgt aacccactga gaggacagag agaaataagt gccctctccc accctcttcc 2220 tactggtctc tctatgcctc tctacagtct cgtctctttt accctggccc ctctcccttg 2280 ggctctgatg aaaaattgct gactgtagct ttggaagttt agctctgaga accgtagatg 2340 atttcagttc taggaaaata aaacccgttg attact 2376 14 240 PRT Homo sapiens 14 Met Ser Arg Ser Asn Arg Gln Lys Glu Tyr Lys Cys Gly Asp Leu Val 1 5 10 15 Phe Ala Lys Met Lys Gly Tyr Pro His Trp Pro Ala Arg Ile Asp Glu 20 25 30 Met Pro Glu Ala Ala Val Lys Ser Thr Ala Asn Lys Tyr Gln Val Phe 35 40 45 Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp Leu Phe 50 55 60 Pro Tyr Glu Glu Ser Lys Glu Lys Phe Gly Lys Pro Asn Lys Arg Lys 65 70 75 80 Gly Phe Ser Glu Gly Leu Trp Glu Ile Glu Asn Asn Pro Thr Val Lys 85 90 95 Ala Ser Gly Tyr Gln Ser Ser Gln Lys Lys Ser Cys Val Glu Glu Pro 100 105 110 Glu Pro Glu Pro Glu Ala Ala Glu Gly Asp Gly Asp Lys Lys Gly Asn 115 120 125 Ala Glu Gly Ser Ser Asp Glu Glu Gly Lys Leu Val Ile Asp Glu Pro 130 135 140 Ala Lys Glu Lys Asn Glu Lys Gly Ala Leu Lys Arg Arg Ala Gly Asp 145 150 155 160 Leu Leu Glu Asp Ser Pro Lys Arg Pro Lys Glu Ala Glu Asn Pro Glu 165 170 175 Gly Glu Glu Lys Glu Ala Ala Thr Leu Glu Val Glu Arg Pro Leu Pro 180 185 190 Met Glu Val Glu Lys Asn Ser Thr Pro Ser Glu Pro Gly Ser Gly Arg 195 200 205 Gly Pro Pro Gln Glu Glu Glu Glu Glu Glu Asp Glu Glu Glu Glu Ala 210 215 220 Thr Lys Glu Asp Ala Glu Ala Pro Gly Ile Arg Asp His Glu Ser Leu 225 230 235 240 15 3689 DNA Homo sapiens 15 aagatctcat aaaatctatg ctgaggaatg agcgacagtt caaggaggag aagcttgcag 60 agcagctcaa gcaagctgag gagctcaggc aatataaagt cctggttcac gctcaggaac 120 gagagctgac ccagttaagg gagaagttgc gggaagggag agatgcctcc cgctcattga 180 atgagcatct ccaggccctc ctcactccgg atgagccgga caagtcccag gggcaggacc 240 tccaagaaca gctggctgag gggtgtagac tggcacagca ccttgtccaa aagctcagcc 300 cagaaaatga caacgatgac gatgaagatg ttcaagttga ggtggctgag aaagtgcaga 360 aatcgtctgc ccccagggag atgcagaagg ctgaagaaaa ggaagtccct gaggactcac 420 tggaggaatg tgccatcact tgttcaaata gccatggccc ttatgactcc aaccagccac 480 ataggaaaac caaaatcaca tttgaggaag acaaagtcga ctcaactctc attggctcat 540 cctctcatgt tgaatgggag gatgctgtac acattattcc agaaaatgaa agtgatgatg 600 aggaagagga agaaaaagga ccagtgtctc ccaggaatct gcaggagtct gaagaggagg 660 aagtccccca ggagtcctgg gatgaaggtt attcgactct ctcaattcct cctgaaatgt 720 tggcctcgta caagtcttac agcagcacat ttcactcatt agaggaacag caagtctgca 780 tggctgttga cataggcaga catcggtggg atcaagtgaa aaaggaggac cacgaggcaa 840 caggtcccag gctcagcaga gagctgctgg atgagaaagg gcctgaagtc ttgcaggact 900 cactggatag atgttattca actccttcag gttgtcttga actgactgac tcatgccagc 960 cctacagaag tgccttttac gtattggagc aacagcgtgt tggcttggct gttaacatgg 1020 atgaaattga aaagtaccaa gaagtggaag aagaccaaga cccatcatgc cccaggctca 1080 gcagggagct gctggatgag aaagagcctg aagtcttgca ggactcactg ggtagatgtt 1140 attcgactcc ttcaggttat cttgaactgc ctgacttagg ccagccctac agcagtgctg 1200 tttactcatt ggaggaacag taccttggct tggctcttga cgtggacaga attaaaaagg 1260 accaagaaga ggaagaagac caaggcccac catgccccag gctcagcagg gagctgctgg 1320 aggtagtaga gcctgaagtc ttgcaggact cactggatag atgttattca actccttcca 1380 gttgtcttga acagcctgac tcctgccagc cctatggaag ttccttttat gcattggagg 1440 aaaagcatgt tggcttttct cttgacgtgg gagaaattga aaagaagggg aaggggaaga 1500 aaagaagggg aagaagatca aagaaggaaa gaagaagggg aagaaaagaa ggggaagaag 1560 atcaaaaccc accatgcccc aggctcagca gggagctgct ggatgagaaa gggcctgaag 1620 tcttgcagga ctcactggat agatgttatt caactccttc aggttgtctt gaactgactg 1680 actcatgcca gccctacaga agtgcctttt acatattgga gcaacagcgt gttggcttgg 1740 ctgttgacat ggatgaaatt gaaaagtacc aagaagtgga agaagaccaa gacccatcat 1800 gccccaggct cagcggggag ctgttggatg agaaagagcc tgaagtcttg caggagtcac 1860 tggatagatg ctattcaact ccttcaggtt gtcttgaact gactgactca tgccagccct 1920 acagaagtgc cttttacata ttggagcaac agcgtgttgg cttggctgtt gacatggatg 1980 aaattgaaaa gtaccaagaa gtggaagaag accaagaccc atcatgcccc aggctcagca 2040 gggagctgct ggatgagaaa gagcctgaag tcttgcagga ctcactgggt agatgttatt 2100 cgactccttc aggttatctt gaactgcctg acttaggcca gccctacagc agtgctgttt 2160 actcattgga ggaacagtac cttggcttgg ctcttgacgt ggacagaatt aaaaaggacc 2220 aagaagagga agaagaccaa ggcccaccat gccccaggct cagcagggag ctgctggagg 2280 tagtagagcc tgaagtcttg caggactcac tggatagatg ttattcaact ccttccagtt 2340 gtcttgaaca gcctgactcc tgccagccct atggaagttc cttttatgca ttggaggaaa 2400 aacatgttgg cttttctctt gacgtgggag aaattgaaaa gaaggggaag gggaagaaaa 2460 gaaggggaag aagatcaaag aaggaaagaa gaaggggaag aaaagaaggg gaagaagatc 2520 aaaacccacc atgccccagg ctcaacagca tgctgatgga agtggaagag cctgaagtct 2580 tgcaggactc actggatata tgttattcga ctccgtcaat gtactttgaa ctacctgact 2640 cattccagca ctacagaagt gtgttttact catttgagga agagcatatc agcttcgccc 2700 tttacgtgga caataggttt tttactttga cggtgacaag tctccacctg gtgttccaga 2760 tgggagtcat attcccacaa taagcagccc ttactaagcc gagaggtgtc attcctgcag 2820 gcaggaccta taggcacgtg aagatttgaa tgaaagtaca gttccatttg gaagcccaga 2880 cataggatgg gtcagtgggc atggctctat tcctattctc aaaccatgcc agtggcaacc 2940 tgtgctcagt ctgaagacaa tggacccacg ttaggtgtga cacgttcaca taactgtgca 3000 gcacatgccg ggagtgatca gtcagacatt ttaatttgaa ccacgtatct ctgggtagct 3060 acaaaattcc tcagggatgt cattttgcag gcatgtctct gagcttctat acctgctcaa 3120 ggtcattgtc atctttgtgt ttagctcatc caaaggtgtt accctggttt caatgaacct 3180 aacctcattc tttgtgtctt cagtgttggc ttgttttagc tgatccatct gtaacacagg 3240 agggatcctt ggctgaggat tgtatttcag aaccaccaac tgctcttgac aattgttaac 3300 ccgctaggct cctttggtta gagaagccac agtccttcag cctccaattg gtgtcagtac 3360 ttaggaagac cacagctaga tggacaaaca gcattgggag gccttagccc tgctcctctc 3420 aattccatcc tgtagagaac aggagtcagg agccgctggc aggagacagc atgtcaccca 3480 ggactctgcc ggtgcagaat atgagcaatg ccatgttctt gcagaaaacg cttaacctga 3540 gtttcatagg aggtaatcac cagacaactg cagaatgtag aacactgagc aggacaactg 3600 acctgtctcc ttcacatagt ccatatcacc acaaatcaca caacaaaaag gagaagagat 3660 attttcggtt gaaaaaaagt aaaaagata 3689 16 921 PRT Homo sapiens 16 Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln 1 5 10 15 Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu Val His Ala 20 25 30 Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu Gly Arg 35 40 45 Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu Leu Thr Pro 50 55 60 Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln Leu Ala 65 70 75 80 Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu Ser Pro Glu 85 90 95 Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val Ala Glu Lys 100 105 110 Val Gln Lys Ser Ser Ala Pro Arg Glu Met Gln Lys Ala Glu Glu Lys 115 120 125 Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn 130 135 140 Ser His Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile 145 150 155 160 Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser 165 170 175 His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser 180 185 190 Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu 195 200 205 Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly 210 215 220 Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Lys Ser 225 230 235 240 Tyr Ser Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala 245 250 255 Val Asp Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp His 260 265 270 Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly 275 280 285 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 290 295 300 Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe 305 310 315 320 Tyr Val Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asn Met Asp Glu 325 330 335 Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro 340 345 350 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln 355 360 365 Asp Ser Leu Gly Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 370 375 380 Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu 385 390 395 400 Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln 405 410 415 Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu 420 425 430 Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 435 440 445 Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln 450 455 460 Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe 465 470 475 480 Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg 485 490 495 Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly 500 505 510 Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu 515 520 525 Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 530 535 540 Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr 545 550 555 560 Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Leu Ala Val 565 570 575 Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp 580 585 590 Pro Ser Cys Pro Arg Leu Ser Gly Glu Leu Leu Asp Glu Lys Glu Pro 595 600 605 Glu Val Leu Gln Glu Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly 610 615 620 Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr 625 630 635 640 Ile Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile 645 650 655 Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg 660 665 670 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 675 680 685 Ser Leu Gly Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 690 695 700 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln 705 710 715 720 Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu 725 730 735 Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu 740 745 750 Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 755 760 765 Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro 770 775 780 Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser 785 790 795 800 Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg 805 810 815 Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu 820 825 830 Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Asn Ser Met Leu Met Glu 835 840 845 Val Glu Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Ile Cys Tyr Ser 850 855 860 Thr Pro Ser Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg 865 870 875 880 Ser Val Phe Tyr Ser Phe Glu Glu Glu His Ile Ser Phe Ala Leu Tyr 885 890 895 Val Asp Asn Arg Phe Phe Thr Leu Thr Val Thr Ser Leu His Leu Val 900 905 910 Phe Gln Met Gly Val Ile Phe Pro Gln 915 920 17 664 DNA Homo sapiens 17 aacccaatga tcctgcagca gcccttgcag cgaggccccc agggaggggc ccagcgcctc 60 ccgcgggccg ccttgggggt gacttggggc ctggacgcca gctcccctct ccgaggagct 120 gtgcccatga gcaccaagcg gcgcctggag gaggagcagg agcctctgcg caagcagttt 180 ctgtctgagg agaacatggc cacccacttc tctcaactca gcctgcacaa tgaccacccc 240 tactgcagcc cccccatgac cttctcccca gccctgcccc cactcaggag cccttgctct 300 gagctgcttc tctggcgcta tcctggcagc ctcatccctg aggccctccg tctgctgagg 360 ctgggggaca cccccagtcc cccctaccct gcaaccccag ctggggacat aatggagctc 420 tgagtgctgg tggacagtgc ccctcccacc ttccttcttc cccacaacag aagagaccag 480 cgactcccgc aaagggacaa ggttcctccc tctcctgcag agtaggcatc tgggcaccaa 540 gaccttccct caacagagga cactgagccc aacggagttc tgggatggga ggggtgggag 600 catgggaagg gaggcatccc acccccaaga agaactgaat aaagattgct gagcaaagga 660 aggc 664 18 138 PRT Homo sapiens 18 Met Ile Leu Gln Gln Pro Leu Gln Arg Gly Pro Gln Gly Gly Ala Gln 1 5 10 15 Arg Leu Pro Arg Ala Ala Leu Gly Val Thr Trp Gly Leu Asp Ala Ser 20 25 30 Ser Pro Leu Arg Gly Ala Val Pro Met Ser Thr Lys Arg Arg Leu Glu 35 40 45 Glu Glu Gln Glu Pro Leu Arg Lys Gln Phe Leu Ser Glu Glu Asn Met 50 55 60 Ala Thr His Phe Ser Gln Leu Ser Leu His Asn Asp His Pro Tyr Cys 65 70 75 80 Ser Pro Pro Met Thr Phe Ser Pro Ala Leu Pro Pro Leu Arg Ser Pro 85 90 95 Cys Ser Glu Leu Leu Leu Trp Arg Tyr Pro Gly Ser Leu Ile Pro Glu 100 105 110 Ala Leu Arg Leu Leu Arg Leu Gly Asp Thr Pro Ser Pro Pro Tyr Pro 115 120 125 Ala Thr Pro Ala Gly Asp Ile Met Glu Leu 130 135 19 2056 DNA Homo sapiens 19 ggaaccgcgg ctgctggaca agaggggtgc ggtggatact gacctttgct ccggcctcgt 60 cgtgaagaca cagcgcatct ccccgctgta ggcttctccc acagaacccg tttcgggcct 120 cagagcgtct ggtgagatgc tgttgccgct gctgctgctg ctacccatgt gctgggccgt 180 ggaggtcaag aggccccggg gcgtctccct caccaatcat cacttctacg atgagtccaa 240 gcctttcacc tgcctggacg gttcggccac catcccattt gatcaggtca acgatgacta 300 ttgcgactgc aaagatggct ctgacgagcc aggcacggct gcctgtccta atggcagctt 360 ccactgcacc aacactggct ataagcccct gtatatcccc tccaaccggg tcaacgatgg 420 tgtttgtgac tgctgcgatg gaacagacga gtacaacagc ggcgtcatct gtgagaacac 480 ctgcaaagag aagggccgta aggagagaga gtccctgcag cagatggccg aggtcacccg 540 cgaagggttc cgtctgaaga agatccttat tgaggactgg aagaaggcac gggaggagaa 600 gcagaaaaag ctcattgagc tacaggctgg gaagaagtct ctggaagacc aggtggagat 660 gctgcggaca gtgaaggagg aagctgagaa gccagagaga gaggccaaag agcagcacca 720 gaagctgtgg gaagagcagc tggctgctgc caaggcccaa caggagcagg agctggcggc 780 tgatgccttc aaggagctgg atgatgacat ggacgggacg gtctcggtga ctgagctgca 840 gactcacccg gagctggaca cagatgggga tggggcgttg tcagaagcgg aagctcaggc 900 cctcctcagt ggggacacac agacagacgc cacctctttc tacgaccgcg tctgggccgc 960 catcagggac aagtaccggt ccgaggcact gcccaccgac cttccagcac cttctgcccc 1020 tgacttgacg gagcccaagg aggagcagcc gccagtgccc tcgtcgccca cagaggagga 1080 ggaggaggag gaggaggagg aagaagaggc tgaagaagag gaggaggagg aggattccga 1140 ggaggcccca ccgccactgt cacccccgca gccggccagc cctgctgagg aagacaaaat 1200 gccgccctac gacgagcaga cgcaggcctt catcgatgct gcccaggagg cccgcaacaa 1260 gttcgaggag gccgagcggt cgctgaagga catggaggag tccatcagga acctggagca 1320 agagatttct tttgactttg gccccaacgg ggagtttgct tacctgtaca gccagtgcta 1380 cgagctcacc accaacgaat acgtctaccg cctctgcccc ttcaagcttg tctcgcagaa 1440 acccaaactc gggggctctc ccaccagcct tggcacctgg ggctcatgga ttggccccga 1500 ccacgacaag ttcagtgcca tgaagtatga gcaaggcacg ggctgctggc agggccccaa 1560 ccgctccacc accgtgcgcc tcctgtgcgg gaaagagacc atggtgacca gcaccacaga 1620 gcccagtcgc tgcgagtacc tcatggagct gatgacgcca gccgcctgcc cggagccacc 1680 gcctgaagca cccaccgaag acgaccatga cgagctctag ctggatgggc gcagagaacc 1740 tcaagaaggc atgaagccag cccctgcagt gccgtccacc cgcccctctg ggcctgcctg 1800 tggctctgtt gccctcctct gtggcggcag gacctttgtg gggcttcgtg ccctgctctg 1860 gggcccaggc ggggctggtc cacattccca ggccccaaca gcctccaaag atgggtaaag 1920 gagcttgccc tccctgggcc ccccaccttg gtgactcgcc ccaccacccc cagccctgtc 1980 cctgccaccc ctcctagtgg ggactagtga atgacttgac ctgtgacctc aatacaataa 2040 atgtgatccc ccaccc 2056 20 527 PRT Homo sapiens 20 Met Leu Leu Pro Leu Leu Leu Leu Leu Pro Met Cys Trp Ala Val Glu 1 5 10 15 Val Lys Arg Pro Arg Gly Val Ser Leu Thr Asn His His Phe Tyr Asp 20 25 30 Glu Ser Lys Pro Phe Thr Cys Leu Asp Gly Ser Ala Thr Ile Pro Phe 35 40 45 Asp Gln Val Asn Asp Asp Tyr Cys Asp Cys Lys Asp Gly Ser Asp Glu 50 55 60 Pro Gly Thr Ala Ala Cys Pro Asn Gly Ser Phe His Cys Thr Asn Thr 65 70 75 80 Gly Tyr Lys Pro Leu Tyr Ile Pro Ser Asn Arg Val Asn Asp Gly Val 85 90 95 Cys Asp Cys Cys Asp Gly Thr Asp Glu Tyr Asn Ser Gly Val Ile Cys 100 105 110 Glu Asn Thr Cys Lys Glu Lys Gly Arg Lys Glu Arg Glu Ser Leu Gln 115 120 125 Gln Met Ala Glu Val Thr Arg Glu Gly Phe Arg Leu Lys Lys Ile Leu 130 135 140 Ile Glu Asp Trp Lys Lys Ala Arg Glu Glu Lys Gln Lys Lys Leu Ile 145 150 155 160 Glu Leu Gln Ala Gly Lys Lys Ser Leu Glu Asp Gln Val Glu Met Leu 165 170 175 Arg Thr Val Lys Glu Glu Ala Glu Lys Pro Glu Arg Glu Ala Lys Glu 180 185 190 Gln His Gln Lys Leu Trp Glu Glu Gln Leu Ala Ala Ala Lys Ala Gln 195 200 205 Gln Glu Gln Glu Leu Ala Ala Asp Ala Phe Lys Glu Leu Asp Asp Asp 210 215 220 Met Asp Gly Thr Val Ser Val Thr Glu Leu Gln Thr His Pro Glu Leu 225 230 235 240 Asp Thr Asp Gly Asp Gly Ala Leu Ser Glu Ala Glu Ala Gln Ala Leu 245 250 255 Leu Ser Gly Asp Thr Gln Thr Asp Ala Thr Ser Phe Tyr Asp Arg Val 260 265 270 Trp Ala Ala Ile Arg Asp Lys Tyr Arg Ser Glu Ala Leu Pro Thr Asp 275 280 285 Leu Pro Ala Pro Ser Ala Pro Asp Leu Thr Glu Pro Lys Glu Glu Gln 290 295 300 Pro Pro Val Pro Ser Ser Pro Thr Glu Glu Glu Glu Glu Glu Glu Glu 305 310 315 320 Glu Glu Glu Glu Ala Glu Glu Glu Glu Glu Glu Glu Asp Ser Glu Glu 325 330 335 Ala Pro Pro Pro Leu Ser Pro Pro Gln Pro Ala Ser Pro Ala Glu Glu 340 345 350 Asp Lys Met Pro Pro Tyr Asp Glu Gln Thr Gln Ala Phe Ile Asp Ala 355 360 365 Ala Gln Glu Ala Arg Asn Lys Phe Glu Glu Ala Glu Arg Ser Leu Lys 370 375 380 Asp Met Glu Glu Ser Ile Arg Asn Leu Glu Gln Glu Ile Ser Phe Asp 385 390 395 400 Phe Gly Pro Asn Gly Glu Phe Ala Tyr Leu Tyr Ser Gln Cys Tyr Glu 405 410 415 Leu Thr Thr Asn Glu Tyr Val Tyr Arg Leu Cys Pro Phe Lys Leu Val 420 425 430 Ser Gln Lys Pro Lys Leu Gly Gly Ser Pro Thr Ser Leu Gly Thr Trp 435 440 445 Gly Ser Trp Ile Gly Pro Asp His Asp Lys Phe Ser Ala Met Lys Tyr 450 455 460 Glu Gln Gly Thr Gly Cys Trp Gln Gly Pro Asn Arg Ser Thr Thr Val 465 470 475 480 Arg Leu Leu Cys Gly Lys Glu Thr Met Val Thr Ser Thr Thr Glu Pro 485 490 495 Ser Arg Cys Glu Tyr Leu Met Glu Leu Met Thr Pro Ala Ala Cys Pro 500 505 510 Glu Pro Pro Pro Glu Ala Pro Thr Glu Asp Asp His Asp Glu Leu 515 520 525 21 384 DNA Homo sapiens 21 atgcctaaat caaaggaact tgtttcttca agctcttctg gcagtgattc tgacagtgag 60 gttgacaaaa agttaaagag gaaaaagcaa gttgctccag aaaaacctgt aaagaaacaa 120 aagacaggtg agacttcgag agccctgtca tcttctaaac agagcagcag cagcagagat 180 gataacatgt ttcagattgg gaaaatgagg tacgttagtg ttcgcgattt taaaggcaaa 240 gtgctaattg atattagaga atattggatg gatcctgaag gtgaaatgaa accaggaaga 300 aaaggtattt ctttaaatcc agaacaatgg agccagctga aggaacagat ctctgatata 360 gatgacgcag taagaaagct gtga 384 22 127 PRT Homo sapiens 22 Met Pro Lys Ser Lys Glu Leu Val Ser Ser Ser Ser Ser Gly Ser Asp 1 5 10 15 Ser Asp Ser Glu Val Asp Lys Lys Leu Lys Arg Lys Lys Gln Val Ala 20 25 30 Pro Glu Lys Pro Val Lys Lys Gln Lys Thr Gly Glu Thr Ser Arg Ala 35 40 45 Leu Ser Ser Ser Lys Gln Ser Ser Ser Ser Arg Asp Asp Asn Met Phe 50 55 60 Gln Ile Gly Lys Met Arg Tyr Val Ser Val Arg Asp Phe Lys Gly Lys 65 70 75 80 Val Leu Ile Asp Ile Arg Glu Tyr Trp Met Asp Pro Glu Gly Glu Met 85 90 95 Lys Pro Gly Arg Lys Gly Ile Ser Leu Asn Pro Glu Gln Trp Ser Gln 100 105 110 Leu Lys Glu Gln Ile Ser Asp Ile Asp Asp Ala Val Arg Lys Leu 115 120 125 23 1554 DNA Homo sapiens 23 gaccacaatg gcggccgcca ccctgctgcg cgcgacgccc cacttcagcg gtctcgccgc 60 cggccggacc ttcctgctgc agggtctgtt gcggctgctg aaagccccgg cattgcctct 120 cttgtgccgc ggcctggccg tggaggccaa gaagacttac gtgcgcgaca agccacatgt 180 gaatgtgggt accatcggcc atgtggacca cgggaagacc acgctgactg cagccatcac 240 gaagattcta gctgagggag gtggggctaa gttcaagaag tacgaggaga ttgacaatgc 300 cccggaggag cgagctcggg gtatcaccat caatgcggct catgtggagt atagcactgc 360 cgcccgccac tacgcccaca cagactgccc gggtcatgca gattatgtta agaatatgat 420 cacaggcact gcacccctcg acggctgcat cctggtggta gcagccaatg acggccccat 480 gccccagacc cgagagcact tattactggc cagacagatt ggggtggagc atgtggtggt 540 gtatgtgaac aaggctgacg ctgtccagga ctctgagatg gtggaactgg tggaactgga 600 gatccgggag ctgctcaccg agtttggcta taaaggggag gagaccccag tcatcgtagg 660 ctctgctctc tgtgcccttg agggtcggga ccctgagtta ggcctgaagt ctgtgcagaa 720 gctactggat gctgtggaca cttacatccc agtgcccgcc cgggacctgg agaagccttt 780 cctgctgcct gtggaggcgg tgtactccgt ccctggccgt ggcaccgtgg tgacaggtac 840 actagagcgt ggcattttaa agaagggaga cgagtgtgag ctcctaggac atagcaagaa 900 catccgcact gtggtgacag gcattgagat gttccacaag agcctggaga gggccgaggc 960 cggagataac ctcggggccc tggtccgagg cttgaagcgg gaggacttgc ggcggggcct 1020 ggtcatggtc aagccaggtt ccatcaagcc ccaccagaag gtggaggccc aggtttacat 1080 cctcagcaag gaggaaggtg gccgccacaa gccctttgtg tcccacttca tgcctgtcat 1140 gttctccctg acttggaaca tggcctgtcg gattatcctg cccccagaga aggagcttgc 1200 catgcccggg gaggacctga agttcaacct aatcttgcgg cagccaatga tcttagagaa 1260 aggccagcgt ttcaccctgc gagatggcaa ccggactatt ggcaccggtc tagtcaccaa 1320 cacgctggcc atgactgagg aggagaagaa tatcaaatgg ggttgagtgt gcagatctct 1380 gctcagcttc ccttgcgttt aaggcctgcc ctagccaggg ctccctcctg cttccagtac 1440 cctctcatgg cataggctgc aacccagcag agggcagcta gatggacatt tcccctgctc 1500 ggaagggttg gcctgcctgg ctggggaggt cagtaaactt tgaatagtaa gcca 1554 24 452 PRT Homo sapiens 24 Met Ala Ala Ala Thr Leu Leu Arg Ala Thr Pro His Phe Ser Gly Leu 1 5 10 15 Ala Ala Gly Arg Thr Phe Leu Leu Gln Gly Leu Leu Arg Leu Leu Lys 20 25 30 Ala Pro Ala Leu Pro Leu Leu Cys Arg Gly Leu Ala Val Glu Ala Lys 35 40 45 Lys Thr Tyr Val Arg Asp Lys Pro His Val Asn Val Gly Thr Ile Gly 50 55 60 His Val Asp His Gly Lys Thr Thr Leu Thr Ala Ala Ile Thr Lys Ile 65 70 75 80 Leu Ala Glu Gly Gly Gly Ala Lys Phe Lys Lys Tyr Glu Glu Ile Asp 85 90 95 Asn Ala Pro Glu Glu Arg Ala Arg Gly Ile Thr Ile Asn Ala Ala His 100 105 110 Val Glu Tyr Ser Thr Ala Ala Arg His Tyr Ala His Thr Asp Cys Pro 115 120 125 Gly His Ala Asp Tyr Val Lys Asn Met Ile Thr Gly Thr Ala Pro Leu 130 135 140 Asp Gly Cys Ile Leu Val Val Ala Ala Asn Asp Gly Pro Met Pro Gln 145 150 155 160 Thr Arg Glu His Leu Leu Leu Ala Arg Gln Ile Gly Val Glu His Val 165 170 175 Val Val Tyr Val Asn Lys Ala Asp Ala Val Gln Asp Ser Glu Met Val 180 185 190 Glu Leu Val Glu Leu Glu Ile Arg Glu Leu Leu Thr Glu Phe Gly Tyr 195 200 205 Lys Gly Glu Glu Thr Pro Val Ile Val Gly Ser Ala Leu Cys Ala Leu 210 215 220 Glu Gly Arg Asp Pro Glu Leu Gly Leu Lys Ser Val Gln Lys Leu Leu 225 230 235 240 Asp Ala Val Asp Thr Tyr Ile Pro Val Pro Ala Arg Asp Leu Glu Lys 245 250 255 Pro Phe Leu Leu Pro Val Glu Ala Val Tyr Ser Val Pro Gly Arg Gly 260 265 270 Thr Val Val Thr Gly Thr Leu Glu Arg Gly Ile Leu Lys Lys Gly Asp 275 280 285 Glu Cys Glu Leu Leu Gly His Ser Lys Asn Ile Arg Thr Val Val Thr 290 295 300 Gly Ile Glu Met Phe His Lys Ser Leu Glu Arg Ala Glu Ala Gly Asp 305 310 315 320 Asn Leu Gly Ala Leu Val Arg Gly Leu Lys Arg Glu Asp Leu Arg Arg 325 330 335 Gly Leu Val Met Val Lys Pro Gly Ser Ile Lys Pro His Gln Lys Val 340 345 350 Glu Ala Gln Val Tyr Ile Leu Ser Lys Glu Glu Gly Gly Arg His Lys 355 360 365 Pro Phe Val Ser His Phe Met Pro Val Met Phe Ser Leu Thr Trp Asn 370 375 380 Met Ala Cys Arg Ile Ile Leu Pro Pro Glu Lys Glu Leu Ala Met Pro 385 390 395 400 Gly Glu Asp Leu Lys Phe Asn Leu Ile Leu Arg Gln Pro Met Ile Leu 405 410 415 Glu Lys Gly Gln Arg Phe Thr Leu Arg Asp Gly Asn Arg Thr Ile Gly 420 425 430 Thr Gly Leu Val Thr Asn Thr Leu Ala Met Thr Glu Glu Glu Lys Asn 435 440 445 Ile Lys Trp Gly 450 25 2201 DNA Homo sapiens 25 tttttttttt cgtcttagcc acgcagaagt cgcgtgtcta gtttgtttcg acgccggacc 60 gcgtaagaga cgatgatgtt gggcacggaa ggtggagagg gattcgtggt gaaggtccgg 120 ggcttgccct ggtcttgctc ggccgatgaa gtgcagaggt ttttttctga ctgcaaaatt 180 caaaatgggg ctcaaggtat tcgtttcatc tacaccagag aaggcagacc aagtggcgag 240 gcttttgttg aacttgaatc agaagatgaa gtcaaattgg ccctgaaaaa agacagagaa 300 actatgggac acagatatgt tgaagtattc aagtcaaaca acgttgaaat ggattgggtg 360 ttgaagcata ctggtccaaa tagtcctgac acggccaatg atggctttgt acggcttaga 420 ggacttccct ttggatgtag caaggaagaa attgttcagt tcttctcagg gttggaaatc 480 gtgccaaatg ggataacatt gccggtggac ttccagggga ggagtacggg ggaggccttc 540 gtgcagtttg cttcacagga aatagctgaa aaggctctaa agaaacacaa ggaaagaata 600 gggcacaggt atattgaaat ctttaagagc agtagagctg aagttagaac tcattatgat 660 ccaccacgaa agcttatggc catgcagcgg ccaggtcctt atgacagacc tggggctggt 720 agagggtata acagcattgg cagaggagct ggctttgaga ggatgaggcg tggtgcttat 780 ggtggaggct atggaggcta tgatgattac aatggctata atgatggcta tggatttggg 840 tcagatagat ttggaagaga cctcaattac tgtttttcag gaatgtctga tcacagatac 900 ggggatggtg gctctacttt ccagagcaca acaggacact gtgtacacat gcggggatta 960 ccttacagag ctactgagaa tgacatttat aatttttttt caccgctcaa ccctgtgaga 1020 gtacacattg aaattggtcc tgatggcaga gtaactggtg aagcagatgt cgagttcgca 1080 actcatgaag atgctgtggc agctatgtca aaagacaaag caaatatgca acacagatat 1140 gtagaactct tcttgaattc tacagcagga gcaagcggtg gtgcttacga acacagatat 1200 gtagaactct tcttgaattc tacagcagga gcaagcggtg gtgcttatgg tagccaaatg 1260 atgggaggca tgggcttgtc aaaccagtcc agctacgggg gcccagccag ccagcagctg 1320 agtgggggtt acggaggcgg ctacggtggc cagagcagca tgagtggata cgaccaagtt 1380 ttacaggaaa actccagtga ttttcaatca aacattgcat aggtaaccaa ggagcagtga 1440 acagcagcta ctacagtagt ggaagccgtg catctatggg cgtgaacgga atgggagggt 1500 tgtctagcat gtccagtatg agtggtggat ggggaatgta attgatcgat cctgatcact 1560 gactcttggt caaccttttt tttttttttt ttttctttaa gaaaacttca gtttaacagt 1620 ttctgcaata caagcttgtg atttatgctt actctaagtg gaaatcagga ttgttatgaa 1680 gacttaaggc ccagtatttt tgaatacaat actcatctag gatgtaacag tgaagctgag 1740 taaactataa ctgttaaact taagttccag cttttctcaa gttagttata ggatgtactt 1800 aagcagtaag cgtatttagg taaaagcagt tgaattatgt taaatgttgc cctttgccac 1860 gttaaattga acactgtttt ggatgcatgt tgaaagacat gcttttattt tttttgtaaa 1920 acaatatagg agctgtgtct actattaaaa gtgaaacatt ttggcatgtt tgttaattct 1980 agtttcattt aataacctgt aaggcacgta agtttaagct tttttttttt ttaagttaat 2040 gggaaaaatt tgagacgcaa taccaatact taggattttg gtcttggtgt ttgtatgaaa 2100 ttctgaggcc ttgatttaaa tctttcattg tattgtgatt tccttttagg tatattgcgc 2160 taagtgaaac ttgtcaaata aatcctcctt ttaaaaactg c 2201 26 449 PRT Homo sapiens 26 Met Met Leu Gly Thr Glu Gly Gly Glu Gly Phe Val Val Lys Val Arg 1 5 10 15 Gly Leu Pro Trp Ser Cys Ser Ala Asp Glu Val Gln Arg Phe Phe Ser 20 25 30 Asp Cys Lys Ile Gln Asn Gly Ala Gln Gly Ile Arg Phe Ile Tyr Thr 35 40 45 Arg Glu Gly Arg Pro Ser Gly Glu Ala Phe Val Glu Leu Glu Ser Glu 50 55 60 Asp Glu Val Lys Leu Ala Leu Lys Lys Asp Arg Glu Thr Met Gly His 65 70 75 80 Arg Tyr Val Glu Val Phe Lys Ser Asn Asn Val Glu Met Asp Trp Val 85 90 95 Leu Lys His Thr Gly Pro Asn Ser Pro Asp Thr Ala Asn Asp Gly Phe 100 105 110 Val Arg Leu Arg Gly Leu Pro Phe Gly Cys Ser Lys Glu Glu Ile Val 115 120 125 Gln Phe Phe Ser Gly Leu Glu Ile Val Pro Asn Gly Ile Thr Leu Pro 130 135 140 Val Asp Phe Gln Gly Arg Ser Thr Gly Glu Ala Phe Val Gln Phe Ala 145 150 155 160 Ser Gln Glu Ile Ala Glu Lys Ala Leu Lys Lys His Lys Glu Arg Ile 165 170 175 Gly His Arg Tyr Ile Glu Ile Phe Lys Ser Ser Arg Ala Glu Val Arg 180 185 190 Thr His Tyr Asp Pro Pro Arg Lys Leu Met Ala Met Gln Arg Pro Gly 195 200 205 Pro Tyr Asp Arg Pro Gly Ala Gly Arg Gly Tyr Asn Ser Ile Gly Arg 210 215 220 Gly Ala Gly Phe Glu Arg Met Arg Arg Gly Ala Tyr Gly Gly Gly Tyr 225 230 235 240 Gly Gly Tyr Asp Asp Tyr Asn Gly Tyr Asn Asp Gly Tyr Gly Phe Gly 245 250 255 Ser Asp Arg Phe Gly Arg Asp Leu Asn Tyr Cys Phe Ser Gly Met Ser 260 265 270 Asp His Arg Tyr Gly Asp Gly Gly Ser Thr Phe Gln Ser Thr Thr Gly 275 280 285 His Cys Val His Met Arg Gly Leu Pro Tyr Arg Ala Thr Glu Asn Asp 290 295 300 Ile Tyr Asn Phe Phe Ser Pro Leu Asn Pro Val Arg Val His Ile Glu 305 310 315 320 Ile Gly Pro Asp Gly Arg Val Thr Gly Glu Ala Asp Val Glu Phe Ala 325 330 335 Thr His Glu Asp Ala Val Ala Ala Met Ser Lys Asp Lys Ala Asn Met 340 345 350 Gln His Arg Tyr Val Glu Leu Phe Leu Asn Ser Thr Ala Gly Ala Ser 355 360 365 Gly Gly Ala Tyr Glu His Arg Tyr Val Glu Leu Phe Leu Asn Ser Thr 370 375 380 Ala Gly Ala Ser Gly Gly Ala Tyr Gly Ser Gln Met Met Gly Gly Met 385 390 395 400 Gly Leu Ser Asn Gln Ser Ser Tyr Gly Gly Pro Ala Ser Gln Gln Leu 405 410 415 Ser Gly Gly Tyr Gly Gly Gly Tyr Gly Gly Gln Ser Ser Met Ser Gly 420 425 430 Tyr Asp Gln Val Leu Gln Glu Asn Ser Ser Asp Phe Gln Ser Asn Ile 435 440 445 Ala 27 1852 DNA Homo sapiens 27 acagcccttc gtggggccct gggcaccctg caccagctgg gcatcgtcgt cggcatcctc 60 atcgcccagg tgttcggcct ggactccatc atgggcaaca aggacctgtg gcccctgctg 120 ctgagcatca tcttcatccc ggccctgctg cagtgcatcg tgctgccctt ctgccccgag 180 agtccccgct tcctgctcat caaccgcaac gaggagaacc gggccaagag tgtgctaaag 240 aagctgcgcg ggacagctga cgtgacccat gacctgcagg agatgaagga agagagtcgg 300 cagatgatgc gggagaagaa ggtcaccatc ctggagctgt tccgctcccc cgcctaccgc 360 cagcccatcc tcatcgctgt ggtgctgcag ctgtcccagc agctgtctgg catcaacgct 420 gtcttctatt actccacgag catcttcgag aaggcggggg tgcagcagcc tgtgtatgcc 480 accattggct ccggtatcgt caacacggcc ttcactgtcg tgtcgctgtt tgtggtggag 540 cgagcaggcc ggcggaccct gcacctcata ggcctcgctg gcatggcggg ttgtgccata 600 ctcatgacca tcgcgctagc actgctggag cagctaccct ggatgtccta tctgagcatc 660 gtggccatct ttggctttgt ggccttcttt gaagtgggtc ctggccccat cccatggttc 720 atcgtggctg aactcttcag ccagggtcca cgtccagctg ccattgccgt tgcaggcttc 780 tccaactgga cctcaaattt cattgtgggc atgtgcttcc agtatgtgga gcaactgtgt 840 ggtccctacg tcttcatcat cttcactgtg ctcctggttc tgttcttcat cttcacctac 900 ttcaaagttc ctgagactaa aggccggacc ttcgatgaga tcgcttccgg cttccggcag 960 gggggagcca gccaaagtga caagacaccc gaggagctgt tccatcccct gggggctgat 1020 tcccaagtgt gagtcgcccc agatcaccag cccggcctgc tcccagcagc cctaaggatc 1080 tctcaggagc acaggcagct ggatgagact tccaaacctg acagatgtca gccgagccgg 1140 gcctggggct cctttctcca gccagcaatg atgtccagaa gaatattcag gacttaacgg 1200 ctccaggatt ttaacaaaag caagactgtt gctcaaatct attcagacaa gcaacaggtt 1260 ttataatttt tttattactg attttgttat ttttatatca gcctgagtct cctgtgccca 1320 catcccaggc ttcaccctga atggttccat gcctgagggt ggagactaag ccctgtcgag 1380 acacttgcct tcttcaccca gctaatctgt agggctggac ctatgtccta aggacacact 1440 aatcgaacta tgaactacaa agcttctatc ccaggaggtg gctatggcca cccgttctgc 1500 tggcctggat ctccccactc taggggtcag gctccattag gatttgcccc ttcccatctc 1560 ttcctaccca accactcaaa ttaatctttc tttacctgag accagttggg agcactggag 1620 tgcagggagg agaggggaag ggccagtctg ggctgccggg ttctagtctc ctttgcactg 1680 agggccacac tattaccatg agaagagggc ctgtgggagc ctgcaaactc actgctcaag 1740 aagacatgga gactcctgcc ctgttgtgta tagatgcaag atatttatat atatttttgg 1800 ttgtcaatat taaatacaga cactaagtta tagtaaaaaa aaaaaaaaaa aa 1852 28 343 PRT Homo sapiens 28 Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His Gln Leu Gly Ile Val 1 5 10 15 Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu Asp Ser Ile Met Gly 20 25 30 Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile Ile Phe Ile Pro Ala 35 40 45 Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro Glu Ser Pro Arg Phe 50 55 60 Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala Lys Ser Val Leu Lys 65 70 75 80 Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp Leu Gln Glu Met Lys 85 90 95 Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys Val Thr Ile Leu Glu 100 105 110 Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile Leu Ile Ala Val Val 115 120 125 Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn Ala Val Phe Tyr Tyr 130 135 140 Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln Gln Pro Val Tyr Ala 145 150 155 160 Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe Thr Val Val Ser Leu 165 170 175 Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu His Leu Ile Gly Leu 180 185 190 Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr Ile Ala Leu Ala Leu 195 200 205 Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser Ile Val Ala Ile Phe 210 215 220 Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly Pro Ile Pro Trp Phe 225 230 235 240 Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg Pro Ala Ala Ile Ala 245 250 255 Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe Ile Val Gly Met Cys 260 265 270 Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr Val Phe Ile Ile Phe 275 280 285 Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr Tyr Phe Lys Val Pro 290 295 300 Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile Ala Ser Gly Phe Arg Gln 305 310 315 320 Gly Gly Ala Ser Gln Ser Asp Lys Thr Pro Glu Glu Leu Phe His Pro 325 330 335 Leu Gly Ala Asp Ser Gln Val 340 29 5368 DNA Homo sapiens 29 ggaatcagag aagatcattg ctgagttgaa tgaaacttgg gaagagaagc ttcgtaaaac 60 agaggccatc agaatggaga gagaggcttt gttggctgag atgggagttg ccattcggga 120 agatggagga accctagggg ttttctcacc taaaaagacc ccacatcttg ttaacctcaa 180 tgaagaccca ctaatgtctg agtgcctact ttattacatc aaagatggaa ttacaagggt 240 tggccaagca gatgctgagc ggcgccagga catagtgctg agcggggctc acattaaaga 300 agagcattgt atcttccgga gtgagagaag caacagcggg gaagttatcg tgaccttaga 360 gccctgtgag cgctcagaaa cctacgtaaa tggcaagagg gtgtcccagc ctgttcagct 420 gcgctcagga aaccgtatca tcatgggtaa aaaccatgtt ttccgcttta accacccgga 480 acaagcacga gctgagcgag agaagactcc ttctgctgag accccctctg agcctgtgga 540 ctggacattt gcccagaggg agcttctgga aaaacaagga attgatatga aacaagagat 600 ggagaaaagg ctacaggaaa tggagatctt atacaaaaag gagaaggaag aagcagatct 660 tcttttggag cagcagagac tggactatga gagtaaattg caggccttgc agaagcaggt 720 tgaaacccga tctctggctg cagaaacaac tgaagaggag gaagaagagg aagaagttcc 780 ttggacacag catgaatttg agttggccca atgggccttc cggaaatgga agtctcatca 840 gtttacttca ttacgggact tactctgggg caatgccgtg tacctaaagg aggccaatgc 900 catcagtgtg gaactgaaaa agaaggtgca gtttcagttt gttctgctga ctgacacact 960 gtactcccct ttgcctcctg aattacttcc cactgagatg gaaaaaactc atgaggacag 1020 gcctttccct cgcacagtgg tagcagtaga agtccaggat ttgaagaatg gagcaacaca 1080 ctattggtct ttggagaaac tcaagcagag gctggatttg atgcgagaga tgtatgatag 1140 ggcaggggag atggcctcca gtgcccaaga cgaaagcgaa accactgtga ctggcagcga 1200 tcccttctat gatcggttcc actggttcaa acttgtgggg agctccccca ttttccacgg 1260 ctgtgtgaac gagcgccttg ccgaccgcac accctccccc actttttcca cggccgattc 1320 cgacatcact gagctggctg acgagcagca agatgagatg gaggattttg atgatgaggc 1380 attcgtggat gacgccggct ctgacgcagg gacggaggag ggatcagatc tcttcagtga 1440 cgggcatgac ccgttttacg accgatcccc ttggttcatt ttagtgggaa gggcatttgt 1500 ttacctgagc aatctgctgt atcccgtgcc cctgatccac agggtggcca tcgtcagtga 1560 gaaaggtgaa gtgcggggat ttctgcgtgt ggctgtacag gccatcgcag cggatgaaga 1620 agctcctgat tatggctctg gaattcgaca gtcaggaaca gctaaaatat cttttgataa 1680 tgaatacttt aatcagagtg acttttcgtc tgttgcaatg actcgttctg gtctgtcctt 1740 ggaggagttg aggattgtgg aaggacaggg tcagagttct gaggtcatca ctcctccaga 1800 agaaatcagt cgaattaatg acttggattt gaagtcaagc actttgctgg atggtaagat 1860 ggtaatggaa gggttttctg aagagattgg caaccacctg aaactgggca gtgccttcac 1920 tttccgagta acagtgttgc aggccagtgg aatcctccca gagtatgcag atatcttctg 1980 tcagttcaac tttttgcatc gccatgatga agcattctcc acggagcccc tcaaaaacaa 2040 tggcagagga agtcccctgg ccttttatca tgtgcagaat attgcagtgg agatcactga 2100 atcatttgtg gattacatca aaaccaagcc tattgtattt gaagtctttg ggcattatca 2160 gcagcaccca cttcatctgc aaggacagga gcttaacagt ccgcctcagc cgtgccgccg 2220 attcttccct ccacccatgc cactgtccaa gccagttcca gccaccaagt taaacacgat 2280 gagcaaaacc agccttggcc agagcatgag caagtatgac ctcctggttt ggtttgagat 2340 cagtgaactg gagcctacag gagagtatat cccagctgtg gttgaccaca cagcaggctt 2400 gccttgccag gggacatttt tgcttcatca gggcatccag cgaaggatca cagtgaccat 2460 tatccatgag aaggggagcg agctccattg gaaagatgtt cgtgaactgg tggtaggtcg 2520 tattcggaat aagcctgagg tggatgaagc tgcagttgat gccatcctct ccctaaatat 2580 tatttctgcc aagtacctga agtcttccca caactctagc aggaccttct accgctttga 2640 ggctgtgtgg gatagctctc tgcataactc ccttcttctg aaccgagtga caccctatgg 2700 agaaaagatc tacatgacct tgtcggccta cctagagctg gatcattgca tccagccggc 2760 tgtcatcacc aaggatgtgt gcatggtctt ctactcccga gatgccaaga tctcaccacc 2820 acgctctctg cgtagcctct ttggcagcgg ctactcaaag tcaccagatt cgaatcgagt 2880 cactggcatt tacgaactca gcttatgcaa aatgtcagac acaggtagtc caggtatgca 2940 gagaaggaga agaaaaatct tagatacgtc agtggcatat gtgcggggag aagagaactt 3000 agcaggctgg cggccccgtg gagacagcct catccttgag caccagtggg agctggagaa 3060 gctggagctc ctacatgagg tggaaaaaac ccgccacttt ttgctgctgc gtgagagact 3120 tggtgacagc atccccaaat ccctgagcga ctcgttatcc cccagcctca gcagtgggac 3180 cctcagcacc tccaccagta tctcctctca gatctcaacc actacctttg aaagcgccat 3240 cacacctagc gagagcagtg gctatgattc aggagacatc gaaagcctgg tggaccgaga 3300 gaaagagctg gctaccaagt gcctgcaact tctcacccac actttcaaca gagaattcag 3360 ccaggtgcac ggcagcgtca gtgactgtaa gttgtctgat atctctccaa ttggacggga 3420 tccctctgag tccagtttca gcagtgccac cctcactccc tcctccacct gtccctctct 3480 ggtagactct aggagcaact ctctggatca gaagacccca gaagccaatt cccgggcctc 3540 tagtccctgc ccagaatttg aacagtttca gattgtccca gctgtggaaa caccatattt 3600 ggcccgagca ggaaaaaacg aatttctcaa tcttgttcca gatattgaag aaattagacc 3660 aagctcagtg gtctctaaga aaggatacct tcatttcaag gagcctcttt acagtaactg 3720 ggctaaacat tttgttgtcg tccgtcggcc ttatgtcttc atctataaca gtgacaaaga 3780 ccctgtggag cgtggaatca ttaacctgtc cacagcacag gtggagtaca gtgaggacca 3840 gcaggccatg gtgaagacac caaacacctt tgctgtctgc acaaagcacc gtggggtcct 3900 tttgcaggcc ctcaatgaca aagacatgaa cgactggttg tatgccttca acccacttct 3960 agctggcaca atacggtcaa agctttcccg cagatgcccg agccagtcga aatactaagt 4020 gactctgccg agtgccctca ctcgccttcg agagataaag aaagcgttac ctctcatttc 4080 tctttgtgat tcttgacggt gactcttgta tgtaatcctg tggcttaact acttctccct 4140 ccttgtccag cacttttcta gctctcccgt tccccatctc cattgctctg tactcttttc 4200 ttttttcttg tgctgagaat ctcgttagta gcatgtggcc taacaaaagg aaaaaatgtt 4260 tttaaacaca cacacacaca cacacacaca cacacacata cacagacaaa aacacaaaaa 4320 ctctgagggg atctggtgaa tctccaaatt attgtgggtg tactttggct tccttttgta 4380 tgataggtcc ccatcatgac cacctctgat gtctgtgctg ctgtcaccag gcacctttgt 4440 ttttcaagac aacatacttt ttttttcttt tctctgtttg tgatatcact ttaatttttc 4500 ttgggtggct tagagactaa gggaggagac atctggcctt tttagaacct gagaggaaaa 4560 aaagagtctt tttttcccct ctgtctcttt ttgccatggc taatccctgc atttccattc 4620 agggaaaagg tggtagtgag catagaactg caacagttat attctgagtc aaagttgggg 4680 ctttttacgg cataattatg gaatttttat ttactggtag agaggagacg agaggctttt 4740 tcagtgggcc tgggacagtg gctgctcttg actttgtgtg aagggaaatg ccaaggatgc 4800 ttctggtgga cttcagggga ccccagggtt tggccgtggg ccgtgatggc agcaggcggt 4860 gggatgcttg tagctcctca cagcaggatt cctgcccact gttttttctc tgttgggagg 4920 gaagctcttt tctaggagtg tctcagttct gcttttggca ttagtgatgg tggtggtaca 4980 gttggaatta gtgccatgtc atacacaaat gttccacaag gcgggagtgt ttcactttct 5040 ggtgataaac ttgatggtca ttgttatgat taagataatg ccgggcaggc cgggcacagt 5100 ggctcacgcc tgtaatccaa gcacttgggg aggccgaggc gggcagatca cgagatcagg 5160 agttcaagac cagcctggcc aatgtgatga aaccccgtct ctactaaaaa tacaaaatta 5220 gtcgggtatg gtggcacatg cctgtaattc cagctgcttg ggagcctgag gcaggagaac 5280 tgcttgaacc caggaggcag aggttgcagt gagccaagat cgcgctattg cactccagcc 5340 tgggtgacag agcaagactc tgcctcag 5368 30 1338 PRT Homo sapiens 30 Glu Ser Glu Lys Ile Ile Ala Glu Leu Asn Glu Thr Trp Glu Glu Lys 1 5 10 15 Leu Arg Lys Thr Glu Ala Ile Arg Met Glu Arg Glu Ala Leu Leu Ala 20 25 30 Glu Met Gly Val Ala Ile Arg Glu Asp Gly Gly Thr Leu Gly Val Phe 35 40 45 Ser Pro Lys Lys Thr Pro His Leu Val Asn Leu Asn Glu Asp Pro Leu 50 55 60 Met Ser Glu Cys Leu Leu Tyr Tyr Ile Lys Asp Gly Ile Thr Arg Val 65 70 75 80 Gly Gln Ala Asp Ala Glu Arg Arg Gln Asp Ile Val Leu Ser Gly Ala 85 90 95 His Ile Lys Glu Glu His Cys Ile Phe Arg Ser Glu Arg Ser Asn Ser 100 105 110 Gly Glu Val Ile Val Thr Leu Glu Pro Cys Glu Arg Ser Glu Thr Tyr 115 120 125 Val Asn Gly Lys Arg Val Ser Gln Pro Val Gln Leu Arg Ser Gly Asn 130 135 140 Arg Ile Ile Met Gly Lys Asn His Val Phe Arg Phe Asn His Pro Glu 145 150 155 160 Gln Ala Arg Ala Glu Arg Glu Lys Thr Pro Ser Ala Glu Thr Pro Ser 165 170 175 Glu Pro Val Asp Trp Thr Phe Ala Gln Arg Glu Leu Leu Glu Lys Gln 180 185 190 Gly Ile Asp Met Lys Gln Glu Met Glu Lys Arg Leu Gln Glu Met Glu 195 200 205 Ile Leu Tyr Lys Lys Glu Lys Glu Glu Ala Asp Leu Leu Leu Glu Gln 210 215 220 Gln Arg Leu Asp Tyr Glu Ser Lys Leu Gln Ala Leu Gln Lys Gln Val 225 230 235 240 Glu Thr Arg Ser Leu Ala Ala Glu Thr Thr Glu Glu Glu Glu Glu Glu 245 250 255 Glu Glu Val Pro Trp Thr Gln His Glu Phe Glu Leu Ala Gln Trp Ala 260 265 270 Phe Arg Lys Trp Lys Ser His Gln Phe Thr Ser Leu Arg Asp Leu Leu 275 280 285 Trp Gly Asn Ala Val Tyr Leu Lys Glu Ala Asn Ala Ile Ser Val Glu 290 295 300 Leu Lys Lys Lys Val Gln Phe Gln Phe Val Leu Leu Thr Asp Thr Leu 305 310 315 320 Tyr Ser Pro Leu Pro Pro Glu Leu Leu Pro Thr Glu Met Glu Lys Thr 325 330 335 His Glu Asp Arg Pro Phe Pro Arg Thr Val Val Ala Val Glu Val Gln 340 345 350 Asp Leu Lys Asn Gly Ala Thr His Tyr Trp Ser Leu Glu Lys Leu Lys 355 360 365 Gln Arg Leu Asp Leu Met Arg Glu Met Tyr Asp Arg Ala Gly Glu Met 370 375 380 Ala Ser Ser Ala Gln Asp Glu Ser Glu Thr Thr Val Thr Gly Ser Asp 385 390 395 400 Pro Phe Tyr Asp Arg Phe His Trp Phe Lys Leu Val Gly Ser Ser Pro 405 410 415 Ile Phe His Gly Cys Val Asn Glu Arg Leu Ala Asp Arg Thr Pro Ser 420 425 430 Pro Thr Phe Ser Thr Ala Asp Ser Asp Ile Thr Glu Leu Ala Asp Glu 435 440 445 Gln Gln Asp Glu Met Glu Asp Phe Asp Asp Glu Ala Phe Val Asp Asp 450 455 460 Ala Gly Ser Asp Ala Gly Thr Glu Glu Gly Ser Asp Leu Phe Ser Asp 465 470 475 480 Gly His Asp Pro Phe Tyr Asp Arg Ser Pro Trp Phe Ile Leu Val Gly 485 490 495 Arg Ala Phe Val Tyr Leu Ser Asn Leu Leu Tyr Pro Val Pro Leu Ile 500 505 510 His Arg Val Ala Ile Val Ser Glu Lys Gly Glu Val Arg Gly Phe Leu 515 520 525 Arg Val Ala Val Gln Ala Ile Ala Ala Asp Glu Glu Ala Pro Asp Tyr 530 535 540 Gly Ser Gly Ile Arg Gln Ser Gly Thr Ala Lys Ile Ser Phe Asp Asn 545 550 555 560 Glu Tyr Phe Asn Gln Ser Asp Phe Ser Ser Val Ala Met Thr Arg Ser 565 570 575 Gly Leu Ser Leu Glu Glu Leu Arg Ile Val Glu Gly Gln Gly Gln Ser 580 585 590 Ser Glu Val Ile Thr Pro Pro Glu Glu Ile Ser Arg Ile Asn Asp Leu 595 600 605 Asp Leu Lys Ser Ser Thr Leu Leu Asp Gly Lys Met Val Met Glu Gly 610 615 620 Phe Ser Glu Glu Ile Gly Asn His Leu Lys Leu Gly Ser Ala Phe Thr 625 630 635 640 Phe Arg Val Thr Val Leu Gln Ala Ser Gly Ile Leu Pro Glu Tyr Ala 645 650 655 Asp Ile Phe Cys Gln Phe Asn Phe Leu His Arg His Asp Glu Ala Phe 660 665 670 Ser Thr Glu Pro Leu Lys Asn Asn Gly Arg Gly Ser Pro Leu Ala Phe 675 680 685 Tyr His Val Gln Asn Ile Ala Val Glu Ile Thr Glu Ser Phe Val Asp 690 695 700 Tyr Ile Lys Thr Lys Pro Ile Val Phe Glu Val Phe Gly His Tyr Gln 705 710 715 720 Gln His Pro Leu His Leu Gln Gly Gln Glu Leu Asn Ser Pro Pro Gln 725 730 735 Pro Cys Arg Arg Phe Phe Pro Pro Pro Met Pro Leu Ser Lys Pro Val 740 745 750 Pro Ala Thr Lys Leu Asn Thr Met Ser Lys Thr Ser Leu Gly Gln Ser 755 760 765 Met Ser Lys Tyr Asp Leu Leu Val Trp Phe Glu Ile Ser Glu Leu Glu 770 775 780 Pro Thr Gly Glu Tyr Ile Pro Ala Val Val Asp His Thr Ala Gly Leu 785 790 795 800 Pro Cys Gln Gly Thr Phe Leu Leu His Gln Gly Ile Gln Arg Arg Ile 805 810 815 Thr Val Thr Ile Ile His Glu Lys Gly Ser Glu Leu His Trp Lys Asp 820 825 830 Val Arg Glu Leu Val Val Gly Arg Ile Arg Asn Lys Pro Glu Val Asp 835 840 845 Glu Ala Ala Val Asp Ala Ile Leu Ser Leu Asn Ile Ile Ser Ala Lys 850 855 860 Tyr Leu Lys Ser Ser His Asn Ser Ser Arg Thr Phe Tyr Arg Phe Glu 865 870 875 880 Ala Val Trp Asp Ser Ser Leu His Asn Ser Leu Leu Leu Asn Arg Val 885 890 895 Thr Pro Tyr Gly Glu Lys Ile Tyr Met Thr Leu Ser Ala Tyr Leu Glu 900 905 910 Leu Asp His Cys Ile Gln Pro Ala Val Ile Thr Lys Asp Val Cys Met 915 920 925 Val Phe Tyr Ser Arg Asp Ala Lys Ile Ser Pro Pro Arg Ser Leu Arg 930 935 940 Ser Leu Phe Gly Ser Gly Tyr Ser Lys Ser Pro Asp Ser Asn Arg Val 945 950 955 960 Thr Gly Ile Tyr Glu Leu Ser Leu Cys Lys Met Ser Asp Thr Gly Ser 965 970 975 Pro Gly Met Gln Arg Arg Arg Arg Lys Ile Leu Asp Thr Ser Val Ala 980 985 990 Tyr Val Arg Gly Glu Glu Asn Leu Ala Gly Trp Arg Pro Arg Gly Asp 995 1000 1005 Ser Leu Ile Leu Glu His Gln Trp Glu Leu Glu Lys Leu Glu Leu Leu 1010 1015 1020 His Glu Val Glu Lys Thr Arg His Phe Leu Leu Leu Arg Glu Arg Leu 1025 1030 1035 1040 Gly Asp Ser Ile Pro Lys Ser Leu Ser Asp Ser Leu Ser Pro Ser Leu 1045 1050 1055 Ser Ser Gly Thr Leu Ser Thr Ser Thr Ser Ile Ser Ser Gln Ile Ser 1060 1065 1070 Thr Thr Thr Phe Glu Ser Ala Ile Thr Pro Ser Glu Ser Ser Gly Tyr 1075 1080 1085 Asp Ser Gly Asp Ile Glu Ser Leu Val Asp Arg Glu Lys Glu Leu Ala 1090 1095 1100 Thr Lys Cys Leu Gln Leu Leu Thr His Thr Phe Asn Arg Glu Phe Ser 1105 1110 1115 1120 Gln Val His Gly Ser Val Ser Asp Cys Lys Leu Ser Asp Ile Ser Pro 1125 1130 1135 Ile Gly Arg Asp Pro Ser Glu Ser Ser Phe Ser Ser Ala Thr Leu Thr 1140 1145 1150 Pro Ser Ser Thr Cys Pro Ser Leu Val Asp Ser Arg Ser Asn Ser Leu 1155 1160 1165 Asp Gln Lys Thr Pro Glu Ala Asn Ser Arg Ala Ser Ser Pro Cys Pro 1170 1175 1180 Glu Phe Glu Gln Phe Gln Ile Val Pro Ala Val Glu Thr Pro Tyr Leu 1185 1190 1195 1200 Ala Arg Ala Gly Lys Asn Glu Phe Leu Asn Leu Val Pro Asp Ile Glu 1205 1210 1215 Glu Ile Arg Pro Ser Ser Val Val Ser Lys Lys Gly Tyr Leu His Phe 1220 1225 1230 Lys Glu Pro Leu Tyr Ser Asn Trp Ala Lys His Phe Val Val Val Arg 1235 1240 1245 Arg Pro Tyr Val Phe Ile Tyr Asn Ser Asp Lys Asp Pro Val Glu Arg 1250 1255 1260 Gly Ile Ile Asn Leu Ser Thr Ala Gln Val Glu Tyr Ser Glu Asp Gln 1265 1270 1275 1280 Gln Ala Met Val Lys Thr Pro Asn Thr Phe Ala Val Cys Thr Lys His 1285 1290 1295 Arg Gly Val Leu Leu Gln Ala Leu Asn Asp Lys Asp Met Asn Asp Trp 1300 1305 1310 Leu Tyr Ala Phe Asn Pro Leu Leu Ala Gly Thr Ile Arg Ser Lys Leu 1315 1320 1325 Ser Arg Arg Cys Pro Ser Gln Ser Lys Tyr 1330 1335 31 3094 DNA Homo sapiens 31 tttgactggc cgtagagtct gcgcagttgg tgaatggcgt tggtggcggg aaagttgagt 60 ctctcctgcg ccgagccttc ggggcgatgt gtagtgcctt ccatagggct gagtctggga 120 ccgagctcct tgcccgactt gaaggtagaa gttccttgaa agaaatagaa ccaaatctgt 180 ttgctgatga agattcacct gtgcatggtg atattcttga atttcatggc ccagaaggaa 240 caggaaaaac agaaatgctt tatcacctaa cagcacgatg tatacttccc aaatcagaag 300 gtggcctgga agtagaagtc ttatttattg atacagatta ccactttgat atgctccggc 360 tagttacaat tcttgagcac agactatccc aaagctctga agaaataatc aaatactgcc 420 tgggaagatt ttttttggtg tactgcagta gtagcaccca cttacttctt acactttact 480 cactagaaag tatgttttgt agtcacccat ctctctgcct tttgattttg gatagcctgt 540 cagcttttta ctggatagac cgcgtcaatg gaggagaaag tgtgaactta caggagtcta 600 ctctgaggaa atgttctcag tgcttagaga agcttgtaaa tgactatcgc ctggttcttt 660 ttgcaacgac acaaactata atgcagaaag cctcgagctc atcagaagaa ccttctcatg 720 cctctcgacg actgtgtgat gtggacatag actacagacc ttatctctgt aaggcatggc 780 agcaactggt gaagcacagg atgtttttct ccaaacaaga tgattctcaa agcagcaacc 840 aattttcatt agtttcacgt tgtttaaaaa gtaacagttt aaaaaaacat ttttttatta 900 ttggagaaag tggggttgaa ttttgttgat atacatcata aaatagtctt ttgcagggta 960 ctacgcaagc cttaaaattt ttcttaagac agagtcttgc tctgtctccc aggctggagt 1020 gcagtggcac aatcatggct cactgcagcc ttgaactcct ggcctcaagg gatcctccta 1080 tgtgtgcctc ctagagtgca gggattacag gcgtgagcca ctgctcgtgg ccaaaagttt 1140 tctttttttt tttttttctt tttgaaacag tcttactctg tctcccaggc tgctggagtg 1200 cagtggcaca atctcggccc gctgcagcct ctgcctcttg ggttcaagtg attcttccac 1260 ctcagcctcc caggtagctg ggattacagg cacccaccac cacgcctggc taatttttgt 1320 atttttaata gagacggggt ttcaccatgt tggccaggct ggtctcgaac tcctgacctc 1380 aagtgatcca cccacctcgg cctcccaaag tgctaggatt acaggcccgt gcccagccct 1440 aaagttttaa actctagggg aattaacagt atttctttac agaatggatt tgttaaacta 1500 gcacagtaaa agtaaagact attctgtttc taggctgttg aatcaaagtg attttagcaa 1560 ttaaactttg tattaattta ccaccaatat ttcttcacaa aggaactttt aaaagattat 1620 ctcagaaagt aaatctgaga ggtaagaagt aataatgagt aaatggtaag tacttgagta 1680 aatctaaaga aatattgata gtaaggcaat cctaagcaaa aagaacaaag ctggaggcat 1740 cacgctaccc agcttcaaac tatactacaa ggctacagta accaaaacag catagtactg 1800 gcacaaaaac acacgtagac tgatggaaca gaatagagaa tttagaaatg agaccacaca 1860 cctataattt ttttgatctt cgatgaacct gacaaaaaca agcaatgggc aatggattct 1920 ctattcaata aatcgtgctg ggataactgg ccagccatat ggaaaagatt gaaaatggac 1980 gccttcctta tgccatatac aaaaattaac tcaagatgga ttaaagactt aatgtaaaac 2040 ccaaaacagt aaaaatcctg gaagacaacc caggcagtac cattcaggac ataggcacag 2100 gcaaagattt catgacgaag acgccaaaaa caattgcaac agaagcaaaa attcacaaat 2160 gggatctaat taaactaaag agctgcacag caaaagaaac tatcaagaga gtaaacagac 2220 agcttacaga atgggagaaa attgttgcaa actatgcatc tgagaaaggt ctgaaatcca 2280 gcatctatac gtaatttaaa caaatttaga agaaaaaacc accccattaa aaagtgggca 2340 aaggacatga acagacactt ttcaaaagaa gacatctgtg gccaacaatc ctatggaaaa 2400 aagcccagca tcactgatca ttagagaaat gcaaatcgaa acaacaacga gataccatct 2460 cacaccagtc caaatggcta ttataaaaat gtcagaaaat aacagatgct ggtgaggttg 2520 tggagaaaaa gatatgctta tacactgttg gtggaaatgt aaattaaatt agttcagcca 2580 ttgtggaaga cagtgtgggg ataaagacag agataccatt caacccagca atctcattac 2640 tgggtatata cccaaaggaa tagaaatcat tgttataaag acacatgcac gcgtatgttc 2700 gttgcagcac tgcccatcag tgacagactg gattaaaaaa atgtggtaca tacacaccag 2760 ggaatactat acagccataa aaaggaacaa gactgactgg gcgtggtggc tcatgcctgt 2820 gatcctagca ctttgcgagg ccgaggtggg tggattgccc gcgctcagga ggtcaagacc 2880 agcctgggca acacggtgaa accccatctc tattaaaata caaaaaatta gctgggcatg 2940 gtggtgcgtg cctgtagtgc cagctactca ggaggccgag gcaggagaat tgctggaacc 3000 caggaggtgg aggttgcagt gagctgagat cgcgccattg cactcccgcc tgggcgactc 3060 catctctaaa aaaaaaaaaa aaaaaaaaaa aaaa 3094 32 280 PRT Homo sapiens 32 Met Cys Ser Ala Phe His Arg Ala Glu Ser Gly Thr Glu Leu Leu Ala 1 5 10 15 Arg Leu Glu Gly Arg Ser Ser Leu Lys Glu Ile Glu Pro Asn Leu Phe 20 25 30 Ala Asp Glu Asp Ser Pro Val His Gly Asp Ile Leu Glu Phe His Gly 35 40 45 Pro Glu Gly Thr Gly Lys Thr Glu Met Leu Tyr His Leu Thr Ala Arg 50 55 60 Cys Ile Leu Pro Lys Ser Glu Gly Gly Leu Glu Val Glu Val Leu Phe 65 70 75 80 Ile Asp Thr Asp Tyr His Phe Asp Met Leu Arg Leu Val Thr Ile Leu 85 90 95 Glu His Arg Leu Ser Gln Ser Ser Glu Glu Ile Ile Lys Tyr Cys Leu 100 105 110 Gly Arg Phe Phe Leu Val Tyr Cys Ser Ser Ser Thr His Leu Leu Leu 115 120 125 Thr Leu Tyr Ser Leu Glu Ser Met Phe Cys Ser His Pro Ser Leu Cys 130 135 140 Leu Leu Ile Leu Asp Ser Leu Ser Ala Phe Tyr Trp Ile Asp Arg Val 145 150 155 160 Asn Gly Gly Glu Ser Val Asn Leu Gln Glu Ser Thr Leu Arg Lys Cys 165 170 175 Ser Gln Cys Leu Glu Lys Leu Val Asn Asp Tyr Arg Leu Val Leu Phe 180 185 190 Ala Thr Thr Gln Thr Ile Met Gln Lys Ala Ser Ser Ser Ser Glu Glu 195 200 205 Pro Ser His Ala Ser Arg Arg Leu Cys Asp Val Asp Ile Asp Tyr Arg 210 215 220 Pro Tyr Leu Cys Lys Ala Trp Gln Gln Leu Val Lys His Arg Met Phe 225 230 235 240 Phe Ser Lys Gln Asp Asp Ser Gln Ser Ser Asn Gln Phe Ser Leu Val 245 250 255 Ser Arg Cys Leu Lys Ser Asn Ser Leu Lys Lys His Phe Phe Ile Ile 260 265 270 Gly Glu Ser Gly Val Glu Phe Cys 275 280 33 691 DNA Homo sapiens 33 gtcctcctcg ccctccaggc cgcccgcgcc gcgccggagt ccgctgtccg ccagctaccc 60 gcttcctgcc gcccgccgct gccatgctgc ccgccgcgct gctccgccgc ccgggacttg 120 gccgcctcgt ccgccacgcc cgtgcctatg ccgaggccgc cgccgccccg gctgccgcct 180 ctggccccaa ccagatgtcc ttcaccttcg cctctcccac gcaggtgttc ttcaacggtg 240 ccaacgtccg gcaggtggac gtgcccacgc tgaccggagc cttcggcatc ctggcggccc 300 acgtgcccac gctgcaggtc ctgcggccgg ggctggtcgt ggtgcatgca gaggacggca 360 ccacctccaa atactttgtg agcagcggtt ccatcgcagt gaacgccgac tcttcggtgc 420 agttgttggc cgaagaggcc gtgacgctgg acatgttgga cctgggggca gccaaggcaa 480 acttggagaa ggcccaggcg gagctggtgg ggacagctga cgaggccacg cgggcagaga 540 tccagatccg aatcgaggcc aacgaggccc tggtgaaggc cctggagtag gcgagccagc 600 cgccaaggtt gacctcagct tcggagccac ctctggatga actgccccca gcccccgccc 660 cattaaagac ccggaagcct gaaaaaaaaa a 691 34 168 PRT Homo sapiens 34 Met Leu Pro Ala Ala Leu Leu Arg Arg Pro Gly Leu Gly Arg Leu Val 1 5 10 15 Arg His Ala Arg Ala Tyr Ala Glu Ala Ala Ala Ala Pro Ala Ala Ala 20 25 30 Ser Gly Pro Asn Gln Met Ser Phe Thr Phe Ala Ser Pro Thr Gln Val 35 40 45 Phe Phe Asn Gly Ala Asn Val Arg Gln Val Asp Val Pro Thr Leu Thr 50 55 60 Gly Ala Phe Gly Ile Leu Ala Ala His Val Pro Thr Leu Gln Val Leu 65 70 75 80 Arg Pro Gly Leu Val Val Val His Ala Glu Asp Gly Thr Thr Ser Lys 85 90 95 Tyr Phe Val Ser Ser Gly Ser Ile Ala Val Asn Ala Asp Ser Ser Val 100 105 110 Gln Leu Leu Ala Glu Glu Ala Val Thr Leu Asp Met Leu Asp Leu Gly 115 120 125 Ala Ala Lys Ala Asn Leu Glu Lys Ala Gln Ala Glu Leu Val Gly Thr 130 135 140 Ala Asp Glu Ala Thr Arg Ala Glu Ile Gln Ile Arg Ile Glu Ala Asn 145 150 155 160 Glu Ala Leu Val Lys Ala Leu Glu 165 35 1378 DNA Homo sapiens 35 gcgcggcccg ctgcaatccg tggaggaacg cgccgccgag ccaccatcat gcctgggcac 60 ttacaggaag gcttcggctg cgtggtcacc aaccgattcg accagttatt tgacgacgaa 120 tcggacccct tcgaggtgct gaaggcagca gagaacaaga aaaaagaagc cggcgggggc 180 ggcgttgggg gccctggggc caagagcgca gctcaggccg cggcccagac caactccaac 240 gcggcaggca aacagctgcg caaggagtcc cagaaagacc gcaagaaccc gctgcccccc 300 agcgttggcg tggttgacaa gaaagaggag acgcagccgc ccgtggcgct taagaaagaa 360 ggaataagac gagttggaag aagacctgat caacaacttc agggtgaagg gaaaataatt 420 gatagaagac cagaaaggcg accacctcgt gaacgaagat tcgaaaagcc acttgaagaa 480 aagggtgaag gaggcgaatt ttcagttgat agaccgatta ttgaccgacc tattcgaggt 540 cgtggtggtc ttggaagagg tcgagggggc cgtggacgtg gaatgggccg aggagatgga 600 tttgattctc gtggcaaacg tgaatttgat aggcatagtg gaagtgatag atcttctttt 660 tcacattaca gtggcctgaa gcacgaggac aaacgtggag gtagcggatc tcacaactgg 720 ggaactgtca aagacgaatt aacagagtcc cccaaataca ttcagaaaca aatatcttat 780 aattacagtg acttggatca atcaaatgtg actgaggaaa cacctgaagg tgaagaacat 840 catccagtgg cagacactga aaataaggag aatgaagttg aagaggtaaa agaggagggt 900 ccaaaagaga tgactttgga tgagtggaag gctattcaaa ataaggaccg ggcaaaagta 960 gaatttaata tccgaaaacc aaatgaaggt gctgatgggc agtggaagaa gggatttgtt 1020 cttcataaat caaagagtga agaggctcat gctgaagatt cggttatgga ccatcatttc 1080 cggaagccag caaatgatat aacgtctcag ctggagatca attttggaga ccttggccgc 1140 ccaggacgtg gcggcagggg aggacgaggt ggacgtgggc gtggtgggcg cccaaaccgt 1200 ggcagcagga ccgacaagtc aagtgcttct gctcctgatg tggatgaccc agaggcattc 1260 ccagctctgg cttaactgga tgccataaga caaccctggt tcctttgtga acccttctgt 1320 tcaaagcttt tgcatgctta aggattccaa acgactaaga aaaaaaaaaa aaaaaaaa 1378 36 2896 DNA Homo sapiens 36 gggcgcgcca gctcgtagca ggggagcgcc cgcggcgtcg ggtttgggct ggaggtcgcc 60 atggggcgag gcagcggcac cttcgagcgt ctcctagaca aggcgaccag ccagctcctg 120 ttggagacag attgggagtc cattttgcag atctgcgacc tgatccgcca aggggacaca 180 caagcaaaat atgctgtgaa ttccatcaag aagaaagtca acgacaagaa cccacacgtc 240 gccttgtatg ccctggaggt catggaatct gtggtaaaga actgtggcca gacagttcat 300 gatgaggtgg ccaacaagca gaccatggag gagctgaagg acctgctgaa gagacaagtg 360 gaggtaaacg tccgtaacaa gatcctgtac ctgatccagg cctgggcgca tgccttccgg 420 aacgagccca agtacaaggt ggtccaggac acctaccaga tcatgaaggt ggaggggcac 480 gtctttccag aattcaaaga gagcgatgcc atgtttgctg ccgagagagc cccagactgg 540 gtggacgctg aggaatgcca ccgctgcagg gtgcagttcg gggtgatgac ccgtaagcac 600 cactgccggg cgtgtgggca gatattctgt ggaaagtgtt cttccaagta ctccaccatc 660 cccaagtttg gcatcgagaa ggaggtgcgc gtgtgtgagc cctgctacga gcagctgaac 720 aggaaagcgg agggaaaggc cacttccacc actgagctgc cccccgagta cctgaccagc 780 cccctgtctc agcagtccca gctgcccccc aagagggacg agacggccct gcaggaggag 840 gaggagctgc agctggccct ggcgctgtca cagtcagagg cggaggagaa ggagaggctg 900 agacagaagt ccacgtacac ttcgtacccc aaggcggagc ccatgccctc ggcctcctca 960 gcgccccccg ccagcagcct gtactcttca cctgtgaact cgtcggcgcc tctggctgag 1020 gacatcgacc ctgagctcgc acggtatctc aaccggaact actgggagaa gaagcaggag 1080 gaggctcgca agagccccac gccatctgcg cccgtgcccc tgacggagcc ggctgcacag 1140 cctggggaag ggcacgcagc ccccaccaac gtggtggaga accccctccc ggagacagac 1200 tctcagccca ttcctccctc tggtggcccc tttagtgagc cacagttcca caatggcgag 1260 tctgaggaga gccacgagca gttcctgaag gcgctgcaga acgccgtcac caccttcgtg 1320 aaccgcatga agagtaacca catgcggggc cgcagcatca ccaatgactc ggccgtgctc 1380 tcactcttcc agtccatcaa cggcatgcac ccgcagctgc tggagctgct caaccagctg 1440 gacgagcgca ggctgtacta tgaggggctg caggacaagc tggcacagat ccgcgatgcc 1500 cggggggcgc tgagtgccct gcgcgaagag caccgggaga agcttcgccg ggcagccgag 1560 gaggcagagc gccagcgcca gatccagctg gcccagaagc tggagataat gcggcagaag 1620 aagcaggagt acctggaggt gcagaggcag ctggccatcc agcgcctgca ggagcaggag 1680 aaggagcggc agatgcggct ggagcagcag aagcagacgg tccagatgcg cgcgcagatg 1740 cccgccttcc ccctgcccta cgcccagctc caggccatgc ccgcagccgg aggtgtgctc 1800 taccagccct cgggaccagc cagcttcccc agcaccttca gccctgccgg ctcggtggag 1860 ggctccccaa tgcacggcgt gtacatgagc cagccggccc ctgccgctgg cccctacccc 1920 agcatgccca gcactgcggc tgatcccagc atggtgagtg cctacatgta cccagcaggg 1980 gccactgggg cgcaggcggc cccccaggcc caggccggac ccaccgccag ccccgcttac 2040 tcatcctacc agcctactcc cacagcgggc taccagaacg tggcctccca ggccccacag 2100 agcctcccgg ccatctctca gcctccgcag tccagcacca tgggctacat ggggagccag 2160 tcagtctcca tgggctacca gccttacaac atgcagaatc tcatgaccac cctcccaagc 2220 caggatgcgt ctctgccacc ccagcagccc tacatcgcgg ggcagcagcc catgtaccag 2280 cagatggcac cctctggcgg tcccccccag cagcagcccc ccgtggccca gcaaccgcag 2340 gcacaggggc cgccggcaca gggcagcgag gcccagctca tttcattcga ctgacccagg 2400 ccatgctcac gtccggagta acactacata cagttcacct gaaacgcctc gtctctaact 2460 gccgtcgtcc tgcctccctg tcctctactg ccggtagtgt cccttctctg cgagtgaggg 2520 ggggccttca ccccaagccc acctcccttg tcctcagcct actgcagtcc ctgagttagt 2580 ctctgctttc tttccccagg gctgggccat ggggagggaa ggactttctc ccaggggaag 2640 cccccagccc tgtgggtcat ggtctgtgag aggtggcagg aatggggacc ctcacccccc 2700 aagcagcctg tgccctctgg ccgcactgtg agctggctgt ggtgtctggg tgtggcctgg 2760 ggctccctct gcaggggcct ctctcggcag ccacagccaa gggtggaggc ttcaggtctc 2820 cagcttctct gcttctcagc tgccatctcc agtgccccag aatggtacag cgataataaa 2880 atgtatttca gaaagg 2896 37 777 PRT Homo sapiens 37 Met Gly Arg Gly Ser Gly Thr Phe Glu Arg Leu Leu Asp Lys Ala Thr 1 5 10 15 Ser Gln Leu Leu Leu Glu Thr Asp Trp Glu Ser Ile Leu Gln Ile Cys 20 25 30 Asp Leu Ile Arg Gln Gly Asp Thr Gln Ala Lys Tyr Ala Val Asn Ser 35 40 45 Ile Lys Lys Lys Val Asn Asp Lys Asn Pro His Val Ala Leu Tyr Ala 50 55 60 Leu Glu Val Met Glu Ser Val Val Lys Asn Cys Gly Gln Thr Val His 65 70 75 80 Asp Glu Val Ala Asn Lys Gln Thr Met Glu Glu Leu Lys Asp Leu Leu 85 90 95 Lys Arg Gln Val Glu Val Asn Val Arg Asn Lys Ile Leu Tyr Leu Ile 100 105 110 Gln Ala Trp Ala His Ala Phe Arg Asn Glu Pro Lys Tyr Lys Val Val 115 120 125 Gln Asp Thr Tyr Gln Ile Met Lys Val Glu Gly His Val Phe Pro Glu 130 135 140 Phe Lys Glu Ser Asp Ala Met Phe Ala Ala Glu Arg Ala Pro Asp Trp 145 150 155 160 Val Asp Ala Glu Glu Cys His Arg Cys Arg Val Gln Phe Gly Val Met 165 170 175 Thr Arg Lys His His Cys Arg Ala Cys Gly Gln Ile Phe Cys Gly Lys 180 185 190 Cys Ser Ser Lys Tyr Ser Thr Ile Pro Lys Phe Gly Ile Glu Lys Glu 195 200 205 Val Arg Val Cys Glu Pro Cys Tyr Glu Gln Leu Asn Arg Lys Ala Glu 210 215 220 Gly Lys Ala Thr Ser Thr Thr Glu Leu Pro Pro Glu Tyr Leu Thr Ser 225 230 235 240 Pro Leu Ser Gln Gln Ser Gln Leu Pro Pro Lys Arg Asp Glu Thr Ala 245 250 255 Leu Gln Glu Glu Glu Glu Leu Gln Leu Ala Leu Ala Leu Ser Gln Ser 260 265 270 Glu Ala Glu Glu Lys Glu Arg Leu Arg Gln Lys Ser Thr Tyr Thr Ser 275 280 285 Tyr Pro Lys Ala Glu Pro Met Pro Ser Ala Ser Ser Ala Pro Pro Ala 290 295 300 Ser Ser Leu Tyr Ser Ser Pro Val Asn Ser Ser Ala Pro Leu Ala Glu 305 310 315 320 Asp Ile Asp Pro Glu Leu Ala Arg Tyr Leu Asn Arg Asn Tyr Trp Glu 325 330 335 Lys Lys Gln Glu Glu Ala Arg Lys Ser Pro Thr Pro Ser Ala Pro Val 340 345 350 Pro Leu Thr Glu Pro Ala Ala Gln Pro Gly Glu Gly His Ala Ala Pro 355 360 365 Thr Asn Val Val Glu Asn Pro Leu Pro Glu Thr Asp Ser Gln Pro Ile 370 375 380 Pro Pro Ser Gly Gly Pro Phe Ser Glu Pro Gln Phe His Asn Gly Glu 385 390 395 400 Ser Glu Glu Ser His Glu Gln Phe Leu Lys Ala Leu Gln Asn Ala Val 405 410 415 Thr Thr Phe Val Asn Arg Met Lys Ser Asn His Met Arg Gly Arg Ser 420 425 430 Ile Thr Asn Asp Ser Ala Val Leu Ser Leu Phe Gln Ser Ile Asn Gly 435 440 445 Met His Pro Gln Leu Leu Glu Leu Leu Asn Gln Leu Asp Glu Arg Arg 450 455 460 Leu Tyr Tyr Glu Gly Leu Gln Asp Lys Leu Ala Gln Ile Arg Asp Ala 465 470 475 480 Arg Gly Ala Leu Ser Ala Leu Arg Glu Glu His Arg Glu Lys Leu Arg 485 490 495 Arg Ala Ala Glu Glu Ala Glu Arg Gln Arg Gln Ile Gln Leu Ala Gln 500 505 510 Lys Leu Glu Ile Met Arg Gln Lys Lys Gln Glu Tyr Leu Glu Val Gln 515 520 525 Arg Gln Leu Ala Ile Gln Arg Leu Gln Glu Gln Glu Lys Glu Arg Gln 530 535 540 Met Arg Leu Glu Gln Gln Lys Gln Thr Val Gln Met Arg Ala Gln Met 545 550 555 560 Pro Ala Phe Pro Leu Pro Tyr Ala Gln Leu Gln Ala Met Pro Ala Ala 565 570 575 Gly Gly Val Leu Tyr Gln Pro Ser Gly Pro Ala Ser Phe Pro Ser Thr 580 585 590 Phe Ser Pro Ala Gly Ser Val Glu Gly Ser Pro Met His Gly Val Tyr 595 600 605 Met Ser Gln Pro Ala Pro Ala Ala Gly Pro Tyr Pro Ser Met Pro Ser 610 615 620 Thr Ala Ala Asp Pro Ser Met Val Ser Ala Tyr Met Tyr Pro Ala Gly 625 630 635 640 Ala Thr Gly Ala Gln Ala Ala Pro Gln Ala Gln Ala Gly Pro Thr Ala 645 650 655 Ser Pro Ala Tyr Ser Ser Tyr Gln Pro Thr Pro Thr Ala Gly Tyr Gln 660 665 670 Asn Val Ala Ser Gln Ala Pro Gln Ser Leu Pro Ala Ile Ser Gln Pro 675 680 685 Pro Gln Ser Ser Thr Met Gly Tyr Met Gly Ser Gln Ser Val Ser Met 690 695 700 Gly Tyr Gln Pro Tyr Asn Met Gln Asn Leu Met Thr Thr Leu Pro Ser 705 710 715 720 Gln Asp Ala Ser Leu Pro Pro Gln Gln Pro Tyr Ile Ala Gly Gln Gln 725 730 735 Pro Met Tyr Gln Gln Met Ala Pro Ser Gly Gly Pro Pro Gln Gln Gln 740 745 750 Pro Pro Val Ala Gln Gln Pro Gln Ala Gln Gly Pro Pro Ala Gln Gly 755 760 765 Ser Glu Ala Gln Leu Ile Ser Phe Asp 770 775 38 2569 DNA Homo sapiens 38 tccctcgtct ctctcgggca acatggcggg cgtggaggag gtagcggcct ccgggagcca 60 cctgaatggc gacctggatc cagacgacag ggaagaagga gctgcctcta cggctgagga 120 agcagccaag aaaaaaagac gaaagaagaa gaagagcaaa gggccttctg cagcagggga 180 acaggaacct gataaagaat caggagcctc agtggatgaa gtagcaagac agttggaaag 240 atcagcattg gaagataaag aaagagatga agatgatgaa gatggagatg gcgatggaga 300 tggagcaact ggaaagaaga agaaaaagaa gaagaagaag agaggaccaa aagttcaaac 360 agaccctccc tcagttccaa tatgtgacct gtatcctaat ggtgtatttc ccaaaggaca 420 agaatgcgaa tacccaccca cacaagatgg gcgaacagct gcttggagaa ctacaagtga 480 agaaaagaaa gcattagatc aggcaagtga agagatttgg aatgattttc gagaagctgc 540 agaagcacat cgacaagtta gaaaatacgt aatgagctgg atcaagcctg ggatgacaat 600 gatagaaatc tgtgaaaagt tggaagactg ttcacgcaag ttaataaaag agaatggatt 660 aaatgcaggc ctggcatttc ctactggatg ttctctcaat aattgtgctg cccattatac 720 tcccaatgcc ggtgacacaa cagtattaca gtatgatgac atctgtaaaa tagactttgg 780 aacacatata agtggtagga ttattgactg tgcttttact gtcactttta atcccaaata 840 tgatacgtta ttaaaagctg taaaagatgc tactaacact ggaataaagt gtgctggaat 900 tgatgttcgt ctgtgtgatg ttggtgaggc catccaagaa gttatggagt cctatgaagt 960 tgaaatagat gggaagacat atcaagtgaa accaatccgt aatctaaatg gacattcaat 1020 tgggcaatat agaatacatg ctggaaaaac agtgccgatt gtgaaaggag gggaggcaac 1080 aagaatggag gaaggagaag tatatgcaat tgaaaccttt ggtagtacag gaaaaggtgt 1140 tgttcatgat gatatggaat gttcacatta catgaaaaat tttgatgttg gacatgtgcc 1200 aataaggctt ccaagaacaa aacacttgtt aaatgtcatc aatgaaaact ttggaaccct 1260 tgccttctgc cgcagatggc tggatcgctt gggagaaagt aaatacttga tggctctgaa 1320 gaatctgtgt gacttgggca ttgtagatcc atatccacca ttatgtgaca ttaaaggatc 1380 atatacagcg caatttgaac ataccatcct gttgcgtcca acatgtaaag aagttgtcag 1440 cagaggagat gactattaaa cttagtccaa agccacctca acacctttat tttctgagct 1500 ttgttggaaa acatgatacc agaattaatt tgccacatgt tgtctgtttt aacagtggac 1560 ccatgtaata cttttatcca tgtttaaaaa agaaggaatt tggacaaagg caaaccgtct 1620 aatgtaatta accaacgaaa aagctttccg gacttttaaa tgctaactgt ttttcccctt 1680 cctgtctagg aaaatgctat aaagctcaaa ttagttagga atgacttata cgttttgttt 1740 tgaataccta agagatactt tttggatatt tatattgcca tattcttact tgaatgcttt 1800 gaatgactac atccagttct gcacctatac cctctggtgt tgctttttaa ccttcctgga 1860 atccattttc taaaaaataa agacacattc ttctcagcac cacacaacac ctattccaaa 1920 atcgaccaca tatttggaag taaagctctc ctcagcaaat gtaaaagaac agaaattata 1980 acaaactgtc tctcagacca cagtataacc aaactagaac tcaggattaa gaaactcact 2040 caaaaccaca caactacatg gaaactgaac aacctgctcc tgaatgacta ctggatacat 2100 aacaaaatga aggcagaaat aaagatgttc tttaaaacca atgagaacaa agacacaaca 2160 taccagaatc tctgggacac attcaaagca gtgtgtagag ggaaatttat agcactaaat 2220 gcccacaaga gaaagcagga aatatctaaa attgacaccc taacatcaca attaaaagaa 2280 ctagagaagc aagagcaaac acattgaaaa gctaagagaa ggcaagaaat aactaagatc 2340 agagcagaac tgaaggaaat agagacacaa aaaactcttc aaaaaatcaa tgaatccagg 2400 agctggtttt ttgaaacgat caacaaaatt gatagacact agcaagacta ataaagaaga 2460 aaggagagaa gaatcaaata gaagcaataa aaaatgataa aggggatatc accaccaatc 2520 ccacagaaat aaaccaccat cagagaatac tacaaacacc tctacgcaa 2569 39 478 PRT Homo sapiens 39 Met Ala Gly Val Glu Glu Val Ala Ala Ser Gly Ser His Leu Asn Gly 1 5 10 15 Asp Leu Asp Pro Asp Asp Arg Glu Glu Gly Ala Ala Ser Thr Ala Glu 20 25 30 Glu Ala Ala Lys Lys Lys Arg Arg Lys Lys Lys Lys Ser Lys Gly Pro 35 40 45 Ser Ala Ala Gly Glu Gln Glu Pro Asp Lys Glu Ser Gly Ala Ser Val 50 55 60 Asp Glu Val Ala Arg Gln Leu Glu Arg Ser Ala Leu Glu Asp Lys Glu 65 70 75 80 Arg Asp Glu Asp Asp Glu Asp Gly Asp Gly Asp Gly Asp Gly Ala Thr 85 90 95 Gly Lys Lys Lys Lys Lys Lys Lys Lys Lys Arg Gly Pro Lys Val Gln 100 105 110 Thr Asp Pro Pro Ser Val Pro Ile Cys Asp Leu Tyr Pro Asn Gly Val 115 120 125 Phe Pro Lys Gly Gln Glu Cys Glu Tyr Pro Pro Thr Gln Asp Gly Arg 130 135 140 Thr Ala Ala Trp Arg Thr Thr Ser Glu Glu Lys Lys Ala Leu Asp Gln 145 150 155 160 Ala Ser Glu Glu Ile Trp Asn Asp Phe Arg Glu Ala Ala Glu Ala His 165 170 175 Arg Gln Val Arg Lys Tyr Val Met Ser Trp Ile Lys Pro Gly Met Thr 180 185 190 Met Ile Glu Ile Cys Glu Lys Leu Glu Asp Cys Ser Arg Lys Leu Ile 195 200 205 Lys Glu Asn Gly Leu Asn Ala Gly Leu Ala Phe Pro Thr Gly Cys Ser 210 215 220 Leu Asn Asn Cys Ala Ala His Tyr Thr Pro Asn Ala Gly Asp Thr Thr 225 230 235 240 Val Leu Gln Tyr Asp Asp Ile Cys Lys Ile Asp Phe Gly Thr His Ile 245 250 255 Ser Gly Arg Ile Ile Asp Cys Ala Phe Thr Val Thr Phe Asn Pro Lys 260 265 270 Tyr Asp Thr Leu Leu Lys Ala Val Lys Asp Ala Thr Asn Thr Gly Ile 275 280 285 Lys Cys Ala Gly Ile Asp Val Arg Leu Cys Asp Val Gly Glu Ala Ile 290 295 300 Gln Glu Val Met Glu Ser Tyr Glu Val Glu Ile Asp Gly Lys Thr Tyr 305 310 315 320 Gln Val Lys Pro Ile Arg Asn Leu Asn Gly His Ser Ile Gly Gln Tyr 325 330 335 Arg Ile His Ala Gly Lys Thr Val Pro Ile Val Lys Gly Gly Glu Ala 340 345 350 Thr Arg Met Glu Glu Gly Glu Val Tyr Ala Ile Glu Thr Phe Gly Ser 355 360 365 Thr Gly Lys Gly Val Val His Asp Asp Met Glu Cys Ser His Tyr Met 370 375 380 Lys Asn Phe Asp Val Gly His Val Pro Ile Arg Leu Pro Arg Thr Lys 385 390 395 400 His Leu Leu Asn Val Ile Asn Glu Asn Phe Gly Thr Leu Ala Phe Cys 405 410 415 Arg Arg Trp Leu Asp Arg Leu Gly Glu Ser Lys Tyr Leu Met Ala Leu 420 425 430 Lys Asn Leu Cys Asp Leu Gly Ile Val Asp Pro Tyr Pro Pro Leu Cys 435 440 445 Asp Ile Lys Gly Ser Tyr Thr Ala Gln Phe Glu His Thr Ile Leu Leu 450 455 460 Arg Pro Thr Cys Lys Glu Val Val Ser Arg Gly Asp Asp Tyr 465 470 475 40 1183 DNA Homo sapiens misc_feature (0)...(0) n = a, t, c or g 40 cgcccaagaa gaaaatggcc ataagtggag tccctgtgct aggatttttc atcatagctg 60 tgctgatgag cgctcaggaa tcatgggcta tcaaagaaga acatgtgatc atccaggccg 120 agttctatct gaatcctgac caatcaggcg agtttatgtt tgactttgat ggtgatgaga 180 ttttccatgt ggatatggca aagaaggaga cggtctggcg gcttgaagaa tttggacgat 240 ttgccagctt tgaggctcaa ggtgcattgg ccaacatagc tgtggacaaa gccaacttgg 300 aaatcatgac aaagcgctcc aactatactc cgatcaccaa tgtacctcca gaggtaactg 360 tgctcacgaa cagccctgtg gaactgagag agcccaacgt cctcatctgt ttcatcgaca 420 agttcacccc accagtggtc aatgtcacgt ggcttcgaaa tggaaaacct gtcaccacag 480 gagtgtcaga gacagtcttc ctgcccaggg aagaccacct tttccgcaag ttccactatc 540 tccccttcct gccctcaact gaggacgttt acgactgcag ggtggagcac tggggcttgg 600 atgagcctct tctcaagcac tgggagtttg atgctccaag ccctctccca gagactacag 660 agaacgtggt gtgtgccctg ggcctgactg tgggtctggt gggcatcatt attgggacca 720 tcttcatcat caagggagtg cgcaaaagca atgcagcaga acgcaggggg cctctgtaag 780 gcacatggag gtgatgatgt ttcttagaga gaagatcact gaagaaactt ctgctttaat 840 gactttacaa agctggcaat attacaatcc ttgacctcag tgaaagcagt catcttcagc 900 gttttccagc cctatagcca ccccaagtgt ggttatgcct cctcgattgc tccgtactct 960 aacatctagc tggcttccct gtctattgcc ttttcctgta tctattttcc tctatttcct 1020 atcattttat tatcaccatg caatgcctct ggaataaaac atacaggagt ctgtctctgc 1080 tatggaatgc cccatggggc atctcttgtg tacttattgt ttaaggtttc ctcaaactgn 1140 gattcttctg aacacaataa actattttga tgatcttggg tgg 1183 41 254 PRT Homo sapiens 41 Met Ala Ile Ser Gly Val Pro Val Leu Gly Phe Phe Ile Ile Ala Val 1 5 10 15 Leu Met Ser Ala Gln Glu Ser Trp Ala Ile Lys Glu Glu His Val Ile 20 25 30 Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met 35 40 45 Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys 50 55 60 Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu 65 70 75 80 Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu 85 90 95 Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn Val Pro Pro 100 105 110 Glu Val Thr Val Leu Thr Asn Ser Pro Val Glu Leu Arg Glu Pro Asn 115 120 125 Val Leu Ile Cys Phe Ile Asp Lys Phe Thr Pro Pro Val Val Asn Val 130 135 140 Thr Trp Leu Arg Asn Gly Lys Pro Val Thr Thr Gly Val Ser Glu Thr 145 150 155 160 Val Phe Leu Pro Arg Glu Asp His Leu Phe Arg Lys Phe His Tyr Leu 165 170 175 Pro Phe Leu Pro Ser Thr Glu Asp Val Tyr Asp Cys Arg Val Glu His 180 185 190 Trp Gly Leu Asp Glu Pro Leu Leu Lys His Trp Glu Phe Asp Ala Pro 195 200 205 Ser Pro Leu Pro Glu Thr Thr Glu Asn Val Val Cys Ala Leu Gly Leu 210 215 220 Thr Val Gly Leu Val Gly Ile Ile Ile Gly Thr Ile Phe Ile Ile Lys 225 230 235 240 Gly Val Arg Lys Ser Asn Ala Ala Glu Arg Arg Gly Pro Leu 245 250 42 266 DNA Homo sapiens 42 atgcccaagt gtcccaagtg caacaaggag gtgtacttcg ccgagagggt gacctctctg 60 ggcaaggact ggcatcggcc ctgcctgaag tgcgagaaat gtgggaagac gctgacctct 120 gggggccacg ctgagcacga aggcaaaccc tactgcaacc acccctgcta cgcagccatg 180 tttgggccta aaggctttgg gcggggcgga gccgagagcc acactttcaa gtaaaccagg 240 tggtggagac ccatccttgg ctgctt 266 43 77 PRT Homo sapiens 43 Met Pro Lys Cys Pro Lys Cys Asn Lys Glu Val Tyr Phe Ala Glu Arg 1 5 10 15 Val Thr Ser Leu Gly Lys Asp Trp His Arg Pro Cys Leu Lys Cys Glu 20 25 30 Lys Cys Gly Lys Thr Leu Thr Ser Gly Gly His Ala Glu His Glu Gly 35 40 45 Lys Pro Tyr Cys Asn His Pro Cys Tyr Ala Ala Met Phe Gly Pro Lys 50 55 60 Gly Phe Gly Arg Gly Gly Ala Glu Ser His Thr Phe Lys 65 70 75 44 1665 DNA Homo sapiens 44 gaaggaactg gttctgctca cacttgctgg cttgcgcatc aggactggct ttatctcctg 60 actcacggtg caaaggtgca ctctgcgaac gttaagtccg tccccagcgc ttggaatcct 120 acggccccca cagccggatc ccctcagcct tccaggtcct caactcccgt ggacgctgaa 180 caatggcctc catggggcta caggtaatgg gcatcgcgct ggccgtcctg ggctggctgg 240 ccgtcatgct gtgctgcgcg ctgcccatgt ggcgcgtgac ggccttcatc ggcagcaaca 300 ttgtcacctc gcagaccatc tgggagggcc tatggatgaa ctgcgtggtg cagagcaccg 360 gccagatgca gtgcaaggtg tacgactcgc tgctggcact gccgcaggac ctgcaggcgg 420 cccgcgccct cgtcatcatc agcatcatcg tggctgctct gggcgtgctg ctgtccgtgg 480 tggggggcaa gtgtaccaac tgcctggagg atgaaagcgc caaggccaag accatgatcg 540 tggcgggcgt ggtgttcctg ttggccggcc ttatggtgat agtgccggtg tcctggacgg 600 cccacaacat catccaagac ttctacaatc cgctggtggc ctccgggcag aagcgggaga 660 tgggtgcctc gctctacgtc ggctgggccg cctccggcct gctgctcctt ggcggggggc 720 tgctttgctg caactgtcca ccccgcacag acaagcctta ctccgccaag tattctgctg 780 cccgctctgc tgctgccagc aactacgtgt aaggtgccac ggctccactc tgttcctctc 840 tgctttgttc ttccctggac tgagctcagc gcaggctgtg accccaggag ggccctgcca 900 cgggccactg gctgctgggg actggggact gggcagagac tgagccaggc aggaaggcag 960 cagccttcag cctctctggc ccactcggac aacttcccaa ggccgcctcc tgctagcaag 1020 aacagagtcc accctcctct ggatattggg gagggacgga agtgacaggg tgtggtggtg 1080 gagtggggag ctggcttctg ctggccagga tagcttaacc ctgactttgg gatctgcctg 1140 catcggcgtt ggccactgtc cccatttaca ttttccccac tctgtctgcc tgcatctcct 1200 ctgttccggg taggccttga tatcacctct gggactgtgc cttgctcacc gaaacccgcg 1260 cccaggagta tggctgaggc cttgcccacc cacctgcctg ggaagtgcag agtggatgga 1320 cgggtttaga ggggaggggc gaaggtgctg taaacaggtt tgggcagtgg tgggggaggg 1380 ggccagagag gcggctcagg ttgcccagct ctgtggcctc aggactctct gcctcacccg 1440 cttcagccca gggcccctgg agactgatcc cctctgagtc ctctgcccct tccaaggaca 1500 ctaatgagcc tgggagggtg gcagggagga ggggacagct tcacccttgg aagtcctggg 1560 gtttttcctc ttccttcttt gtggtttctg ttttgtaatt taagaagagc tattcatcac 1620 tgtaattatt attattttct acaataaatg ggacctgtgc acagg 1665 45 209 PRT Homo sapiens 45 Met Ala Ser Met Gly Leu Gln Val Met Gly Ile Ala Leu Ala Val Leu 1 5 10 15 Gly Trp Leu Ala Val Met Leu Cys Cys Ala Leu Pro Met Trp Arg Val 20 25 30 Thr Ala Phe Ile Gly Ser Asn Ile Val Thr Ser Gln Thr Ile Trp Glu 35 40 45 Gly Leu Trp Met Asn Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys 50 55 60 Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala 65 70 75 80 Arg Ala Leu Val Ile Ile Ser Ile Ile Val Ala Ala Leu Gly Val Leu 85 90 95 Leu Ser Val Val Gly Gly Lys Cys Thr Asn Cys Leu Glu Asp Glu Ser 100 105 110 Ala Lys Ala Lys Thr Met Ile Val Ala Gly Val Val Phe Leu Leu Ala 115 120 125 Gly Leu Met Val Ile Val Pro Val Ser Trp Thr Ala His Asn Ile Ile 130 135 140 Gln Asp Phe Tyr Asn Pro Leu Val Ala Ser Gly Gln Lys Arg Glu Met 145 150 155 160 Gly Ala Ser Leu Tyr Val Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu 165 170 175 Gly Gly Gly Leu Leu Cys Cys Asn Cys Pro Pro Arg Thr Asp Lys Pro 180 185 190 Tyr Ser Ala Lys Tyr Ser Ala Ala Arg Ser Ala Ala Ala Ser Asn Tyr 195 200 205 Val 46 1009 DNA Homo sapiens 46 ggcagtagct tgctgatgct cccagctgaa taaagccctt ccttctacaa tttggtgtct 60 gaggggtttt gtctgcggct cgtcctgcta catttcttgg ttccctgacc aggaaacgag 120 gtaactgatg gacagccgag gcagcccctt aggcggctta ggcctcccct gtggagcatc 180 cctgaggcgg actccggcca gcccgagtga tgcgatccaa agagcactcc cgggtaggaa 240 attgccccgg tggaatgcct caccagagca gcgtgtagca gttccctgtg gaggattaac 300 acagtggctg aacaccggga aggaactggc acttggagtc cggacatctg aaacttggta 360 agactagtct ttggaacttg ccccactcca tctaggtgga agtgtggcct gatcacccac 420 gacatgcctg cattggcact tctgttctgg ttttgacttg acttagattg tgtgatactt 480 tggttttggt tttggtttga cctggcttgg attctagata ctctgatttg gttttgattt 540 tggtttggtg taaactgcaa gagtgtgtat gcccttttta cctgtttttt tgtttgtggc 600 atgtgtgtgg tgtgggtgtg gtgttttgtc tcgaagaagc atgggtcagg tacaaataag 660 cccaccccac taggaactat gttaaaaaaa aattcaagaa agaatttaag ggagattaca 720 gtgttactgt gacaccagga aaacttagaa ctttgtgtga aatagactgg ccagcattag 780 aggtgggttg gccatcagaa ggaagcctgg acaggtccct tgtttcaaag gtatgacaca 840 aggtaacacc aattctaagt taatttgaag tttgcttaaa gttaacagtg taacatgtat 900 tatggtaact tctaatcttg tggccttaga cagtctagtc caaaggcata aagaaagttt 960 gctttaaaaa aaaaaaaaag gaatggttat cttcaaaaaa aaaaaaaaa 1009 47 1250 DNA Homo sapiens 47 aattcggcac gagggcaggt gcaggcgcac gcggcgagag cgtatggagc cgagccgtta 60 gcgcgcgccg tcggtgagtc agtccgtccg tccgtccgtc cgtcggggcg ccgcagctcc 120 cgccaggccc agcggccccg gcccctcgtc tccccgcacc cggagccacc cggtggagcg 180 ggccttgccg cggcagccat gtccatgggc ctggagatca cgggcaccgc gctggccgtg 240 ctgggctggc tgggcaccat cgtgtgctgc gcgttgccca tgtggcgcgt gtcggccttc 300 atcggcagca acatcatcac gtcgcagaac atctgggagg gcctgtggat gaactgcgtg 360 gtgcagagca ccggccagat gcagtgcaag gtgtacgact cgctgctggc actgccacag 420 gaccttcagg cggcccgcgc cctcatcgtg gtggccatcc tgctggccgc cttcgggctg 480 ctagtggcgc tggtgggcgc ccagtgcacc aactgcgtgc aggacgacac ggccaaggcc 540 aagatcacca tcgtggcagg cgtgctgttc cttctcgccg ccctgctcac cctcgtgccg 600 gtgtcctggt cggccaacac cattatccgg gacttctaca accccgtggt gcccgaggcg 660 cagaagcgcg agatgggcgc gggcctgtac gtgggctggg cggccgcggc gctgcagctg 720 ctggggggcg cgctgctctg ctgctcgtgt cccccacgcg agaagaagta cacggccacc 780 aaggtcgtct actccgcgcc gcgctccacc ggcccgggag ccagcctggg cacaggctac 840 gaccgcaagg actacgtcta agggacagac gcagggagac cccaccacca ccaccaccac 900 caacaccacc accaccaccg cgagctggag cgcgcaccag gccatccagc gtgcagcctt 960 gcctcggagg ccagcccacc cccagaagcc aggaagcccc cgcgctggac tggggcagct 1020 tccccagcag ccacggcttt gcgggccggg cagtcgactt cggggcccag ggaccaacct 1080 gcatggactg tgaaacctca cccttctgga gcacggggcc tgggtgaccg ccaatacttg 1140 accaccccgt cgagccccat cgggccgctg cccccatgtc gcgctgggca gggaccggca 1200 gccctggaag gggcacttga tatttttcaa taaaagcctc tcgttttagc 1250 48 220 PRT Homo sapiens 48 Met Ser Met Gly Leu Glu Ile Thr Gly Thr Ala Leu Ala Val Leu Gly 1 5 10 15 Trp Leu Gly Thr Ile Val Cys Cys Ala Leu Pro Met Trp Arg Val Ser 20 25 30 Ala Phe Ile Gly Ser Asn Ile Ile Thr Ser Gln Asn Ile Trp Glu Gly 35 40 45 Leu Trp Met Asn Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys Lys 50 55 60 Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala Arg 65 70 75 80 Ala Leu Ile Val Val Ala Ile Leu Leu Ala Ala Phe Gly Leu Leu Val 85 90 95 Ala Leu Val Gly Ala Gln Cys Thr Asn Cys Val Gln Asp Asp Thr Ala 100 105 110 Lys Ala Lys Ile Thr Ile Val Ala Gly Val Leu Phe Leu Leu Ala Ala 115 120 125 Leu Leu Thr Leu Val Pro Val Ser Trp Ser Ala Asn Thr Ile Ile Arg 130 135 140 Asp Phe Tyr Asn Pro Val Val Pro Glu Ala Gln Lys Arg Glu Met Gly 145 150 155 160 Ala Gly Leu Tyr Val Gly Trp Ala Ala Ala Ala Leu Gln Leu Leu Gly 165 170 175 Gly Ala Leu Leu Cys Cys Ser Cys Pro Pro Arg Glu Lys Lys Tyr Thr 180 185 190 Ala Thr Lys Val Val Tyr Ser Ala Pro Arg Ser Thr Gly Pro Gly Ala 195 200 205 Ser Leu Gly Thr Gly Tyr Asp Arg Lys Asp Tyr Val 210 215 220 49 3321 DNA Homo sapiens 49 atgaagattt tgatacttgg tatttttctg tttttatgta gtaccccagc ctgggcgaaa 60 gaaaagcatt attacattgg aattattgaa acgacttggg attatgcctc tgaccatggg 120 gaaaagaaac ttatttctgt tgacacggaa cattccaata tctatcttca aaatggccca 180 gatagaattg ggagactata taagaaggcc ctttatcttc agtacacaga tgaaaccttt 240 aggacaacta tagaaaaacc ggtctggctt gggtttttag gccctattat caaagctgaa 300 actggagata aagtttatgt acacttaaaa aaccttgcct ctaggcccta cacctttcat 360 tcacatggaa taacttacta taaggaacat gagggggcca tctaccctga taacaccaca 420 gattttcaaa gagcagatga caaagtatat ccaggagagc agtatacata catgttgctt 480 gccactgaag aacaaagtcc tggggaagga gatggcaatt gtgtgactag gatttaccat 540 tcccacattg atgctccaaa agatattgcc tcaggactca tcggaccttt aataatctgt 600 aaaaaagatt ctctagataa agaaaaagaa aaacatattg accgagaatt tgtggtgatg 660 ttttctgtgg tggatgaaaa tttcagctgg tacctagaag acaacattaa aacctactgc 720 tcagaaccag agaaagttga caaagacaac gaagacttcc aggagagtaa cagaatgtat 780 tctgtgaatg gatacacttt tggaagtctc ccaggactct ccatgtgtgc tgaagacaga 840 gtaaaatggt acctttttgg tatgggtaat gaagttgatg tgcacgcagc tttctttcac 900 gggcaagcac tgactaacaa gaactaccgt attgacacaa tcaacctctt tcctgctacc 960 ctgtttgatg cttatatggt ggcccagaac cctggagaat ggatgctcag ctgtcagaat 1020 ctaaaccatc tgaaagccgg tttgcaagcc tttttccagg tccaggagtg taacaagtct 1080 tcatcaaagg ataatatccg tgggaagcat gttagacact actacattgc cgctgaggaa 1140 atcatctgga actatgctcc ctctggtata gacatcttca ctaaagaaaa cttaacagca 1200 cctggaagtg actcagcggt gttttttgaa caaggtacca caagaattgg aggctcttat 1260 aaaaagctgg tttatcgtga gtacacagat gcctccttca caaatcgaaa ggagagaggc 1320 cctgaagaag agcatcttgg catcctgggt cctgtcattt gggcagaggt gggagacacc 1380 atcagagtaa ccttccataa caaaggagca tatcccctca gtattgagcc gattggggtg 1440 agattcaata agaacaacga gggcacatac tattccccaa attacaaccc ccagagcaga 1500 agtgtgcctc cttcagcctc ccatgtggca cccacagaaa cattcaccta tgaatggact 1560 gtccccaaag aagtaggacc cactaatgca gatcctgtgt gtctagctaa gatgtattat 1620 tctgctgtgg atcccactaa agatatattc actgggctta ttgggccaat gaaaatatgc 1680 aagaaaggaa gtttacatgc aaatgggaga cagaaagatg tagacaagga attctatttg 1740 tttcctacag tatttgatga gaatgagagt ttactcctgg aagataatat tagaatgttt 1800 acaactgcac ctgatcaggt ggataaggaa gatgaagact ttcaggaatc taataaaatg 1860 cactccatga atggattcat gtatgggaat cagccgggtc tcactatgtg caaaggagat 1920 tcggtcgtgt ggtacttatt cagcgccgga aatgaggccg atgtacatgg aatatacttt 1980 tcaggaaaca catatctgtg gagaggagaa cggagagaca cagcaaacct cttccctcaa 2040 acaagtctta cgctccacat gtggcctgac acagagggga cttttaatgt tgaatgcctt 2100 acaactgatc attacacagg cggcatgaag caaaaatata ctgtgaacca atgcaggcgg 2160 cagtctgagg attccacctt ctacctggga gagaggacat actatatcgc agcagtggag 2220 gtggaatggg attattcccc acaaagggag tgggaaaagg agctgcatca tttacaagag 2280 cagaatgttt caaatgcatt tttagataag ggagagtttt acataggctc aaagtacaag 2340 aaagttgtgt atcggcagta tactgatagc acattccgtg ttccagtgga gagaaaagct 2400 gaagaagaac atctgggaat tctaggtcca caacttcatg cagatgttgg agacaaagtc 2460 aaaattatct ttaaaaacat ggccacaagg ccctactcaa tacatgccca tggggtacaa 2520 acagagagtt ctacagttac tccaacatta ccaggtgaaa ctctcactta cgtatggaaa 2580 atcccagaaa gatctggagc tggaacagag gattctgctt gtattccatg ggcttattat 2640 tcaactgtgg atcaagttaa ggacctctac agtggattaa ttggccccct gattgtttgt 2700 cgaagacctt acttgaaagt attcaatccc agaaggaagc tggaatttgc ccttctgttt 2760 ctagtttttg atgagaatga atcttggtac ttagatgaca acatcaaaac atactctgat 2820 caccccgaga aagtaaacaa agatgatgag gaattcatag aaagcaataa aatgcatgct 2880 attaatggaa gaatgtttgg aaacctacaa ggcctcacaa tgcacgtggg agatgaagtc 2940 aactggtatc tgatgggaat gggcaatgaa atagacttac acactgtaca ttttcacggc 3000 catagcttcc aatacaagca caggggagtt tatagttctg atgtctttga cattttccct 3060 ggaacatacc aaaccctaga aatgtttcca agaacacctg gaatttggtt actccactgc 3120 catgtgaccg accacattca tgctggaatg gaaaccactt acaccgttct acaaaatgaa 3180 gacaccaaat ctggctgaat gaaataaatt ggtgataagt ggaaaaaaga gaaaaaccaa 3240 tgattcataa caatgtatgt gaaagtgtaa aatagaatgt tactttggaa tgactataaa 3300 cattaaaaga gactggagca t 3321 50 1065 PRT Homo sapiens 50 Met Lys Ile Leu Ile Leu Gly Ile Phe Leu Phe Leu Cys Ser Thr Pro 1 5 10 15 Ala Trp Ala Lys Glu Lys His Tyr Tyr Ile Gly Ile Ile Glu Thr Thr 20 25 30 Trp Asp Tyr Ala Ser Asp His Gly Glu Lys Lys Leu Ile Ser Val Asp 35 40 45 Thr Glu His Ser Asn Ile Tyr Leu Gln Asn Gly Pro Asp Arg Ile Gly 50 55 60 Arg Leu Tyr Lys Lys Ala Leu Tyr Leu Gln Tyr Thr Asp Glu Thr Phe 65 70 75 80 Arg Thr Thr Ile Glu Lys Pro Val Trp Leu Gly Phe Leu Gly Pro Ile 85 90 95 Ile Lys Ala Glu Thr Gly Asp Lys Val Tyr Val His Leu Lys Asn Leu 100 105 110 Ala Ser Arg Pro Tyr Thr Phe His Ser His Gly Ile Thr Tyr Tyr Lys 115 120 125 Glu His Glu Gly Ala Ile Tyr Pro Asp Asn Thr Thr Asp Phe Gln Arg 130 135 140 Ala Asp Asp Lys Val Tyr Pro Gly Glu Gln Tyr Thr Tyr Met Leu Leu 145 150 155 160 Ala Thr Glu Glu Gln Ser Pro Gly Glu Gly Asp Gly Asn Cys Val Thr 165 170 175 Arg Ile Tyr His Ser His Ile Asp Ala Pro Lys Asp Ile Ala Ser Gly 180 185 190 Leu Ile Gly Pro Leu Ile Ile Cys Lys Lys Asp Ser Leu Asp Lys Glu 195 200 205 Lys Glu Lys His Ile Asp Arg Glu Phe Val Val Met Phe Ser Val Val 210 215 220 Asp Glu Asn Phe Ser Trp Tyr Leu Glu Asp Asn Ile Lys Thr Tyr Cys 225 230 235 240 Ser Glu Pro Glu Lys Val Asp Lys Asp Asn Glu Asp Phe Gln Glu Ser 245 250 255 Asn Arg Met Tyr Ser Val Asn Gly Tyr Thr Phe Gly Ser Leu Pro Gly 260 265 270 Leu Ser Met Cys Ala Glu Asp Arg Val Lys Trp Tyr Leu Phe Gly Met 275 280 285 Gly Asn Glu Val Asp Val His Ala Ala Phe Phe His Gly Gln Ala Leu 290 295 300 Thr Asn Lys Asn Tyr Arg Ile Asp Thr Ile Asn Leu Phe Pro Ala Thr 305 310 315 320 Leu Phe Asp Ala Tyr Met Val Ala Gln Asn Pro Gly Glu Trp Met Leu 325 330 335 Ser Cys Gln Asn Leu Asn His Leu Lys Ala Gly Leu Gln Ala Phe Phe 340 345 350 Gln Val Gln Glu Cys Asn Lys Ser Ser Ser Lys Asp Asn Ile Arg Gly 355 360 365 Lys His Val Arg His Tyr Tyr Ile Ala Ala Glu Glu Ile Ile Trp Asn 370 375 380 Tyr Ala Pro Ser Gly Ile Asp Ile Phe Thr Lys Glu Asn Leu Thr Ala 385 390 395 400 Pro Gly Ser Asp Ser Ala Val Phe Phe Glu Gln Gly Thr Thr Arg Ile 405 410 415 Gly Gly Ser Tyr Lys Lys Leu Val Tyr Arg Glu Tyr Thr Asp Ala Ser 420 425 430 Phe Thr Asn Arg Lys Glu Arg Gly Pro Glu Glu Glu His Leu Gly Ile 435 440 445 Leu Gly Pro Val Ile Trp Ala Glu Val Gly Asp Thr Ile Arg Val Thr 450 455 460 Phe His Asn Lys Gly Ala Tyr Pro Leu Ser Ile Glu Pro Ile Gly Val 465 470 475 480 Arg Phe Asn Lys Asn Asn Glu Gly Thr Tyr Tyr Ser Pro Asn Tyr Asn 485 490 495 Pro Gln Ser Arg Ser Val Pro Pro Ser Ala Ser His Val Ala Pro Thr 500 505 510 Glu Thr Phe Thr Tyr Glu Trp Thr Val Pro Lys Glu Val Gly Pro Thr 515 520 525 Asn Ala Asp Pro Val Cys Leu Ala Lys Met Tyr Tyr Ser Ala Val Asp 530 535 540 Pro Thr Lys Asp Ile Phe Thr Gly Leu Ile Gly Pro Met Lys Ile Cys 545 550 555 560 Lys Lys Gly Ser Leu His Ala Asn Gly Arg Gln Lys Asp Val Asp Lys 565 570 575 Glu Phe Tyr Leu Phe Pro Thr Val Phe Asp Glu Asn Glu Ser Leu Leu 580 585 590 Leu Glu Asp Asn Ile Arg Met Phe Thr Thr Ala Pro Asp Gln Val Asp 595 600 605 Lys Glu Asp Glu Asp Phe Gln Glu Ser Asn Lys Met His Ser Met Asn 610 615 620 Gly Phe Met Tyr Gly Asn Gln Pro Gly Leu Thr Met Cys Lys Gly Asp 625 630 635 640 Ser Val Val Trp Tyr Leu Phe Ser Ala Gly Asn Glu Ala Asp Val His 645 650 655 Gly Ile Tyr Phe Ser Gly Asn Thr Tyr Leu Trp Arg Gly Glu Arg Arg 660 665 670 Asp Thr Ala Asn Leu Phe Pro Gln Thr Ser Leu Thr Leu His Met Trp 675 680 685 Pro Asp Thr Glu Gly Thr Phe Asn Val Glu Cys Leu Thr Thr Asp His 690 695 700 Tyr Thr Gly Gly Met Lys Gln Lys Tyr Thr Val Asn Gln Cys Arg Arg 705 710 715 720 Gln Ser Glu Asp Ser Thr Phe Tyr Leu Gly Glu Arg Thr Tyr Tyr Ile 725 730 735 Ala Ala Val Glu Val Glu Trp Asp Tyr Ser Pro Gln Arg Glu Trp Glu 740 745 750 Lys Glu Leu His His Leu Gln Glu Gln Asn Val Ser Asn Ala Phe Leu 755 760 765 Asp Lys Gly Glu Phe Tyr Ile Gly Ser Lys Tyr Lys Lys Val Val Tyr 770 775 780 Arg Gln Tyr Thr Asp Ser Thr Phe Arg Val Pro Val Glu Arg Lys Ala 785 790 795 800 Glu Glu Glu His Leu Gly Ile Leu Gly Pro Gln Leu His Ala Asp Val 805 810 815 Gly Asp Lys Val Lys Ile Ile Phe Lys Asn Met Ala Thr Arg Pro Tyr 820 825 830 Ser Ile His Ala His Gly Val Gln Thr Glu Ser Ser Thr Val Thr Pro 835 840 845 Thr Leu Pro Gly Glu Thr Leu Thr Tyr Val Trp Lys Ile Pro Glu Arg 850 855 860 Ser Gly Ala Gly Thr Glu Asp Ser Ala Cys Ile Pro Trp Ala Tyr Tyr 865 870 875 880 Ser Thr Val Asp Gln Val Lys Asp Leu Tyr Ser Gly Leu Ile Gly Pro 885 890 895 Leu Ile Val Cys Arg Arg Pro Tyr Leu Lys Val Phe Asn Pro Arg Arg 900 905 910 Lys Leu Glu Phe Ala Leu Leu Phe Leu Val Phe Asp Glu Asn Glu Ser 915 920 925 Trp Tyr Leu Asp Asp Asn Ile Lys Thr Tyr Ser Asp His Pro Glu Lys 930 935 940 Val Asn Lys Asp Asp Glu Glu Phe Ile Glu Ser Asn Lys Met His Ala 945 950 955 960 Ile Asn Gly Arg Met Phe Gly Asn Leu Gln Gly Leu Thr Met His Val 965 970 975 Gly Asp Glu Val Asn Trp Tyr Leu Met Gly Met Gly Asn Glu Ile Asp 980 985 990 Leu His Thr Val His Phe His Gly His Ser Phe Gln Tyr Lys His Arg 995 1000 1005 Gly Val Tyr Ser Ser Asp Val Phe Asp Ile Phe Pro Gly Thr Tyr Gln 1010 1015 1020 Thr Leu Glu Met Phe Pro Arg Thr Pro Gly Ile Trp Leu Leu His Cys 1025 1030 1035 1040 His Val Thr Asp His Ile His Ala Gly Met Glu Thr Thr Tyr Thr Val 1045 1050 1055 Leu Gln Asn Glu Asp Thr Lys Ser Gly 1060 1065 51 1603 DNA Homo sapiens 51 ggccagggat caggcagcgg ctcaggcgac cctgagtgtg cccccacccc gccatggccc 60 ggctgctgca ggcgtcctgc ctgctttccc tgctcctggc cggcttcgtc tcgcagagcc 120 ggggacaaga gaagtcgaag atggactgcc atggtggcat aagtggcacc atttacgagt 180 acggagccct caccattgat ggggaggagt acatcccctt caagcagtat gctggcaaat 240 acgtcctctt tgtcaacgtg gccagctact gaggcctgac gggccagtac attgaactga 300 atgcactaca ggaagagctt gcaccattcg gtctggtcat tctgggcttt ccctgcaacc 360 aatttggaaa acaggaacca ggagagaact cagagatcct tcctaccctc aagtatgtcc 420 gaccaggtgg aggctttgtc cctaatttcc agctctttga gaaaggggat gtcaatggag 480 agaaagagca gaaattctac actttcctaa agaactcctg tcctcccacc tcggagctcc 540 tgggtacatc tgaccgcctc ttctgggaac ccatgaaggt tcacgacatc cgctggaact 600 ttgagaagtt cctggtgggg ccagatggta tacccatcat gcgctggcac caccggacca 660 cggtcagcaa cgtcaagatg gacatcctgt cctacatgag gcggcaggca gccctggggg 720 tcaagaggaa gtaactgaag gccgtctcat cccatgtcca ccatgtaggg gagggacttt 780 gttcaggaag aaatccgtgt ctccaaccac actatctacc catcacagac ccctttccta 840 tcactcaagg ccccagcctg gcacaaatgg atgcatacag ttctgtgtac tgccaggcat 900 gtgggtgtgg gtgcatgtgg gtgtttacac acatgcctac aggtatgcgt gattgtgtgt 960 gtgtgcatgg gtgtacagcc acgtgtccta cctatgtgtc tttctgggaa tgtgtaccat 1020 ctgtgtgcct gcagctgtgt agtgctggac agtgacaacc ctttctctcc agttctccac 1080 tccaatgata atagttcact tacacctaaa cccaaaggaa aaaccagctc taggtccaat 1140 tgttctgctc taactgatac ctcaaccttg gggccagcat ctcccactgc ctccaaatat 1200 tagtaactat gactgacgtc cccagaagtt tctgggtcta ccacactccc caacccccca 1260 ctcctacttc ctgaagggcc ctcccaaggc tacatcccca ccccacagtt ctccctgaga 1320 gagatcaacc tccctagatc aaccaaggca gatgtgacaa gcaagggcca cggaccccat 1380 aggcaggggt ggcgtcttca tgagggaggg gcccaaagcc cttgtgggcg gacctcccct 1440 gagcctgtct gaggggccag cccttagtgc attcaggcta aggcccctgg gcagggatgc 1500 caccctgctc cttcggagga cgtgccctca cccctcactg gtccactggc ttgagactca 1560 ccccgtctgc ccagtaaaag cctttctgca gcaaaaaacc ccc 1603 52 226 PRT Homo sapiens VARIANT 0-00 Xaa = any amino acid 52 Met Ala Arg Leu Leu Gln Ala Ser Cys Leu Leu Ser Leu Leu Leu Ala 1 5 10 15 Gly Phe Val Ser Gln Ser Arg Gly Gln Glu Lys Ser Lys Met Asp Cys 20 25 30 His Gly Gly Ile Ser Gly Thr Ile Tyr Glu Tyr Gly Ala Leu Thr Ile 35 40 45 Asp Gly Glu Glu Tyr Ile Pro Phe Lys Gln Tyr Ala Gly Lys Tyr Val 50 55 60 Leu Phe Val Asn Val Ala Ser Tyr Xaa Gly Leu Thr Gly Gln Tyr Ile 65 70 75 80 Glu Leu Asn Ala Leu Gln Glu Glu Leu Ala Pro Phe Gly Leu Val Ile 85 90 95 Leu Gly Phe Pro Cys Asn Gln Phe Gly Lys Gln Glu Pro Gly Glu Asn 100 105 110 Ser Glu Ile Leu Pro Thr Leu Lys Tyr Val Arg Pro Gly Gly Gly Phe 115 120 125 Val Pro Asn Phe Gln Leu Phe Glu Lys Gly Asp Val Asn Gly Glu Lys 130 135 140 Glu Gln Lys Phe Tyr Thr Phe Leu Lys Asn Ser Cys Pro Pro Thr Ser 145 150 155 160 Glu Leu Leu Gly Thr Ser Asp Arg Leu Phe Trp Glu Pro Met Lys Val 165 170 175 His Asp Ile Arg Trp Asn Phe Glu Lys Phe Leu Val Gly Pro Asp Gly 180 185 190 Ile Pro Ile Met Arg Trp His His Arg Thr Thr Val Ser Asn Val Lys 195 200 205 Met Asp Ile Leu Ser Tyr Met Arg Arg Gln Ala Ala Leu Gly Val Lys 210 215 220 Arg Lys 225 53 399 DNA Homo sapiens 53 atgaagtcca gcggcctctt ccccttcctg gtgctgcttg ccctgggaac tctggcacct 60 tgggctgtgg aaggctctgg aaagtccttc aaagctggag tctgtcctcc taagaaatct 120 gcccagtgcc ttagatacaa gaaacctgag tgccagagtg actggcagtg tccagggaag 180 aagagatgtt gtcctgacac ttgtggcatc aaatgcctgg atcctgttga caccccaaac 240 ccaacaagga ggaagcctgg gaagtgccca gtgacttatg gccaatgttt gatgcttaac 300 ccccccaatt tctgtgagat ggatggccag tgcaagcgtg acttgaagtg ttgcatgggc 360 atgtgtggga aatcctgcgt ttcccctgtg aaagcttga 399 54 132 PRT Homo sapiens 54 Met Lys Ser Ser Gly Leu Phe Pro Phe Leu Val Leu Leu Ala Leu Gly 1 5 10 15 Thr Leu Ala Pro Trp Ala Val Glu Gly Ser Gly Lys Ser Phe Lys Ala 20 25 30 Gly Val Cys Pro Pro Lys Lys Ser Ala Gln Cys Leu Arg Tyr Lys Lys 35 40 45 Pro Glu Cys Gln Ser Asp Trp Gln Cys Pro Gly Lys Lys Arg Cys Cys 50 55 60 Pro Asp Thr Cys Gly Ile Lys Cys Leu Asp Pro Val Asp Thr Pro Asn 65 70 75 80 Pro Thr Arg Arg Lys Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys 85 90 95 Leu Met Leu Asn Pro Pro Asn Phe Cys Glu Met Asp Gly Gln Cys Lys 100 105 110 Arg Asp Leu Lys Cys Cys Met Gly Met Cys Gly Lys Ser Cys Val Ser 115 120 125 Pro Val Lys Ala 130 55 3557 DNA Homo sapiens 55 gagagggtcc ttcagggtct gcttatgccc ttgttcaaga acaccagtgt cagctctctg 60 tactctggtt gcagactgac cttgctcagg cctgagaagg atggggcagc caccagagtg 120 gatgctgtct gcacccatcg tcctgacccc aaaagccctg gactggacag agagcggctg 180 tactggaagc tgagccagct gacccacggc atcactgagc tgggccccta caccctggac 240 aggcacagtc tctatgtcaa tggtttcacc catcagagct ctatgacgac caccagaact 300 cctgatacct ccacaatgca cctggcaacc tcgagaactc cagcctccct gtctggacct 360 acgaccgcca gccctctcct ggtgctattc acaattaact tcaccatcac taacctgcgg 420 tatgaggaga acatgcatca ccctggctct agaaagttta acaccacgga gagagtcctt 480 cagggtctgc tcaggcctgt gttcaagaac accagtgttg gccctctgta ctctggctgc 540 agactgacct tgctcaggcc caagaaggat ggggcagcca ccaaagtgga tgccatctgc 600 acctaccgcc ctgatcccaa aagccctgga ctggacagag agcagctata ctgggagctg 660 agccagctaa cccacagcat cactgagctg ggcccctaca ccctggacag ggacagtctc 720 tatgtcaatg gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc 780 acagtggacc tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc 840 cctctcctgg tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac 900 atgcagcacc ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc 960 aggtccctgt tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg 1020 ctcaggcctg aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct 1080 gaccccaaaa gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc 1140 cacaatatca ctgagctggg ccactatgcc ctggacaacg acagcctctt tgtcaatggt 1200 ttcactcatc ggagctctgt gtccaccacc agcactcctg ggacccccac agtgtatctg 1260 ggagcatcta agactccagc ctcgatattt ggcccttcag ctgccagcca tctcctgata 1320 ctattcaccc tcaacttcac catcactaac ctgcggtatg aggagaacat gtggcctggc 1380 tccaggaagt tcaacactac agagagggtc cttcagggcc tgctaaggcc cttgttcaag 1440 aacaccagtg ttggccctct gtactctggc tccaggctga ccttgctcag gccagagaaa 1500 gatggggaag ccaccggagt ggatgccatc tgcacccacc gccctgaccc cacaggccct 1560 gggctggaca gagagcagct gtatttggag ctgagccagc tgacccacag catcactgag 1620 ctgggcccct acacactgga cagggacagt ctctatgtca atggtttcac ccatcggagc 1680 tctgtaccca ccaccagcac cggggtggtc agcgaggagc cattcacact gaacttcacc 1740 atcaacaacc tgcgctacat ggcggacatg ggccaacccg gctccctcaa gttcaacatc 1800 acagacaacg tcatgaagca cctgctcagt cctttgttcc agaggagcag cctgggtgca 1860 cggtacacag gctgcagggt catcgcacta aggtctgtga agaacggtgc tgagacacgg 1920 gtggacctcc tctgcaccta cctgcagccc ctcagcggcc caggtctgcc tatcaagcag 1980 gtgttccatg agctgagcca gcagacccat ggcatcaccc ggctgggccc ctactctctg 2040 gacaaagaca gcctctacct taacggttac aatgaacctg gtctagatga gcctcctaca 2100 actcccaagc cagccaccac attcctgcct cctctgtcag aagccacaac agccatgggg 2160 taccacctga agaccctcac actcaacttc accatctcca atctccagta ttcaccagat 2220 atgggcaagg gctcagctac attcaactcc accgaggggg tccttcagca cctgctcaga 2280 cccttgttcc agaagagcag catgggcccc ttctacttgg gttgccaact gatctccctc 2340 aggcctgaga aggatggggc agccactggt gtggacacca cctgcaccta ccaccctgac 2400 cctgtgggcc ccgggctgga catacagcag ctttactggg agctgagtca gctgacccat 2460 ggtgtcaccc aactgggctt ctatgtcctg gacagggata gcctcttcat caatggctat 2520 gcaccccaga atttatcaat ccggggcgag taccagataa atttccacat tgtcaactgg 2580 aacctcagta atccagaccc cacatcctca gagtacatca ccctgctgag ggacatccag 2640 gacaaggtca ccacactcta caaaggcagt caactacatg acacattccg cttctgcctg 2700 gtcaccaact tgacgatgga ctccgtgttg gtcactgtca aggcattgtt ctcctccaat 2760 ttggacccca gcctggtgga gcaagtcttt ctagataaga ccctgaatgc ctcattccat 2820 tggctgggct ccacctacca gttggtggac atccatgtga cagaaatgga gtcatcagtt 2880 tatcaaccaa caagcagctc cagcacccag cacttctacc cgaatttcac catcaccaac 2940 ctaccatatt cccaggacaa agcccagcca ggcaccacca attaccagag gaacaaaagg 3000 aatattgagg atgcgctcaa ccaactcttc cgaaacagca gcatcaagag ttatttttct 3060 gactgtcaag tttcaacatt caggtctgtc cccaacaggc accacaccgg ggtggactcc 3120 ctgtgtaact tctcgccact ggctcggaga gtagacagag ttgccatcta tgaggaattt 3180 ctgcggatga cccggaatgg tacccagctg cagaacttca ccctggacag gagcagtgtc 3240 cttgtggatg ggtattctcc caacagaaat gagcccttaa ctgggaattc tgaccttccc 3300 ttctgggctg tcatcttcat cggcttggca ggactcctgg gactcatcac atgcctgatc 3360 tgcggtgtcc tggtgaccac ccgccggcgg aagaaggaag gagaatacaa cgtccagcaa 3420 cagtgcccag gctactacca gtcacaccta gacctggagg atctgcaatg actggaactt 3480 gccggtgcct ggggtgcctt tcccccagcc agggtccaaa gaagcttggc tggggcagaa 3540 ataaaccata ttggtcg 3557 56 1148 PRT Homo sapiens 56 Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys 1 5 10 15 Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val 20 25 30 Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp 35 40 45 Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr 50 55 60 Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly 65 70 75 80 Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser 85 90 95 Thr Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro 100 105 110 Thr Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile 115 120 125 Thr Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys 130 135 140 Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Phe 145 150 155 160 Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu 165 170 175 Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile Cys 180 185 190 Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln Leu 195 200 205 Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro 210 215 220 Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg 225 230 235 240 Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Pro Thr Val Asp Leu 245 250 255 Gly Thr Ser Gly Thr Pro Val Ser Lys Pro Gly Pro Ser Ala Ala Ser 260 265 270 Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg 275 280 285 Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr 290 295 300 Glu Arg Val Leu Gln Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser 305 310 315 320 Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu 325 330 335 Lys Asp Gly Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro 340 345 350 Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu 355 360 365 Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly His Tyr Ala Leu Asp 370 375 380 Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser Val Ser 385 390 395 400 Thr Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala Ser Lys 405 410 415 Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala Ser His Leu Leu Ile 420 425 430 Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn 435 440 445 Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln 450 455 460 Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr 465 470 475 480 Ser Gly Ser Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu Ala 485 490 495 Thr Gly Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Thr Gly Pro 500 505 510 Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu Ser Gln Leu Thr His 515 520 525 Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr 530 535 540 Val Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly 545 550 555 560 Val Val Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu 565 570 575 Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile 580 585 590 Thr Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser 595 600 605 Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser 610 615 620 Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu 625 630 635 640 Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu 645 650 655 Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu 660 665 670 Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Leu Asp 675 680 685 Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro Leu 690 695 700 Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr Leu 705 710 715 720 Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly 725 730 735 Ser Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg 740 745 750 Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln 755 760 765 Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp 770 775 780 Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile 785 790 795 800 Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln 805 810 815 Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr 820 825 830 Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His 835 840 845 Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr 850 855 860 Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys 865 870 875 880 Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr Asn Leu 885 890 895 Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser Ser Asn 900 905 910 Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn 915 920 925 Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His 930 935 940 Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser 945 950 955 960 Thr Gln His Phe Tyr Pro Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser 965 970 975 Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg 980 985 990 Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys 995 1000 1005 Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn 1010 1015 1020 Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala 1025 1030 1035 1040 Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr 1045 1050 1055 Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val 1060 1065 1070 Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn 1075 1080 1085 Ser Asp Leu Pro Phe Trp Ala Val Ile Phe Ile Gly Leu Ala Gly Leu 1090 1095 1100 Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg 1105 1110 1115 1120 Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly 1125 1130 1135 Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln 1140 1145 57 853 DNA Homo sapiens 57 ctagtcctga cttcacttct gatgaggaag cctctctcct tagccttcag cctttcctcc 60 caccctgcca taagtaattt gatcctcaag aagttaaacc acacctcatt ggtccctggc 120 taattcacca atttacaaac agcaggaaat agaaacttaa gagaaataca cacttctgag 180 aaactgaaac gacaggggaa aggaggtctc actgagcacc gtcccagcat ccggacacca 240 cagcggccct tcgctccacg cagaaaacca cacttctcaa accttcactc aacacttcct 300 tccccaaagc cagaagatgc acaaggagga acatgaggtg gctgtgctgg gggcaccccc 360 cagcaccatc cttccaaggt ccaccgtgat caacatccac agcgagacct ccgtgcccga 420 ccatgtcgtc tggtccctgt tcaacaccct cttcttgaac tggtgctgtc tgggcttcat 480 agcattcgcc tactccgtga agtctaggga caggaagatg gttggcgacg tgaccggggc 540 ccaggcctat gcctccaccg ccaagtgcct gaacatctgg gccctgattc tgggcatcct 600 catgaccatt ggattcatcc tgtcactggt attcggctct gtgacagtct accatattat 660 gttacagata atacaggaaa aacggggtta ctagtagccg cccatagcct gcaacctttg 720 cactccactg tgcaatgctg gccctgcacg ctggggctgt tgcccctgcc cccttggtcc 780 tgcccctaga tacagcagtt tatacccaca cacctgtcta cagtgtcatt caataaagtg 840 cacgtgcttg tga 853 58 125 PRT Homo sapiens 58 Met His Lys Glu Glu His Glu Val Ala Val Leu Gly Ala Pro Pro Ser 1 5 10 15 Thr Ile Leu Pro Arg Ser Thr Val Ile Asn Ile His Ser Glu Thr Ser 20 25 30 Val Pro Asp His Val Val Trp Ser Leu Phe Asn Thr Leu Phe Leu Asn 35 40 45 Trp Cys Cys Leu Gly Phe Ile Ala Phe Ala Tyr Ser Val Lys Ser Arg 50 55 60 Asp Arg Lys Met Val Gly Asp Val Thr Gly Ala Gln Ala Tyr Ala Ser 65 70 75 80 Thr Ala Lys Cys Leu Asn Ile Trp Ala Leu Ile Leu Gly Ile Leu Met 85 90 95 Thr Ile Gly Phe Ile Leu Ser Leu Val Phe Gly Ser Val Thr Val Tyr 100 105 110 His Ile Met Leu Gln Ile Ile Gln Glu Lys Arg Gly Tyr 115 120 125 59 1512 DNA Homo sapiens 59 ttccggtccc ccaggacatg tccaatcagg gaagtaagta cgtcaataag gaaattcaaa 60 atgctgtcaa cggggtgaaa cagataaaga ctctcataga aaaaacaaac gaagagcgca 120 agacactgct cagcaaccta gaagaagcca agaagaagaa agaggatgcc ctaaatgaga 180 ccagggaatc agagacaaag ctgaaggagc tcccaggagt gtgcaatgag accatgatgg 240 ccctctggga agagtgtaag ccctgcctga aacagacctg catgaagttc tacgcacgcg 300 tctgcagaag tggctcaggc ctggttggcc gccagcttga ggagttcctg aaccagagct 360 cgcccttcta cttctggatg aatggtgacc gcatcgactc cctgctggag aacgaccggc 420 agcagacgca catgctggat gtcatgcagg accacttcag ccgcgcgtcc agcatcatag 480 acgagctctt ccaggacagg ttcttcaccc gggagcccca ggatacctac cactacctgc 540 ccttcagcct gccccaccgg aggcctcact tcttctttcc caagtcccgc atcgtccgca 600 gcttgatgcc cttctctccg tacgagcccc tgaacttcca cgccatgttc cagcccttcc 660 ttgagatgat acacgaggct cagcaggcca tggacatcca cttccacagc ccggccttcc 720 agcacccgcc aacagaattc atacgagaag gcgacgatga ccggactgtg tgccgggaga 780 tccgccacaa ctccacgggc tgcctgcgga tgaaggacca gtgtgacaag tgccgggaga 840 tcttgtctgt ggactgttcc accaacaacc cctcccaggc taagctgcgg cgggagctcg 900 acgaatccct ccaggtcgct gagaggttga ccaggaaata caacgagctg ctaaagtcct 960 accagtggaa gatgctcaac acctcctcct tgctggagca gctgaacgag cagtttaact 1020 gggtgtcccg gctggcaaac ctcacgcaag gcgaagacca gtactatctg cgggtcacca 1080 cggtggcttc ccacacttct gactcggacg ttccttccgg tgtcactgag gtggtcgtga 1140 agctctttga ctctgatccc atcactgtga cggtccctgt agaagtctcc aggaagaacc 1200 ctaaatttat ggagaccgtg gcggagaaag cgctgcagga ataccgcaaa aagcaccggg 1260 aggagtgaga tgtggatgtt gcttttgcac ctacgggggc atctgagtcc agctcccccc 1320 aagatgagct gcagcccccc agagagagct ctgcacgtca ccaagtaacc aggccccagc 1380 ctccaggccc ccaactccgc ccagcctctc cccgctctgg atcctgcact ctaacactcg 1440 actctgctgc tcatgggaag aacagaattg ctcctgcatg caactaattc aataaaactg 1500 tcttgtgagc tg 1512 60 416 PRT Homo sapiens 60 Met Ser Asn Gln Gly Ser Lys Tyr Val Asn Lys Glu Ile Gln Asn Ala 1 5 10 15 Val Asn Gly Val Lys Gln Ile Lys Thr Leu Ile Glu Lys Thr Asn Glu 20 25 30 Glu Arg Lys Thr Leu Leu Ser Asn Leu Glu Glu Ala Lys Lys Lys Lys 35 40 45 Glu Asp Ala Leu Asn Glu Thr Arg Glu Ser Glu Thr Lys Leu Lys Glu 50 55 60 Leu Pro Gly Val Cys Asn Glu Thr Met Met Ala Leu Trp Glu Glu Cys 65 70 75 80 Lys Pro Cys Leu Lys Gln Thr Cys Met Lys Phe Tyr Ala Arg Val Cys 85 90 95 Arg Ser Gly Ser Gly Leu Val Gly Arg Gln Leu Glu Glu Phe Leu Asn 100 105 110 Gln Ser Ser Pro Phe Tyr Phe Trp Met Asn Gly Asp Arg Ile Asp Ser 115 120 125 Leu Leu Glu Asn Asp Arg Gln Gln Thr His Met Leu Asp Val Met Gln 130 135 140 Asp His Phe Ser Arg Ala Ser Ser Ile Ile Asp Glu Leu Phe Gln Asp 145 150 155 160 Arg Phe Phe Thr Arg Glu Pro Gln Asp Thr Tyr His Tyr Leu Pro Phe 165 170 175 Ser Leu Pro His Arg Arg Pro His Phe Phe Phe Pro Lys Ser Arg Ile 180 185 190 Val Arg Ser Leu Met Pro Phe Ser Pro Tyr Glu Pro Leu Asn Phe His 195 200 205 Ala Met Phe Gln Pro Phe Leu Glu Met Ile His Glu Ala Gln Gln Ala 210 215 220 Met Asp Ile His Phe His Ser Pro Ala Phe Gln His Pro Pro Thr Glu 225 230 235 240 Phe Ile Arg Glu Gly Asp Asp Asp Arg Thr Val Cys Arg Glu Ile Arg 245 250 255 His Asn Ser Thr Gly Cys Leu Arg Met Lys Asp Gln Cys Asp Lys Cys 260 265 270 Arg Glu Ile Leu Ser Val Asp Cys Ser Thr Asn Asn Pro Ser Gln Ala 275 280 285 Lys Leu Arg Arg Glu Leu Asp Glu Ser Leu Gln Val Ala Glu Arg Leu 290 295 300 Thr Arg Lys Tyr Asn Glu Leu Leu Lys Ser Tyr Gln Trp Lys Met Leu 305 310 315 320 Asn Thr Ser Ser Leu Leu Glu Gln Leu Asn Glu Gln Phe Asn Trp Val 325 330 335 Ser Arg Leu Ala Asn Leu Thr Gln Gly Glu Asp Gln Tyr Tyr Leu Arg 340 345 350 Val Thr Thr Val Ala Ser His Thr Ser Asp Ser Asp Val Pro Ser Gly 355 360 365 Val Thr Glu Val Val Val Lys Leu Phe Asp Ser Asp Pro Ile Thr Val 370 375 380 Thr Val Pro Val Glu Val Ser Arg Lys Asn Pro Lys Phe Met Glu Thr 385 390 395 400 Val Ala Glu Lys Ala Leu Gln Glu Tyr Arg Lys Lys His Arg Glu Glu 405 410 415 61 1564 DNA Homo sapiens 61 cggacgcgtg ggcggacgcg tgggcgaggg cgcgagtgag gagcagaccc aggcatcgcg 60 cgccgagaag gccggagcgt cggcacctga acgcgaggcg ctccattgcg cgtgcgcgtt 120 gaggggcttc ccgcacctga tcgcgagacc ccaacggctg gtggcgtcgc ctgcgcgggc 180 gtccccacac tgccggtccg gaaaggcgac ttccgggggc tttggcacct ggcggacgct 240 cccggagcgt cggcacctga acgcgaggcg ctccattgcg cgtgcgcgtt gaggggcttc 300 ccgcacctga tcgcgagacc ccaacggctg gtggcgtcgc ctgcgcgtct cggctgagct 360 ggccatggcg cacctgtgcg ggctgaggcg gagccgggcg tttctcgccc tgctgggatc 420 gctgctcctc tctggggtcc tggcggccga ccgagaacgc agcatccacg acttctgcct 480 ggtgtcgaag gtggtgggca gatgccgggc ctccatgcct aagtggtggt acaatgtcac 540 tgacggatcc tgccagctgt ttgtgtatgg gggctgtgac ggaaacagca ataattacct 600 gaccaaggag gagtgcctca agaaatgtgc cactgtcaca gagaatgcca cgggtgacct 660 ggccaccagc aggaatgcag cggattcctc tgtcccaagt gctcccagaa ggcaggattc 720 tgaagaccac tccagcgata tgttcaacta tgaagaatac tgcaccgcca acgcagtcac 780 tgggccttgc cgtgcatcct tcccacgctg gtactttgac gtggagagga actcctgcaa 840 taacttcatc tatggaggct gccggggcaa taagaacagc taccgctctg aggaggcctg 900 catgctccgc tgcttccgcc agcaggagaa tcctcccctg ccccttggct caaaggtggt 960 ggttctggcg gggctgttcg tgatggtgtt gatcctcttc ctgggagcct ccatggtcta 1020 cctgatccgg gtggcacgga ggaaccagga gcgtgccctg cgcaccgtct ggagctccgg 1080 acatgacaag gagcagctgg tgaagaacac atatgtcctg tgaccgccct gtcgccaaga 1140 ggactgggga agggagggga gactatgtgt gagctttttt taaatagcgg gattgactcg 1200 gatttgagtg atcattaggg ctgaggtgtg tttctctggg aggtaggacg gctgcttcct 1260 ggtctggcag ggatgggttt gctttggaaa tcctctagga ggctcctcct cgcatggcct 1320 gcagtctggc agcagccccg agttgtttcc tcgctgatcg atttctttcc tccaggtaga 1380 gttttctttg cttatgttga attccattgc ctcttttctc atcacagaag tgatgttgga 1440 atcgtttctt ttgtttgtct gatttatggt ttttttaagt ataaacaaaa gttttttatt 1500 aacatctgaa agaaggaaag taaaatgtac aagtttaata aaaaggggcc ttccccttta 1560 gaat 1564 62 252 PRT Homo sapiens 62 Met Ala His Leu Cys Gly Leu Arg Arg Ser Arg Ala Phe Leu Ala Leu 1 5 10 15 Leu Gly Ser Leu Leu Leu Ser Gly Val Leu Ala Ala Asp Arg Glu Arg 20 25 30 Ser Ile His Asp Phe Cys Leu Val Ser Lys Val Val Gly Arg Cys Arg 35 40 45 Ala Ser Met Pro Lys Trp Trp Tyr Asn Val Thr Asp Gly Ser Cys Gln 50 55 60 Leu Phe Val Tyr Gly Gly Cys Asp Gly Asn Ser Asn Asn Tyr Leu Thr 65 70 75 80 Lys Glu Glu Cys Leu Lys Lys Cys Ala Thr Val Thr Glu Asn Ala Thr 85 90 95 Gly Asp Leu Ala Thr Ser Arg Asn Ala Ala Asp Ser Ser Val Pro Ser 100 105 110 Ala Pro Arg Arg Gln Asp Ser Glu Asp His Ser Ser Asp Met Phe Asn 115 120 125 Tyr Glu Glu Tyr Cys Thr Ala Asn Ala Val Thr Gly Pro Cys Arg Ala 130 135 140 Ser Phe Pro Arg Trp Tyr Phe Asp Val Glu Arg Asn Ser Cys Asn Asn 145 150 155 160 Phe Ile Tyr Gly Gly Cys Arg Gly Asn Lys Asn Ser Tyr Arg Ser Glu 165 170 175 Glu Ala Cys Met Leu Arg Cys Phe Arg Gln Gln Glu Asn Pro Pro Leu 180 185 190 Pro Leu Gly Ser Lys Val Val Val Leu Ala Gly Leu Phe Val Met Val 195 200 205 Leu Ile Leu Phe Leu Gly Ala Ser Met Val Tyr Leu Ile Arg Val Ala 210 215 220 Arg Arg Asn Gln Glu Arg Ala Leu Arg Thr Val Trp Ser Ser Gly His 225 230 235 240 Asp Lys Glu Gln Leu Val Lys Asn Thr Tyr Val Leu 245 250 63 1147 DNA Homo sapiens 63 ggacgtcctt ccccaggagc cgactggcca atcacaggca ggaagatgaa ggttctgtgg 60 gctgcgttgc tggtcacatt cctggcagga tgccaggcca aggtggagca agcggtggag 120 acagagccgg agcccgagct gcgccagcag accgagtggc agagcggcca gcgctgggaa 180 ctggcactgg gtcgcttttg ggattacctg cgctgggtgc agacactgtc tgagcaggtg 240 caggaggagc tgctcagctc ccaggtcacc caggaactga gggcgctgat ggacgagacc 300 atgaaggagt tgaaggccta caaatcggaa ctggaggaac aactgacccc ggtggcggag 360 gagacgcggg cacggctgtc caaggagctg caggcggcgc aggcccggct gggcgcggac 420 atggaggacg tgtgcggccg cctggtgcag taccgcggcg aggtgcaggc catgctcggc 480 cagagcaccg aggagctgcg ggtgcgcctc gcctcccacc tgcgcaagct gcgtaagcgg 540 ctcctccgcg atgccgatga cctgcagaag cgcctggcag tgtaccaggc cggggcccgc 600 gagggcgccg agcgcggcct cagcgccatc cgcgagcgcc tggggcccct ggtggaacag 660 ggccgcgtgc gggccgccac tgtgggctcc ctggccggcc agccgctaca ggagcgggcc 720 caggcctggg gcgagcggct gcgcgcgcgg atggaggaga tgggcagccg gacccgcgac 780 cgcctggacg aggtgaagga gcaggtggcg gaggtgcgcg ccaagctgga ggagcaggcc 840 cagcagatac gcctgcaggc cgaggccttc caggcccgcc tcaagagctg gttcgagccc 900 ctggtggaag acatgcagcg ccagtgggcc gggctggtgg agaaggtgca ggctgccgtg 960 ggcaccagcg ccgcccctgt gcccagcgac aatcactgaa cgccgaagcc tgcagccatg 1020 cgaccccacg ccaccccgtg cctcctgcct ccgcgcagcc tgcagcggga gaccctgtcc 1080 ccgccccagc cgtcctcctg gggtggaccc tagtttaata aagattcacc aagtttcacg 1140 caaaaaa 1147 64 317 PRT Homo sapiens 64 Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys 1 5 10 15 Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu 20 25 30 Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu 35 40 45 Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln 50 55 60 Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala 65 70 75 80 Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu 85 90 95 Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser 100 105 110 Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp 115 120 125 Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu 130 135 140 Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg 145 150 155 160 Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg 165 170 175 Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu 180 185 190 Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val 195 200 205 Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg 210 215 220 Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly 225 230 235 240 Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu 245 250 255 Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala 260 265 270 Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu 275 280 285 Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala 290 295 300 Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His 305 310 315 65 2493 DNA Homo sapiens 65 ggatcgattt gagtaagagc atagctgtcg ggagagccca ggattcaaca cgggccttga 60 gaaatgtggc tcttgtacct cctggtgccg gccctgttct gcagggcagg aggctccatt 120 cccatccctc agaagttatt tggggaggtg acttcccctc tgttccccaa gccttacccc 180 aacaactttg aaacaaccac tgtgatcaca gtccccacgg gatacagggt gaagctcgtc 240 ttccagcagt ttgacctgga gccttctgaa ggctgcttct atgattatgt caagatctct 300 gctgataaga aaagcctggg gaggttctgt gggcaactgg gttctccact gggcaacccc 360 ccgggaaaga aggaatttat gtcccaaggg aacaagatgc tgctgacctt ccacacagac 420 ttctccaacg aggagaatgg gaccatcatg ttctacaagg gcttcctggc ctactaccaa 480 gctgtggacc ttgatgaatg tgcttcccgg agcaaatcag gggaggagga tccccagccc 540 cagtgccagc acctgtgtca caactacgtt ggaggctact tctgttcctg ccgtccaggc 600 tatgagcttc aggaagacag gcattcctgc caggctgagt gcagcagcga gctgtacacg 660 gaggcatcag gctacatctc cagcctggag taccctcggt cctacccccc tgacctgcgc 720 tgcaactaca gcatccgggt ggagcggggc ctcaccctgc acctcaagtt cctggagcct 780 tttgatattg atgaccacca gcaagtacac tgcccctatg accagctaca gatctatgcc 840 aacgggaaga acattggcga gttctgtggg aagcaaaggc cccccgacct cgacaccagc 900 agcaatgctg tggatctgct gttcttcaca gatgagtcgg gggacagccg gggctggaag 960 ctgcgctaca ccaccgagat catcaagtgc ccccagccca agaccctaga cgagttcacc 1020 atcatccaga acctgcagcc tcagtaccag ttccgtgact acttcattgc tacctgcaag 1080 caaggctacc agctcataga ggggaaccag gtgctgcatt ccttcacagc tgtctgccag 1140 gatgatggca cgtggcatcg tgccatgccc agatgcaaga tcaaggactg tgggcagccc 1200 cgaaacctgc ctaatggtga cttccgttac accaccacaa tgggagtgaa cacctacaag 1260 gcccgtatcc agtactactg ccatgagcca tattacaaga tgcagaccag agctggcagc 1320 agggagtctg agcaaggggt gtacacctgc acagcacagg gcatttggaa gaatgaacag 1380 aagggagaga agattcctcg gtgcttgcca gtgtgtggga agcccgtgaa ccccgtggaa 1440 cagaggcagc gcataatcgg agggcaaaaa gccaagatgg gcaacttccc ctggcaggtg 1500 ttcaccaaca tccacgggcg cgggggcggg gccctgctgg gcgaccgctg gatcctcaca 1560 gctgcccaca ccctgtatcc caaggaacac gaagcgcaaa gcaacgcctc tttggatgtg 1620 ttcctgggcc acacaaatgt ggaagagctc atgaagctag gaaatcaccc catccgcagg 1680 gtcagcgtcc acccggacta ccgtcaggat gagtcctaca attttgaggg ggacatcgcc 1740 ctgctggagc tggaaaatag tgtcaccctg ggtcccaacc tcctccccat ctgcctccct 1800 gacaacgata ccttctacga cctgggcttg atgggctatg tcagtggctt cggggtcatg 1860 gaggagaaga ttgctcatga cctcaggttt gtccgtctgc ccgtagctaa tccacaggcc 1920 tgtgagaact ggctccgggg aaagaatagg atggatgtgt tctctcaaaa catgttctgt 1980 gctggacacc catctctaaa gcaggacgcc tgccaggggg atagtggggg cgtttttgca 2040 gtaagggacc cgaacactga tcgctgggtg gccacgggca tcgtgtcctg gggcatcggg 2100 tgcagcaggg gctatggctt ctacaccaaa gtgctcaact acgtggactg gatcaagaaa 2160 gagatggagg aggaggactg agcccagaat tcactaggtt cgaatccaga gagcagtgtg 2220 gaaaaaaaaa aaacaaaaaa caactgacca gttgttgata accactaaga gtctctatta 2280 aaattactga tgcagaaaga ccgtgtgtga aattctcttt cctgtagtcc cattgatgta 2340 ctttacctga aacaacccaa aggccccttt ctttcttctg aggattgcag aggatatagt 2400 tatcaatctc tagttgtcac tttcctcttc cactttgata ccattgggtc attgaatata 2460 actttttcca aataaagttt tatgagaaat gcc 2493 66 705 PRT Homo sapiens 66 Met Trp Leu Leu Tyr Leu Leu Val Pro Ala Leu Phe Cys Arg Ala Gly 1 5 10 15 Gly Ser Ile Pro Ile Pro Gln Lys Leu Phe Gly Glu Val Thr Ser Pro 20 25 30 Leu Phe Pro Lys Pro Tyr Pro Asn Asn Phe Glu Thr Thr Thr Val Ile 35 40 45 Thr Val Pro Thr Gly Tyr Arg Val Lys Leu Val Phe Gln Gln Phe Asp 50 55 60 Leu Glu Pro Ser Glu Gly Cys Phe Tyr Asp Tyr Val Lys Ile Ser Ala 65 70 75 80 Asp Lys Lys Ser Leu Gly Arg Phe Cys Gly Gln Leu Gly Ser Pro Leu 85 90 95 Gly Asn Pro Pro Gly Lys Lys Glu Phe Met Ser Gln Gly Asn Lys Met 100 105 110 Leu Leu Thr Phe His Thr Asp Phe Ser Asn Glu Glu Asn Gly Thr Ile 115 120 125 Met Phe Tyr Lys Gly Phe Leu Ala Tyr Tyr Gln Ala Val Asp Leu Asp 130 135 140 Glu Cys Ala Ser Arg Ser Lys Ser Gly Glu Glu Asp Pro Gln Pro Gln 145 150 155 160 Cys Gln His Leu Cys His Asn Tyr Val Gly Gly Tyr Phe Cys Ser Cys 165 170 175 Arg Pro Gly Tyr Glu Leu Gln Glu Asp Arg His Ser Cys Gln Ala Glu 180 185 190 Cys Ser Ser Glu Leu Tyr Thr Glu Ala Ser Gly Tyr Ile Ser Ser Leu 195 200 205 Glu Tyr Pro Arg Ser Tyr Pro Pro Asp Leu Arg Cys Asn Tyr Ser Ile 210 215 220 Arg Val Glu Arg Gly Leu Thr Leu His Leu Lys Phe Leu Glu Pro Phe 225 230 235 240 Asp Ile Asp Asp His Gln Gln Val His Cys Pro Tyr Asp Gln Leu Gln 245 250 255 Ile Tyr Ala Asn Gly Lys Asn Ile Gly Glu Phe Cys Gly Lys Gln Arg 260 265 270 Pro Pro Asp Leu Asp Thr Ser Ser Asn Ala Val Asp Leu Leu Phe Phe 275 280 285 Thr Asp Glu Ser Gly Asp Ser Arg Gly Trp Lys Leu Arg Tyr Thr Thr 290 295 300 Glu Ile Ile Lys Cys Pro Gln Pro Lys Thr Leu Asp Glu Phe Thr Ile 305 310 315 320 Ile Gln Asn Leu Gln Pro Gln Tyr Gln Phe Arg Asp Tyr Phe Ile Ala 325 330 335 Thr Cys Lys Gln Gly Tyr Gln Leu Ile Glu Gly Asn Gln Val Leu His 340 345 350 Ser Phe Thr Ala Val Cys Gln Asp Asp Gly Thr Trp His Arg Ala Met 355 360 365 Pro Arg Cys Lys Ile Lys Asp Cys Gly Gln Pro Arg Asn Leu Pro Asn 370 375 380 Gly Asp Phe Arg Tyr Thr Thr Thr Met Gly Val Asn Thr Tyr Lys Ala 385 390 395 400 Arg Ile Gln Tyr Tyr Cys His Glu Pro Tyr Tyr Lys Met Gln Thr Arg 405 410 415 Ala Gly Ser Arg Glu Ser Glu Gln Gly Val Tyr Thr Cys Thr Ala Gln 420 425 430 Gly Ile Trp Lys Asn Glu Gln Lys Gly Glu Lys Ile Pro Arg Cys Leu 435 440 445 Pro Val Cys Gly Lys Pro Val Asn Pro Val Glu Gln Arg Gln Arg Ile 450 455 460 Ile Gly Gly Gln Lys Ala Lys Met Gly Asn Phe Pro Trp Gln Val Phe 465 470 475 480 Thr Asn Ile His Gly Arg Gly Gly Gly Ala Leu Leu Gly Asp Arg Trp 485 490 495 Ile Leu Thr Ala Ala His Thr Leu Tyr Pro Lys Glu His Glu Ala Gln 500 505 510 Ser Asn Ala Ser Leu Asp Val Phe Leu Gly His Thr Asn Val Glu Glu 515 520 525 Leu Met Lys Leu Gly Asn His Pro Ile Arg Arg Val Ser Val His Pro 530 535 540 Asp Tyr Arg Gln Asp Glu Ser Tyr Asn Phe Glu Gly Asp Ile Ala Leu 545 550 555 560 Leu Glu Leu Glu Asn Ser Val Thr Leu Gly Pro Asn Leu Leu Pro Ile 565 570 575 Cys Leu Pro Asp Asn Asp Thr Phe Tyr Asp Leu Gly Leu Met Gly Tyr 580 585 590 Val Ser Gly Phe Gly Val Met Glu Glu Lys Ile Ala His Asp Leu Arg 595 600 605 Phe Val Arg Leu Pro Val Ala Asn Pro Gln Ala Cys Glu Asn Trp Leu 610 615 620 Arg Gly Lys Asn Arg Met Asp Val Phe Ser Gln Asn Met Phe Cys Ala 625 630 635 640 Gly His Pro Ser Leu Lys Gln Asp Ala Cys Gln Gly Asp Ser Gly Gly 645 650 655 Val Phe Ala Val Arg Asp Pro Asn Thr Asp Arg Trp Val Ala Thr Gly 660 665 670 Ile Val Ser Trp Gly Ile Gly Cys Ser Arg Gly Tyr Gly Phe Tyr Thr 675 680 685 Lys Val Leu Asn Tyr Val Asp Trp Ile Lys Lys Glu Met Glu Glu Glu 690 695 700 Asp 705 67 777 DNA Homo sapiens 67 gctccgggct gaagattgct tctcttctct cctccaaggt ctagtgacgg agcccgcgcg 60 cgcgccacca tgcggcagaa ggcggtatcc gttttcttgt gctacctgct gctcttcact 120 tgcagtgggg tggaggcagg taagaaaaag tgctcggaga gctcggacag cggctccggg 180 ttctggaagg ccctgacctt catggccgtc ggaggaggac tcgcagtcgc cgggctgccc 240 gcgctgggct tcaccggcgc cggcatcgcg gccaactcgg tggctgcctc gctgatgagc 300 tggtctgcga tcctgaatgg gggcggcgtg cccgccgggg ggctagtggc cacgctgcag 360 agcctcgggg ctggtggcag cagcgtcgtc ataggtaata ttggtgccct gatgcggtac 420 gccacccaca agtatctcga tagtgaggag gatgaggagt agccagcagc tcccagaacc 480 tcttcttcct tcttggccta actcttccag ttaggatcta gaactttgcc tttttttttt 540 tttttttttt tttgagatgg gttctcacta tattgtccag gctagagtgc agtggctatt 600 cacagatgcg aacatagtac actgcagcct ccaactccta gcctcaagtg atcctcctgt 660 ctcaacctcc caagtaggat tacaagcatg cgccgacgat gcccagaatc cagaactttg 720 tctatcactc tccccaacaa cctagatgtg aaaacagaat aaacttcacc cagaaaa 777 68 130 PRT Homo sapiens 68 Met Arg Gln Lys Ala Val Ser Val Phe Leu Cys Tyr Leu Leu Leu Phe 1 5 10 15 Thr Cys Ser Gly Val Glu Ala Gly Lys Lys Lys Cys Ser Glu Ser Ser 20 25 30 Asp Ser Gly Ser Gly Phe Trp Lys Ala Leu Thr Phe Met Ala Val Gly 35 40 45 Gly Gly Leu Ala Val Ala Gly Leu Pro Ala Leu Gly Phe Thr Gly Ala 50 55 60 Gly Ile Ala Ala Asn Ser Val Ala Ala Ser Leu Met Ser Trp Ser Ala 65 70 75 80 Ile Leu Asn Gly Gly Gly Val Pro Ala Gly Gly Leu Val Ala Thr Leu 85 90 95 Gln Ser Leu Gly Ala Gly Gly Ser Ser Val Val Ile Gly Asn Ile Gly 100 105 110 Ala Leu Met Arg Tyr Ala Thr His Lys Tyr Leu Asp Ser Glu Glu Asp 115 120 125 Glu Glu 130 69 2402 DNA Homo sapiens 69 agtctccgcc gccgccgtga acatggagcc cccggacgca ccggcccagg cgcgcggggc 60 cccgcggctg ctgttgctcg cagtcctgct ggcggcgcac ccagatgccc aggcggaggt 120 gcgcttgtct gtacccccgc tggtggaggt gatgcgagga aagtctgtca ttctggactg 180 cacccctacg ggaacccacg accattatat gctggaatgg ttccttaccg accgctcggg 240 agctcgcccc cgcctagcct cggctgagat gcagggctct gagctccagg tcacaatgca 300 cgacacccgg ggccgcagtc ccccatacca gctggactcc caggggcgcc tggtgctggc 360 tgaggcccag gtgggcgacg agcgagacta cgtgtgcgtg gtgagggcag gggcggcagg 420 cactgctgag gccactgcgc ggctcaacgt gtttgcaaag ccagaggcca ctgaggtctc 480 ccccaacaaa gggacactgt ctgtgatgga ggactctgcc caggagatcg ccacctgcaa 540 cagccggaac gggaacccgg cccccaagat cacgtggtat cgcaacgggc agcgcctgga 600 ggtgcccgta gagatgaacc cagagggcta catgaccagc cgcacggtcc gggaggcctc 660 gggcctgctc tccctcacca gcaccctcta cctgcggctc cgcaaggatg accgagacgc 720 cagcttccac tgcgccgccc actacagcct gcccgagggc cgccacggcc gcctggacag 780 ccccaccttc cacctcaccc tgcactatcc cacggagcac gtgcagttct gggtgggcag 840 cccgtccacc ccagcaggct gggtacgcga gggtgacact gtccagctgc tctgccgggg 900 ggacggcagc cccagcccgg agtatacgct tttccgcctt caggatgagc aggaggaagt 960 gctgaatgtg aatctcgagg ggaacttgac cctggaggga gtgacccggg gccagagcgg 1020 gacctatggc tgcagagtgg aggattacga cgcggcagat gacgtgcagc tctccaagac 1080 gctggagctg cgcgtggcct atctggaccc cctggagctc agcgagggga aggtgctttc 1140 cttacctcta aacagcagtg cagtcgtgaa ctgctccgtg cacggcctgc ccacccctgc 1200 cctacgctgg accaaggact ccactcccct gggcgatggc cccatgctgt cgctcagttc 1260 tatcaccttc gattccaatg gcacctacgt atgtgaggcc tccctgccca cagtcccggt 1320 cctcagccgc acccagaact tcacgctgct ggtccaaggc tcgccagagc taaagacagc 1380 ggaaatagag cccaaggcag atggcagctg gagggaagga gacgaagtca cactcatctg 1440 ctctgcccgc ggccatccag accccaaact cagctggagc caattggggg gcagccccgc 1500 agagccaatc cccggacggc agggttgggt gagcagctct ctgaccctga aagtgaccag 1560 cgccctgagc cgcgatggca tctcctgtga agcctccaac ccccacggga acaagcgcca 1620 tgtcttccac ttcggcgccg tgagccccca gacctcccag gctggagtgg ccgtcatggc 1680 cgtggccgtc agcgtgggcc tcctgctcct cgtcgttgct gtcttctact gcgtgagacg 1740 caaagggggc ccctgctgcc gccagcggcg ggagaagggg gctccgccgc caggggagcc 1800 agggctgagc cactcggggt cggagcaacc agagcagacc ggccttctca tgggaggtgc 1860 ctccggagga gccaggggtg gcagcggggg cttcggagac gagtgctgag ccaagaacct 1920 cctagaggct gtccctggac ctggagctgc aggcatcaga gaaccagccc tgctcacgcc 1980 atgcccgccc ccgccttccc tcttccctct tccctctccc tgcccagccc tcccttcctt 2040 cctctgccgg caaggcaggg acccacagtg gctgcctgcc tccgggaggg aaggagaggg 2100 agggtgggtg ggtgggaggg ggccttcctc cagggaatgt gactctccca ggccccagaa 2160 tagctcctgg acccaagccc aaggcccagc ctgggacaag gctccgaggg tcggctggcc 2220 ggagctattt ttacctcccg cctcccctgc tggtcccccc acctgacgtc ttgctgcaga 2280 gtctgacact ggattccccc ccctcacccc gcccctggtc ccactcctgc ccccgcccta 2340 cctccgcccc accccatcat ctgtggacac tggagtctgg aataaatgct gtttgtcaca 2400 tc 2402 70 628 PRT Homo sapiens 70 Met Glu Pro Pro Asp Ala Pro Ala Gln Ala Arg Gly Ala Pro Arg Leu 1 5 10 15 Leu Leu Leu Ala Val Leu Leu Ala Ala His Pro Asp Ala Gln Ala Glu 20 25 30 Val Arg Leu Ser Val Pro Pro Leu Val Glu Val Met Arg Gly Lys Ser 35 40 45 Val Ile Leu Asp Cys Thr Pro Thr Gly Thr His Asp His Tyr Met Leu 50 55 60 Glu Trp Phe Leu Thr Asp Arg Ser Gly Ala Arg Pro Arg Leu Ala Ser 65 70 75 80 Ala Glu Met Gln Gly Ser Glu Leu Gln Val Thr Met His Asp Thr Arg 85 90 95 Gly Arg Ser Pro Pro Tyr Gln Leu Asp Ser Gln Gly Arg Leu Val Leu 100 105 110 Ala Glu Ala Gln Val Gly Asp Glu Arg Asp Tyr Val Cys Val Val Arg 115 120 125 Ala Gly Ala Ala Gly Thr Ala Glu Ala Thr Ala Arg Leu Asn Val Phe 130 135 140 Ala Lys Pro Glu Ala Thr Glu Val Ser Pro Asn Lys Gly Thr Leu Ser 145 150 155 160 Val Met Glu Asp Ser Ala Gln Glu Ile Ala Thr Cys Asn Ser Arg Asn 165 170 175 Gly Asn Pro Ala Pro Lys Ile Thr Trp Tyr Arg Asn Gly Gln Arg Leu 180 185 190 Glu Val Pro Val Glu Met Asn Pro Glu Gly Tyr Met Thr Ser Arg Thr 195 200 205 Val Arg Glu Ala Ser Gly Leu Leu Ser Leu Thr Ser Thr Leu Tyr Leu 210 215 220 Arg Leu Arg Lys Asp Asp Arg Asp Ala Ser Phe His Cys Ala Ala His 225 230 235 240 Tyr Ser Leu Pro Glu Gly Arg His Gly Arg Leu Asp Ser Pro Thr Phe 245 250 255 His Leu Thr Leu His Tyr Pro Thr Glu His Val Gln Phe Trp Val Gly 260 265 270 Ser Pro Ser Thr Pro Ala Gly Trp Val Arg Glu Gly Asp Thr Val Gln 275 280 285 Leu Leu Cys Arg Gly Asp Gly Ser Pro Ser Pro Glu Tyr Thr Leu Phe 290 295 300 Arg Leu Gln Asp Glu Gln Glu Glu Val Leu Asn Val Asn Leu Glu Gly 305 310 315 320 Asn Leu Thr Leu Glu Gly Val Thr Arg Gly Gln Ser Gly Thr Tyr Gly 325 330 335 Cys Arg Val Glu Asp Tyr Asp Ala Ala Asp Asp Val Gln Leu Ser Lys 340 345 350 Thr Leu Glu Leu Arg Val Ala Tyr Leu Asp Pro Leu Glu Leu Ser Glu 355 360 365 Gly Lys Val Leu Ser Leu Pro Leu Asn Ser Ser Ala Val Val Asn Cys 370 375 380 Ser Val His Gly Leu Pro Thr Pro Ala Leu Arg Trp Thr Lys Asp Ser 385 390 395 400 Thr Pro Leu Gly Asp Gly Pro Met Leu Ser Leu Ser Ser Ile Thr Phe 405 410 415 Asp Ser Asn Gly Thr Tyr Val Cys Glu Ala Ser Leu Pro Thr Val Pro 420 425 430 Val Leu Ser Arg Thr Gln Asn Phe Thr Leu Leu Val Gln Gly Ser Pro 435 440 445 Glu Leu Lys Thr Ala Glu Ile Glu Pro Lys Ala Asp Gly Ser Trp Arg 450 455 460 Glu Gly Asp Glu Val Thr Leu Ile Cys Ser Ala Arg Gly His Pro Asp 465 470 475 480 Pro Lys Leu Ser Trp Ser Gln Leu Gly Gly Ser Pro Ala Glu Pro Ile 485 490 495 Pro Gly Arg Gln Gly Trp Val Ser Ser Ser Leu Thr Leu Lys Val Thr 500 505 510 Ser Ala Leu Ser Arg Asp Gly Ile Ser Cys Glu Ala Ser Asn Pro His 515 520 525 Gly Asn Lys Arg His Val Phe His Phe Gly Ala Val Ser Pro Gln Thr 530 535 540 Ser Gln Ala Gly Val Ala Val Met Ala Val Ala Val Ser Val Gly Leu 545 550 555 560 Leu Leu Leu Val Val Ala Val Phe Tyr Cys Val Arg Arg Lys Gly Gly 565 570 575 Pro Cys Cys Arg Gln Arg Arg Glu Lys Gly Ala Pro Pro Pro Gly Glu 580 585 590 Pro Gly Leu Ser His Ser Gly Ser Glu Gln Pro Glu Gln Thr Gly Leu 595 600 605 Leu Met Gly Gly Ala Ser Gly Gly Ala Arg Gly Gly Ser Gly Gly Phe 610 615 620 Gly Asp Glu Cys 625 71 5460 DNA Homo sapiens 71 cgggcccggt gctgaagggc agggaacaac ttgatggtgc tactttgaac tgcttttctt 60 ttctcctttt tgcacaaaga gtctcatgtc tgatatttag acatgatgag ctttgtgcaa 120 aaggggagct ggctacttct cgctctgctt catcccacta ttattttggc acaacaggaa 180 gctgttgaag gaggatgttc ccatcttggt cagtcctatg cggatagaga tgtctggaag 240 ccagaaccat gccaaatatg tgtctgtgac tcaggatccg ttctctgcga tgacataata 300 tgtgacgatc aagaattaga ctgccccaac ccagaaattc catttggaga atgttgtgca 360 gtttgcccac agcctccaac tgctcctact cgccctccta atggtcaagg acctcaaggc 420 cccaagggag atccaggccc tcctggtatt cctgggagaa atggtgaccc tggtattcca 480 ggacaaccag ggtcccctgg ttctcctggc ccccctggaa tctgtgaatc atgccctact 540 ggtcctcaga actattctcc ccagtatgat tcatatgatg tcaagtctgg agtagcagta 600 ggaggactcg caggctatcc tggaccagct ggccccccag gccctcccgg tccccctggt 660 acatctggtc atcctggttc ccctggatct ccaggatacc aaggaccccc tggtgaacct 720 gggcaagctg gtccttcagg ccctccagga cctcctggtg ctataggtcc atctggtcct 780 gctggaaaag atggagaatc aggtagaccc ggacgacctg gagagcgagg attgcctgga 840 cctccaggta tcaaaggtcc agctgggata cctggattcc ctggtatgaa aggacacaga 900 ggcttcgatg gacgaaatgg agaaaagggt gaaacaggtg ctcctggatt aaagggtgaa 960 aatggtcttc caggcgaaaa tggagctcct ggacccatgg gtccaagagg ggctcctggt 1020 gagcgaggac ggccaggact tcctggggct gcaggtgctc ggggtaatga cggtgctcga 1080 ggcagtgatg gtcaaccagg ccctcctggt cctcctggaa ctgccggatt ccctggatcc 1140 cctggtgcta agggtgaagt tggacctgca gggtctcctg gttcaaatgg tgcccctgga 1200 caaagaggag aacctggacc tcagggacac gctggtgctc aaggtcctcc tggccctcct 1260 gggattaatg gtagtcctgg tggtaaaggc gaaatgggtc ccgctggcat tcctggagct 1320 cctggactga tgggagcccg gggtcctcca ggaccagccg gtgctaatgg tgctcctgga 1380 ctgcgaggtg gtgcaggtga gcctggtaag aatggtgcca aaggagagcc cggaccacgt 1440 ggtgaacgcg gtgaggctgg tattccaggt gttccaggag ctaaaggcga agatggcaag 1500 gatggatcac ctggagaacc tggtgcaaat gggcttccag gagctgcagg agaaaggggt 1560 gcccctgggt tccgaggacc tgctggacca aatggcatcc caggagaaaa gggtcctgct 1620 ggagagcgtg gtgctccagg ccctgcaggg cccagaggag ctgctggaga acctggcaga 1680 gatggcgtcc ctggaggtcc aggaatgagg ggcatgcccg gaagtccagg aggaccagga 1740 agtgatggga aaccagggcc tcccggaagt caaggagaaa gtggtcgacc aggtcctcct 1800 gggccatctg gtccccgagg tcagcctggt gtcatgggct tccccggtcc taaaggaaat 1860 gatggtgctc ctggtaagaa tggagaacga ggtggccctg gaggacctgg ccctcagggt 1920 cctcctggaa agaatggtga aactggacct caaggacccc cagggcctac tgggcctggt 1980 ggtgacaaag gagacacagg accccctggt ccacaaggat tacaaggctt gcctggtaca 2040 ggtggtcctc caggagaaaa tggaaaacct ggggaaccag gtccaaaggg tgatgccggt 2100 gcacctggag ctccaggagg caagggtgat gctggtgccc ctggtgaacg tggacctcct 2160 ggattggcag gggccccagg acttagaggt ggagctggtc cccctggtcc cgaaggagga 2220 aagggtgctg ctggtcctcc tgggccacct ggtgctgctg gtactcctgg tctgcaagga 2280 atgcctggag aaagaggagg tcttggaagt cctggtccaa agggtgacaa gggtgaacca 2340 ggcggcccag gtgctgatgg tgtcccaggg aaagatggcc caaggggtcc tactggtcct 2400 attggtcctc ctggcccagc tggccagcct ggagataagg gtgaaggtgg tgcccccgga 2460 cttccaggta tagctggacc tcgtggtagc cctggtgaga gaggtgaaac tggccctcca 2520 ggacctgctg gtttccctgg tgctcctgga cagaatggtg aacctggtgg taaaggagaa 2580 agaggggctc cgggtgagaa aggtgaagga ggccctcctg gagttgcagg accccctgga 2640 ggttctggac ctgctggtcc tcctggtccc caaggtgtca aaggtgaacg tggcagtcct 2700 ggtggacctg gtgctgctgg cttccctggt gctcgtggtc ttcctggtcc tcctggtagt 2760 aatggtaacc caggaccccc aggtcccagc ggttctccag gcaaggatgg gcccccaggt 2820 cctgcgggta acactggtgc tcctggcagc cctggagtgt ctggaccaaa aggtgatgct 2880 ggccaaccag gagagaaggg atcgcctggt gcccagggcc caccaggagc tccaggccca 2940 cttgggattg ctgggatcac tggagcacgg ggtcttgcag gaccaccagg catgccaggt 3000 cctaggggaa gccctggccc tcagggtgtc aagggtgaaa gtgggaaacc aggagctaac 3060 ggtctcagtg gagaacgtgg tccccctgga ccccagggtc ttcctggtct ggctggtaca 3120 gctggtgaac ctggaagaga tggaaaccct ggatcagatg gtcttccagg ccgagatgga 3180 tctcctggtg gcaagggtga tcgtggtgaa aatggctctc ctggtgcccc tggcgctcct 3240 ggtcatccag gcccacctgg tcctgtcggt ccagctggaa agagtggtga cagaggagaa 3300 agtggccctg ctggccctgc tggtgctccc ggtcctgctg gttcccgagg tgctcctggt 3360 cctcaaggcc cacgtggtga caaaggtgaa acaggtgaac gtggagctgc tggcatcaaa 3420 ggacatcgag gattccctgg taatccaggt gccccaggtt ctccaggccc tgctggtcag 3480 cagggtgcaa tcggcagtcc aggacctgca ggccccagag gacctgttgg acccagtgga 3540 cctcctggca aagatggaac cagtggacat ccaggtccca ttggaccacc agggcctcga 3600 ggtaacagag gtgaaagagg atctgagggc tccccaggcc acccagggca accaggccct 3660 cctggacctc ctggtgcccc tggtccttgc tgtggtggtg ttggagccgc tgccattgct 3720 gggattggag gtgaaaaagc tggcggtttt gccccgtatt atggagatga accaatggat 3780 ttcaaaatca acaccgatga gattatgact tcactcaagt ctgttaatgg acaaatagaa 3840 agcctcatta gtcctgatgg ttctcgtaaa aaccccgcta gaaactgcag agacctgaaa 3900 ttctgccatc ctgaactcaa gagtggagaa tactgggttg accctaacca aggatgcaaa 3960 ttggatgcta tcaaggtatt ctgtaatatg gaaactgggg aaacatgcat aagtgccaat 4020 cctttgaatg ttccacggaa acactggtgg acagattcta gtgctgagaa gaaacacgtt 4080 tggtttggag agtccatgga tggtggtttt cagtttagct acggcaatcc tgaacttcct 4140 gaagatgtcc ttgatgtgca gctggcattc cttcgacttc tctccagccg agcttcccag 4200 aacatcacat atcactgcaa aaatagcatt gcatacatgg atcaggccag tggaaatgta 4260 aagaaggccc tgaagctgat ggggtcaaat gaaggtgaat tcaaggctga aggaaatagc 4320 aaattcacct acacagttct ggaggatggt tgcacgaaac acactgggga atggagcaaa 4380 acagtctttg aatatcgaac acgcaaggct gtgagactac ctattgtaga tattgcaccc 4440 tatgacattg gtggtcctga tcaagaattt ggtgtggacg ttggccctgt ttgcttttta 4500 taaaccaaac tctatctgaa atcccaacaa aaaaaattta actccatatg tgttcctctt 4560 gttctaatct tgtcaaccag tgcaagtgac cgacaaaatt ccagttattt atttccaaaa 4620 tgtttggaaa cagtataatt tgacaaagaa aaatgatact tctctttttt tgctgttcca 4680 ccaaatacaa ttcaaatgct ttttgtttta tttttttacc aattccaatt tcaaaatgtc 4740 tcaatggtgc tataataaat aaacttcaac actctttatg ataacaacac tgtgttatat 4800 tctttgaatc ctagcccatc tgcagagcaa tgactgtgct caccagtaaa agataacctt 4860 tctttctgaa atagtcaaat acgaaattag aaaagccctc cctattttaa ctacctcaac 4920 tggtcagaaa cacagattgt attctatgag tcccagaaga tgaaaaaaat tttatacgtt 4980 gataaaactt ataaatttca ttgattaatc tcctggaaga ttggtttaaa aagaaaagtg 5040 taatgcaaga atttaaagaa atatttttaa agccacaatt attttaatat tggatatcaa 5100 ctgcttgtaa aggtgctcct cttttttctt gtcattgctg gtcaagatta ctaatatttg 5160 ggaaggcttt aaagacgcat gttatggtgc taatgtactt tcacttttaa actctagatc 5220 agaattgttg acttgcattc agaacataaa tgcacaaaat ctgtacatgt ctcccatcag 5280 aaagattcat tggcatgcca cagggattct cctccttcat cctgtaaagg tcaacaataa 5340 aaaccaaatt atggggctgc ttttgtcaca ctagcataga gaatgtgttg aaatttaact 5400 ttgtaagctt gtatgtggtt gttgatcttt tttttcctta cagacaccca taataaaata 5460 72 1466 PRT Homo sapiens 72 Met Met Ser Phe Val Gln Lys Gly Ser Trp Leu Leu Leu Ala Leu Leu 1 5 10 15 His Pro Thr Ile Ile Leu Ala Gln Gln Glu Ala Val Glu Gly Gly Cys 20 25 30 Ser His Leu Gly Gln Ser Tyr Ala Asp Arg Asp Val Trp Lys Pro Glu 35 40 45 Pro Cys Gln Ile Cys Val Cys Asp Ser Gly Ser Val Leu Cys Asp Asp 50 55 60 Ile Ile Cys Asp Asp Gln Glu Leu Asp Cys Pro Asn Pro Glu Ile Pro 65 70 75 80 Phe Gly Glu Cys Cys Ala Val Cys Pro Gln Pro Pro Thr Ala Pro Thr 85 90 95 Arg Pro Pro Asn Gly Gln Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly 100 105 110 Pro Pro Gly Ile Pro Gly Arg Asn Gly Asp Pro Gly Ile Pro Gly Gln 115 120 125 Pro Gly Ser Pro Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys 130 135 140 Pro Thr Gly Pro Gln Asn Tyr Ser Pro Gln Tyr Asp Ser Tyr Asp Val 145 150 155 160 Lys Ser Gly Val Ala Val Gly Gly Leu Ala Gly Tyr Pro Gly Pro Ala 165 170 175 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Thr Ser Gly His Pro Gly 180 185 190 Ser Pro Gly Ser Pro Gly Tyr Gln Gly Pro Pro Gly Glu Pro Gly Gln 195 200 205 Ala Gly Pro Ser Gly Pro Pro Gly Pro Pro Gly Ala Ile Gly Pro Ser 210 215 220 Gly Pro Ala Gly Lys Asp Gly Glu Ser Gly Arg Pro Gly Arg Pro Gly 225 230 235 240 Glu Arg Gly Leu Pro Gly Pro Pro Gly Ile Lys Gly Pro Ala Gly Ile 245 250 255 Pro Gly Phe Pro Gly Met Lys Gly His Arg Gly Phe Asp Gly Arg Asn 260 265 270 Gly Glu Lys Gly Glu Thr Gly Ala Pro Gly Leu Lys Gly Glu Asn Gly 275 280 285 Leu Pro Gly Glu Asn Gly Ala Pro Gly Pro Met Gly Pro Arg Gly Ala 290 295 300 Pro Gly Glu Arg Gly Arg Pro Gly Leu Pro Gly Ala Ala Gly Ala Arg 305 310 315 320 Gly Asn Asp Gly Ala Arg Gly Ser Asp Gly Gln Pro Gly Pro Pro Gly 325 330 335 Pro Pro Gly Thr Ala Gly Phe Pro Gly Ser Pro Gly Ala Lys Gly Glu 340 345 350 Val Gly Pro Ala Gly Ser Pro Gly Ser Asn Gly Ala Pro Gly Gln Arg 355 360 365 Gly Glu Pro Gly Pro Gln Gly His Ala Gly Ala Gln Gly Pro Pro Gly 370 375 380 Pro Pro Gly Ile Asn Gly Ser Pro Gly Gly Lys Gly Glu Met Gly Pro 385 390 395 400 Ala Gly Ile Pro Gly Ala Pro Gly Leu Met Gly Ala Arg Gly Pro Pro 405 410 415 Gly Pro Ala Gly Ala Asn Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly 420 425 430 Glu Pro Gly Lys Asn Gly Ala Lys Gly Glu Pro Gly Pro Arg Gly Glu 435 440 445 Arg Gly Glu Ala Gly Ile Pro Gly Val Pro Gly Ala Lys Gly Glu Asp 450 455 460 Gly Lys Asp Gly Ser Pro Gly Glu Pro Gly Ala Asn Gly Leu Pro Gly 465 470 475 480 Ala Ala Gly Glu Arg Gly Ala Pro Gly Phe Arg Gly Pro Ala Gly Pro 485 490 495 Asn Gly Ile Pro Gly Glu Lys Gly Pro Ala Gly Glu Arg Gly Ala Pro 500 505 510 Gly Pro Ala Gly Pro Arg Gly Ala Ala Gly Glu Pro Gly Arg Asp Gly 515 520 525 Val Pro Gly Gly Pro Gly Met Arg Gly Met Pro Gly Ser Pro Gly Gly 530 535 540 Pro Gly Ser Asp Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser 545 550 555 560 Gly Arg Pro Gly Pro Pro Gly Pro Ser Gly Pro Arg Gly Gln Pro Gly 565 570 575 Val Met Gly Phe Pro Gly Pro Lys Gly Asn Asp Gly Ala Pro Gly Lys 580 585 590 Asn Gly Glu Arg Gly Gly Pro Gly Gly Pro Gly Pro Gln Gly Pro Pro 595 600 605 Gly Lys Asn Gly Glu Thr Gly Pro Gln Gly Pro Pro Gly Pro Thr Gly 610 615 620 Pro Gly Gly Asp Lys Gly Asp Thr Gly Pro Pro Gly Pro Gln Gly Leu 625 630 635 640 Gln Gly Leu Pro Gly Thr Gly Gly Pro Pro Gly Glu Asn Gly Lys Pro 645 650 655 Gly Glu Pro Gly Pro Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly 660 665 670 Gly Lys Gly Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro Pro Gly Leu 675 680 685 Ala Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly Pro Pro Gly Pro Glu 690 695 700 Gly Gly Lys Gly Ala Ala Gly Pro Pro Gly Pro Pro Gly Ala Ala Gly 705 710 715 720 Thr Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Gly Leu Gly Ser 725 730 735 Pro Gly Pro Lys Gly Asp Lys Gly Glu Pro Gly Gly Pro Gly Ala Asp 740 745 750 Gly Val Pro Gly Lys Asp Gly Pro Arg Gly Pro Thr Gly Pro Ile Gly 755 760 765 Pro Pro Gly Pro Ala Gly Gln Pro Gly Asp Lys Gly Glu Gly Gly Ala 770 775 780 Pro Gly Leu Pro Gly Ile Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg 785 790 795 800 Gly Glu Thr Gly Pro Pro Gly Pro Ala Gly Phe Pro Gly Ala Pro Gly 805 810 815 Gln Asn Gly Glu Pro Gly Gly Lys Gly Glu Arg Gly Ala Pro Gly Glu 820 825 830 Lys Gly Glu Gly Gly Pro Pro Gly Val Ala Gly Pro Pro Gly Gly Ser 835 840 845 Gly Pro Ala Gly Pro Pro Gly Pro Gln Gly Val Lys Gly Glu Arg Gly 850 855 860 Ser Pro Gly Gly Pro Gly Ala Ala Gly Phe Pro Gly Ala Arg Gly Leu 865 870 875 880 Pro Gly Pro Pro Gly Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser 885 890 895 Gly Ser Pro Gly Lys Asp Gly Pro Pro Gly Pro Ala Gly Asn Thr Gly 900 905 910 Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln 915 920 925 Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro Gly Ala Pro 930 935 940 Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly 945 950 955 960 Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val 965 970 975 Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg 980 985 990 Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly 995 1000 1005 Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg 1010 1015 1020 Asp Gly Ser Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn Gly Ser Pro 1025 1030 1035 1040 Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val Gly 1045 1050 1055 Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro Ala Gly Pro 1060 1065 1070 Ala Gly Ala Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro Gly Pro Gln 1075 1080 1085 Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly Ala Ala Gly 1090 1095 1100 Ile Lys Gly His Arg Gly Phe Pro Gly Asn Pro Gly Ala Pro Gly Ser 1105 1110 1115 1120 Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala 1125 1130 1135 Gly Pro Arg Gly Pro Val Gly Pro Ser Gly Pro Pro Gly Lys Asp Gly 1140 1145 1150 Thr Ser Gly His Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly Asn 1155 1160 1165 Arg Gly Glu Arg Gly Ser Glu Gly Ser Pro Gly His Pro Gly Gln Pro 1170 1175 1180 Gly Pro Pro Gly Pro Pro Gly Ala Pro Gly Pro Cys Cys Gly Gly Val 1185 1190 1195 1200 Gly Ala Ala Ala Ile Ala Gly Ile Gly Gly Glu Lys Ala Gly Gly Phe 1205 1210 1215 Ala Pro Tyr Tyr Gly Asp Glu Pro Met Asp Phe Lys Ile Asn Thr Asp 1220 1225 1230 Glu Ile Met Thr Ser Leu Lys Ser Val Asn Gly Gln Ile Glu Ser Leu 1235 1240 1245 Ile Ser Pro Asp Gly Ser Arg Lys Asn Pro Ala Arg Asn Cys Arg Asp 1250 1255 1260 Leu Lys Phe Cys His Pro Glu Leu Lys Ser Gly Glu Tyr Trp Val Asp 1265 1270 1275 1280 Pro Asn Gln Gly Cys Lys Leu Asp Ala Ile Lys Val Phe Cys Asn Met 1285 1290 1295 Glu Thr Gly Glu Thr Cys Ile Ser Ala Asn Pro Leu Asn Val Pro Arg 1300 1305 1310 Lys His Trp Trp Thr Asp Ser Ser Ala Glu Lys Lys His Val Trp Phe 1315 1320 1325 Gly Glu Ser Met Asp Gly Gly Phe Gln Phe Ser Tyr Gly Asn Pro Glu 1330 1335 1340 Leu Pro Glu Asp Val Leu Asp Val Gln Leu Ala Phe Leu Arg Leu Leu 1345 1350 1355 1360 Ser Ser Arg Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile 1365 1370 1375 Ala Tyr Met Asp Gln Ala Ser Gly Asn Val Lys Lys Ala Leu Lys Leu 1380 1385 1390 Met Gly Ser Asn Glu Gly Glu Phe Lys Ala Glu Gly Asn Ser Lys Phe 1395 1400 1405 Thr Tyr Thr Val Leu Glu Asp Gly Cys Thr Lys His Thr Gly Glu Trp 1410 1415 1420 Ser Lys Thr Val Phe Glu Tyr Arg Thr Arg Lys Ala Val Arg Leu Pro 1425 1430 1435 1440 Ile Val Asp Ile Ala Pro Tyr Asp Ile Gly Gly Pro Asp Gln Glu Phe 1445 1450 1455 Gly Val Asp Val Gly Pro Val Cys Phe Leu 1460 1465 73 1051 DNA Homo sapiens 73 cgcggagtct gagcggcgct cgtcccgtcc caaggccgac gccagcacgc cgtcatggcc 60 cccgcagcgg cgacgggggg cagcaccctg cccagtggct tctcggtctt caccaccttg 120 cccgacttgc tcttcatctt tgagtttatc ttcgggggcc tggtgtggat cctggtggcc 180 tcctccctgg tgccctggcc cctggtccag ggctgggtga tgttcgtgtc tgtgttctgc 240 ttcgtggcca ccaccacctt gatcatcctg tacataattg gagcccacgg tggagagact 300 tcctgggtca ccttggacgc agcctaccac tgcaccgctg ccctctttta cctcagcgcc 360 tcagtcctgg aggccctggc caccatcacg atgcaagacg gcttcaccta caggcactac 420 catgaaaaca ttgctgccgt ggtgttctcc tacatagcca ctctgctcta cgtggtccat 480 gcggtgttct ctttaatcag atggaagtct tcataaagcc gcagtagaac ttgagctgaa 540 aacccagatg gtgttaactg gccgccccac tttccggcat aactttttag aaaacagaaa 600 tgcccttgat ggtggaaaaa agaaaacaac caccccccca ctgcccaaaa aaaaaagccc 660 tgccctgttg ctcgtgggtg ctgtgtttac tctcccgtgt gccttcgcgt ccgggttggg 720 agcttgctgt gtctaacctc caactgctgt gctgtctgct agggtcacct cctgtttgtg 780 aaaggggacc ttcttgttcg ggggtgggaa gtggcgaccg tgacctgaga aggaaagaaa 840 gatcctctgc tgacccctgg agcagctctc gagaactacc tgttggtatt gtccacaagc 900 tctcccgagc gccccatctt gtgccatgtt ttaagtcttc atggatgttc tgcatgtcat 960 ggggactaaa actcacccaa cagatctttc cagaggtcca tggtggaaga cgataaccct 1020 gtgaaatact ttataaaatg tcttaatgtt c 1051 74 153 PRT Homo sapiens 74 Met Ala Pro Ala Ala Ala Thr Gly Gly Ser Thr Leu Pro Ser Gly Phe 1 5 10 15 Ser Val Phe Thr Thr Leu Pro Asp Leu Leu Phe Ile Phe Glu Phe Ile 20 25 30 Phe Gly Gly Leu Val Trp Ile Leu Val Ala Ser Ser Leu Val Pro Trp 35 40 45 Pro Leu Val Gln Gly Trp Val Met Phe Val Ser Val Phe Cys Phe Val 50 55 60 Ala Thr Thr Thr Leu Ile Ile Leu Tyr Ile Ile Gly Ala His Gly Gly 65 70 75 80 Glu Thr Ser Trp Val Thr Leu Asp Ala Ala Tyr His Cys Thr Ala Ala 85 90 95 Leu Phe Tyr Leu Ser Ala Ser Val Leu Glu Ala Leu Ala Thr Ile Thr 100 105 110 Met Gln Asp Gly Phe Thr Tyr Arg His Tyr His Glu Asn Ile Ala Ala 115 120 125 Val Val Phe Ser Tyr Ile Ala Thr Leu Leu Tyr Val Val His Ala Val 130 135 140 Phe Ser Leu Ile Arg Trp Lys Ser Ser 145 150 75 5416 DNA Homo sapiens 75 gtgtcccata gtgtttccaa acttggaaag ggcgggggag ggcgggagga tgcggagggc 60 ggaggtatgc agacaacgag tcagagtttc cccttgaaag cctcaaaagt gtccacgtcc 120 tcaaaaagaa tggaaccaat ttaagaagcc agccccgtgg ccacgtccct tcccccattc 180 gggccctcct ctgcgccccc gcaggctcct cccagctgtg gctgcccggg cccccagccc 240 cagccctccc attggtggag gcccttttgg aggcacccta gggccaggga aacttttgcc 300 gtataaatag ggcagatccg ggatttgtta ttttagcacc acggcagcag gaggtttcgg 360 ctaagttgga ggtactggcc acgactgcat gcccgcgccc gccatgtgat acctccgccg 420 gtgacccagg gctctgcgac acaaggagtc gcatgtctaa gtgctagaca tgctcagctt 480 tgtggatacg cggactttgt tgctgcttgc agtaacctta tgcctagcaa catgccaatc 540 tttacaagag gaaactgtaa gaaagggccc agccggagat agaggaccac gtggagaaag 600 gggtccacca ggccccccag gcagagatgg tgaagatggt cccacaggcc ctcctggtcc 660 acctggtcct cctggccccc ctggtctcgg tgggaacttt gctgctcagt atgatggaaa 720 aggagttgga cttggccctg gaccaatggg cttaatggga cctagaggcc cacctggtgc 780 agctggagcc ccaggccctc aaggtttcca aggacctgct ggtgagcctg gtgaacctgg 840 tcaaactggt cctgcaggtg ctcgtggtcc agctggccct cctggcaagg ctggtgaaga 900 tggtcaccct ggaaaacccg gacgacctgg tgagagagga gttgttggac cacagggtgc 960 tcgtggtttc cctggaactc ctggacttcc tggcttcaaa ggcattaggg gacacaatgg 1020 tctggatgga ttgaagggac agcccggtgc tcctggtgtg aagggtgaac ctggtgcccc 1080 tggtgaaaat ggaactccag gtcaaacagg agcccgtggt cttcctggtg agagaggacg 1140 tgttggtgcc cctggtccag ctggtgcccg tggaagtgat ggaagtgtgg gtcccgtagg 1200 tcctgctggt cctaatgggt ctgctggccc tccaggtttc ccaggtgccc ctggtcccaa 1260 gggtgaaatt ggagctgttg gtaacgctgg tcctactgga cccgccggtc cccgtggtga 1320 agtgggtctt ccaggcctct ccggccccgt tggacctcct ggtaatcctg gagcaaacgg 1380 ccttactggt gccaagggtg ctgctggcct tcccggcgtt gctggggctc ccggcctccc 1440 tggaccccgc ggtattcctg gccctcctgg tgctgccggt actactggtg ccagaggact 1500 tgttggtgag cctggtccag ctggctccaa aggagagagc ggtaacaagg gtgagcccgg 1560 ctccgctggt ccccaaggtc ctcctggtcc cagtggtgaa gaaggaaaga gaggccctaa 1620 tggggaagct ggatctgccg gccctccagg acctcctggg ctgagaggta gtcctggttc 1680 tcgtggtctt cctggagctg atggcagagc tggcgtcatg ggccctcctg gtagtcgtgg 1740 tgcaagtggc cctgctggag tccgaggacc taatggagat gctggtcgcc ctggggagcc 1800 tggtctcatg ggacccagag gtcttcctgg ttcccctgga aatatcggcc ccgctggaaa 1860 agaaggtcct gtcggcctcc ctggcatcga cggcaggcct ggcccaattg gccccgttgg 1920 agcaagagga gagcctggca acattggatt ccctggaccc aaaggcccca ctggtgaccc 1980 tggcaaaaac ggtgataaag gtcatgctgg tcttgctggt gctcggggtg ctccaggtcc 2040 tgatggaaac aatggtgctc agggacctcc tggaccacag ggtgttcaag gtggaaaagg 2100 tgaacagggt cccgctggtc ctccaggctt ccagggtctg cctggcccct caggtcccgc 2160 tggtgaagtt ggcaaaccag gagaaagggg tctccatggt gagtttggtc tccctggtcc 2220 tgctggtcca agaggggaac gcggtccccc aggtgagagt ggtgctgccg gtcctactgg 2280 tcctattgga agccgaggtc cttctggacc cccagggcct gatggaaaca agggtgaacc 2340 tggtgtggtt ggtgctgtgg gcactgctgg tccatctggt cctagtggac tcccaggaga 2400 gaggggtgct gctggcatac ctggaggcaa gggagaaaag ggtgaacctg gtctcagagg 2460 tgaaattggt aaccctggca gagatggtgc tcgtggtgct catggtgctg taggtgcccc 2520 tggtcctgct ggagccacag gtgaccgggg cgaagctggg gctgctggtc ctgctggtcc 2580 tgctggtcct cggggaagcc ctggtgaacg tggcgaggtc ggtcctgctg gccccaacgg 2640 atttgctggt ccggctggtg ctgctggtca accgggtgct aaaggagaaa gaggaggcaa 2700 agggcctaag ggtgaaaacg gtgttgttgg tcccacaggc cccgttggag ctgctggccc 2760 agctggtcca aatggtcccc ccggtcctgc tggaagtcgt ggtgatggag gcccccctgg 2820 tatgactggt ttccctggtg ctgctggacg gactggtccc ccaggaccct ctggtatttc 2880 tggccctcct ggtccccctg gtcctgctgg gaaagaaggg cttcgtggtc ctcgtggtga 2940 ccaaggtcca gttggccgaa ctggagaagt aggtgcagtt ggtccccctg gcttcgctgg 3000 tgagaagggt ccctctggag aggctggtac tgctggacct cctggcactc caggtcctca 3060 gggtcttctt ggtgctcctg gtattctggg tctccctggc tcgagaggtg aacgtggtct 3120 acctggtgtt gctggtgctg tgggtgaacc tggtcctctt ggcattgccg gccctcctgg 3180 ggcccgtggt cctcctggtg ctgtgggtag tcctggagtc aacggtgctc ctggtgaagc 3240 tggtcgtgat ggcaaccctg ggaacgatgg tcccccaggt cgcgatggtc aacccggaca 3300 caagggagag cgcggttacc ctggcaatat tggtcccgtt ggtgctgcag gtgcacctgg 3360 tcctcatggc cccgtgggtc ctgctggcaa acatggaaac cgtggtgaaa ctggtccttc 3420 tggtcctgtt ggtcctgctg gtgctgttgg cccaagaggt cctagtggcc cacaaggcat 3480 tcgtggcgat aagggagagc ccggtgaaaa ggggcccaga ggtcttcctg gcttcaaggg 3540 acacaatgga ttgcaaggtc tgcctggtat cgctggtcac catggtgatc aaggtgctcc 3600 tggctccgtg ggtcctgctg gtcctagggg ccctgctggt ccttctggcc ctgctggaaa 3660 agatggtcgc actggacatc ctggtacggt tggacctgct ggcattcgag gccctcaggg 3720 tcaccaaggc cctgctggcc cccctggtcc ccctggccct cctggacctc caggtgtaag 3780 cggtggtggt tatgactttg gttacgatgg agacttctac agggctgacc agcctcgctc 3840 agcaccttct ctcagaccca aggactatga agttgatgct actctgaagt ctctcaacaa 3900 ccagattgag acccttctta ctcctgaagg ctctagaaag aacccagctc gcacatgccg 3960 tgacttgaga ctcagccacc cagagtggag cagcggttac tactggattg accccaacca 4020 aggatgcact atggaagcca tcaaagtata ctgtgatttc cctaccggcg aaacctgtat 4080 ccgggcccaa cctgaaaaca tcccagccaa gaactggtat aggagctcca aggacaagaa 4140 acacgtctgg ctaggagaaa ctatcaatgc tggcagccag tttgaatata atgttgaagg 4200 agtgacttcc aaggaaatgg ctacccaact tgccttcatg cgcctgctgg ccaactatgc 4260 ctctcagaac atcacctacc actgcaagaa cagcattgca tacatggatg aggagactgg 4320 caacctgaaa aaggctgtca ttctacaggg ctctaatgat gttgaacttg ttgctgaggg 4380 caacagcagg ttcacttaca ctgttcttgt agatggctgc tctaaaaaga caaatgaatg 4440 gggaaagaca atcattgaat acaaaacaaa taagccatca cgcctgccct tccttgatat 4500 tgcacctttg gacatcggtg gtgctgacca tgaattcttt gtggacattg gcccagtctg 4560 tttcaaataa atgaactcaa tctaaattaa aaaagaaaga aatttgaaaa aactttctct 4620 ttgccatttc ttcttcttct tttttaactg aaagctgaat ccttccattt cttctgcaca 4680 tctacttgct taaattgtgg gcaaaagaga aaaagaagga ttgatcagag cattgtgcaa 4740 tacagtttca ttaactcctt cccccgctcc cccaaaaatt tgaatttttt tttcaacact 4800 cttacacctg ttatggaaaa tgtcaacctt tgtaagaaaa ccaaaataaa aattgaaaaa 4860 taaaaaccat aaacatttgc accacttgtg gcttttgaat atcttccaca gagggaagtt 4920 taaaacccaa acttccaaag gtttaaacta cctcaaaaca ctttcccatg agtgtgatcc 4980 acattgttag gtgctgacct agacagagat gaactgaggt ccttgttttg ttttgttcat 5040 aatacaaagg tgctaattaa tagtatttca gatacttgaa gaatgttgat ggtgctagaa 5100 gaatttgaga agaaatactc ctgtattgag ttgtatcgtg tggtgtattt tttaaaaaat 5160 ttgatttagc attcatattt tccatcttat tcccaattaa aagtatgcag attatttgcc 5220 caaagttgtc ctcttcttca gattcagcat ttgttctttg ccagtctcat tttcatcttc 5280 ttccatggtt ccacagaagc tttgtttctt gggcaagcag aaaaattaaa ttgtacctat 5340 tttgtatatg tgagatgttt aaataaattg tgaaaaaaat gaaataaagc atgtttggtt 5400 ttccaaaaga acatat 5416 76 1366 PRT Homo sapiens 76 Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr 1 5 10 15 Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys 20 25 30 Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly 35 40 45 Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro 50 55 60 Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln 65 70 75 80 Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met 85 90 95 Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly 100 105 110 Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro 115 120 125 Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp 130 135 140 Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly 145 150 155 160 Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe 165 170 175 Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro 180 185 190 Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly 195 200 205 Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg 210 215 220 Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val 225 230 235 240 Gly Pro Val Gly Pro Ala Gly Pro Asn Gly Ser Ala Gly Pro Pro Gly 245 250 255 Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn 260 265 270 Ala Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro 275 280 285 Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly 290 295 300 Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala 305 310 315 320 Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Pro Gly Ala Ala 325 330 335 Gly Thr Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly 340 345 350 Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro 355 360 365 Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn 370 375 380 Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu Arg Gly 385 390 395 400 Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val 405 410 415 Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg 420 425 430 Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly 435 440 445 Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys 450 455 460 Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile 465 470 475 480 Gly Pro Val Gly Ala Arg Gly Glu Pro Gly Asn Ile Gly Phe Pro Gly 485 490 495 Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His 500 505 510 Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn 515 520 525 Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly 530 535 540 Glu Gln Gly Pro Ala Gly Pro Pro Gly Phe Gln Gly Leu Pro Gly Pro 545 550 555 560 Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His 565 570 575 Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly 580 585 590 Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser 595 600 605 Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro 610 615 620 Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly 625 630 635 640 Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu 645 650 655 Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp 660 665 670 Gly Ala Arg Gly Ala His Gly Ala Val Gly Ala Pro Gly Pro Ala Gly 675 680 685 Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro 690 695 700 Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala 705 710 715 720 Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly 725 730 735 Ala Lys Gly Glu Arg Gly Gly Lys Gly Pro Lys Gly Glu Asn Gly Val 740 745 750 Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn 755 760 765 Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly 770 775 780 Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro 785 790 795 800 Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu 805 810 815 Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly 820 825 830 Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro 835 840 845 Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln 850 855 860 Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly 865 870 875 880 Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro 885 890 895 Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val 900 905 910 Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly 915 920 925 Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His 930 935 940 Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala 945 950 955 960 Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly 965 970 975 Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala 980 985 990 Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys 995 1000 1005 Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Phe Lys Gly 1010 1015 1020 His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His Gly Asp 1025 1030 1035 1040 Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala 1045 1050 1055 Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly 1060 1065 1070 Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro 1075 1080 1085 Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser 1090 1095 1100 Gly Gly Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp 1105 1110 1115 1120 Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp 1125 1130 1135 Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr Pro 1140 1145 1150 Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu 1155 1160 1165 Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln 1170 1175 1180 Gly Cys Thr Met Glu Ala Ile Lys Val Tyr Cys Asp Phe Pro Thr Gly 1185 1190 1195 1200 Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp 1205 1210 1215 Tyr Arg Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile 1220 1225 1230 Asn Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys 1235 1240 1245 Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr Ala 1250 1255 1260 Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr Met Asp 1265 1270 1275 1280 Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn 1285 1290 1295 Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val 1300 1305 1310 Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile 1315 1320 1325 Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile 1330 1335 1340 Ala Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile 1345 1350 1355 1360 Gly Pro Val Cys Phe Lys 1365 77 1082 DNA Homo sapiens 77 agctcccttt agcgagtcct tcttttcctg actgcagctc ttttcatttt gccatccttt 60 tccagcacca tgatggttct gcaggtttct gcggcccccc ggacagtggc tctgacggcg 120 ttactgatgg tgctgctcac atctgtggtc cagggcaggg ccactccaga gaattacctt 180 ttccagggac ggcaggaatg ctacgcgttt aatgggacac agcgcttcct ggagagatac 240 atctacaacc gggaggagtt cgcgcgcttc gacagcgacg tgggggagtt ccgggcggtg 300 acggagctgg ggcggcctgc tgcggagtac tggaacagcc agaaggacat cctggaggag 360 aagcgggcag tgccggacag gatgtgcaga cacaactacg agctgggcgg gcccatgacc 420 ctgcagcgcc gagtccagcc tagggtgaat gtttccccct ccaagaaggg gcccttgcag 480 caccacaacc tgcttgtctg ccacgtgacg gatttctacc caggcagcat tcaagtccga 540 tggttcctga atggacagga ggaaacagct ggggtcgtgt ccaccaacct gatccgtaat 600 ggagactgga ccttccagat cctggtgatg ctggaaatga ccccccagca gggagatgtc 660 tacacctgcc aagtggagca caccagcctg gatagtcctg tcaccgtgga gtggaaggca 720 cagtctgatt ctgcccggag taagacattg acgggagctg ggggcttcgt gctggggctc 780 atcatctgtg gagtgggcat cttcatgcac aggaggagca agaaagttca acgaggatct 840 gcataaacag ggttcctgag ctcactgaaa agactattgt gccttaggaa aagcatttgc 900 tgtgtttcgt tagcatctgg ctccaggaca gaccttcaac ttccaaattg atactgctgc 960 caagaagttg ctctgaagtc agtttctatc attctgctct ttgattcaaa gcactgtttc 1020 tctcactggg cctccaacca tgttcccttc ttcttagcac cacaaataat caaaacccaa 1080 ca 1082 78 258 PRT Homo sapiens 78 Met Met Val Leu Gln Val Ser Ala Ala Pro Arg Thr Val Ala Leu Thr 1 5 10 15 Ala Leu Leu Met Val Leu Leu Thr Ser Val Val Gln Gly Arg Ala Thr 20 25 30 Pro Glu Asn Tyr Leu Phe Gln Gly Arg Gln Glu Cys Tyr Ala Phe Asn 35 40 45 Gly Thr Gln Arg Phe Leu Glu Arg Tyr Ile Tyr Asn Arg Glu Glu Phe 50 55 60 Ala Arg Phe Asp Ser Asp Val Gly Glu Phe Arg Ala Val Thr Glu Leu 65 70 75 80 Gly Arg Pro Ala Ala Glu Tyr Trp Asn Ser Gln Lys Asp Ile Leu Glu 85 90 95 Glu Lys Arg Ala Val Pro Asp Arg Met Cys Arg His Asn Tyr Glu Leu 100 105 110 Gly Gly Pro Met Thr Leu Gln Arg Arg Val Gln Pro Arg Val Asn Val 115 120 125 Ser Pro Ser Lys Lys Gly Pro Leu Gln His His Asn Leu Leu Val Cys 130 135 140 His Val Thr Asp Phe Tyr Pro Gly Ser Ile Gln Val Arg Trp Phe Leu 145 150 155 160 Asn Gly Gln Glu Glu Thr Ala Gly Val Val Ser Thr Asn Leu Ile Arg 165 170 175 Asn Gly Asp Trp Thr Phe Gln Ile Leu Val Met Leu Glu Met Thr Pro 180 185 190 Gln Gln Gly Asp Val Tyr Thr Cys Gln Val Glu His Thr Ser Leu Asp 195 200 205 Ser Pro Val Thr Val Glu Trp Lys Ala Gln Ser Asp Ser Ala Arg Ser 210 215 220 Lys Thr Leu Thr Gly Ala Gly Gly Phe Val Leu Gly Leu Ile Ile Cys 225 230 235 240 Gly Val Gly Ile Phe Met His Arg Arg Ser Lys Lys Val Gln Arg Gly 245 250 255 Ser Ala 79 996 DNA Homo sapiens 79 gtggaattca tggcatctac ttcgtatgac tattgcagag tgcccatgga agacggggat 60 aagcgctgta agcttctgct ggggatagga attctggtgc tcctgatcat cgtgattctg 120 ggggtgccct tgattatctt caccatcaag gccaacagcg aggcctgccg ggacggcctt 180 cgggcagtga tggagtgtcg caatgtcacc catctcctgc aacaagagct gaccgaggcc 240 cagaagggct ttcaggatgt ggaggcccag gccgccacct gcaaccacac tgtgatggcc 300 ctaatggctt ccctggatgc agagaaggcc caaggacaaa agaaagtgga ggagcttgag 360 ggagagatca ctacattaaa ccataagctt caggacgcgt ctgcagaggt ggagcgactg 420 agaagagaaa accaggtctt aagcgtgaga atcgcggaca agaagtacta ccccagctcc 480 caggactcca gctccgctgc ggcgccccag ctgctgattg tgctgctggg cctcagcgct 540 ctgctgcagt gagatcccag gaagctggca catcttggaa ggtccgtcct gctcggcttt 600 tcgcttgaac attcccttga tctcatcagt tctgagcggg tcatggggca acacggttag 660 cggggagagc acggggtagc cggagaaggg cctctggagc aggtctggag gggccatggg 720 gcagtcctgg gtgtggggac acagtcgggt tgacccaggg ctgtctccct ccagagcctc 780 cctccggaca atgagtcccc cctcttgtct cccaccctga gattgggcat ggggtgcggt 840 gtggggggca tgtgctgcct gttgttatgg gttttttttg cggggggggt tgcttttttc 900 tggggtcttt gagctccaaa aaataaacac ttcctttgag ggagagcaaa aaaaaaaaaa 960 aaaaaaaaaa aaaaaaaaaa aaagaattcc accaca 996 80 180 PRT Homo sapiens 80 Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly 1 5 10 15 Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu 20 25 30 Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala 35 40 45 Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg 50 55 60 Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly 65 70 75 80 Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met 85 90 95 Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys 100 105 110 Val Glu Glu Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu Gln 115 120 125 Asp Ala Ser Ala Glu Val Glu Arg Leu Arg Arg Glu Asn Gln Val Leu 130 135 140 Ser Val Arg Ile Ala Asp Lys Lys Tyr Tyr Pro Ser Ser Gln Asp Ser 145 150 155 160 Ser Ser Ala Ala Ala Pro Gln Leu Leu Ile Val Leu Leu Gly Leu Ser 165 170 175 Ala Leu Leu Gln 180 81 4316 DNA Homo sapiens 81 ctgcagctaa taaaaaaaaa aaaagaaaga aagaaactgg tctctgtcct atttcatatg 60 ctcaggtaca acttttccag agaagaagag gaggggggcg gggaggagca ggaggaggag 120 gaaagaagga ggagaaggag aaggagaaga agaggaagag gaagaggaag aagaagaaga 180 agaagaagag gaagaggaag aggaagaaga agaagaagaa gaagaagaag aagaagaaga 240 agaagaagaa gaagaagaag aagaagaaga ggaagaagag gaagaagaag aaactgtctc 300 tagaccttca ttctcaggac aagttcattg tctggcacca agctccttgg ggtgaatttt 360 cttccaaaag agtccgggga gtccaggtat ggaatgggag gcagaaagtt caatcaaggg 420 actgggattt cggaatgaat aatgaaggga gatggactgg gtccatgccg aaggtttctc 480 cctggtttct cagcccccgg gcgaagactc agggagacat tgagacacac cctgcacagg 540 agggggaggg ggagggggag ggcaaagtcc cagggcccca ggagtggctc tcaagggctc 600 aggccccgag gcggtgtctg gggttggaag gctcagtatt gagaattccc catctcccca 660 gagtttctct ttctctccca acccgtgtca ggtccttcat cctggatact cataacgcgg 720 ccccatttct cactcccatt gggcgtcgcg tttctagaga agccaatcag tgtcgccgca 780 gttcccaggt tctaaagtcc cacgcacccc gcgggactca tatttttccc agacgcggag 840 gttggggtca tggcgccccg aagcctcctc ctgctgctct caggggccct ggccctgacc 900 gatacttggg cgggtgagtg cggggtccag agagaaacgg cctctgtggg gaggagtgag 960 gggcccgccc ggtgggggcg caggactcag ggagccgcgc ccggaggagg gtctggcggg 1020 tctcaccccc tcctcgcccc caggctccca ctccttgagg tatttcagca ccgctgtgtc 1080 gcggcccggc cgcggggagc cccgctacat cgccgtggag tacgtagacg acacgcaatt 1140 cctgcggttc gacagcgacg ccgcgattcc gaggatggag ccgcgggagc cgtgggtgga 1200 gcaagagggg ccgcagtatt gggagtggac cacagggtac gccaaggcca acgcacagac 1260 tgaccgagtg gccctgagga acctgctccg ccgctacaac cagagcgagg ctggtgagtg 1320 aacccggccg ggggcgcagg tcacgaccac cccccatccg ccacggaccg cccgggtccc 1380 cccgagtctc cggatccgaa atctaccccg aggcagcgga cccgcccaga ccctccaccc 1440 gggagagtcc caggcgcctt taccgaggtt cattttcagt ttaggccaaa atccccgcgg 1500 gttgggcggg gagggggcgg ggctagctgg gcggggctga ctgcggggac cggctagggt 1560 ctcacaccct ccagggaatg aatggctgcg acatggggcc cgacggacgc ctcctccgcg 1620 ggtatcacca gcacgcgtac gacggcaagg attacatctc cctgaacgag gacctgcgct 1680 cctggaccgc ggcggacacc gtggctcaga tcacccagcg cttctatgag gcagaggaat 1740 atgcagagga gttcaggacc tacctggagg gcgagtgcct ggagttgctc cgcagatact 1800 tggagaatgg gaaggagacg ctacagcgcg caggtaccag gggccatggg cgccttccct 1860 atctcctgta gatctcttgg gatggcctcg cacaaggttg ggaggaaagt gggcccaatg 1920 ctaggatatc gccctccctc tagtcctgag taggaagaat cttcctggct ttcgagatcc 1980 ggtaccagag agtgactgtg agagtccgcc ctgctctctg ggacaattaa gggatgaaat 2040 ctctgaggga atggagggaa gacagtccct ggaataccga tccgcggtcc cctttgagcc 2100 ctccaacagc cttgggcccc gtgacttttc tctcaagttt tgttctctgc ctcacactca 2160 atgtgtttgg ggctctgatt ccagtccctc ggcctccact taggtcaggg ccagaagtcc 2220 ctgctcccca ctcagagact cgaactttcc aaggaatagg agattttccc aggtgtctgt 2280 gtccaggctg gtgtctgggt tctgtgctcc cttccccacc ccaggtgtcc tgtccattct 2340 caggttggtc acatgggtgc tgctggggtt tcccatgagg agtgcaaagt gcctgaattt 2400 tctgactctt ctcagatcct ccaaaggcac acgttgccca ccaccccatc tctgaccatg 2460 aggccaccct gaggtgctgg gccctgggct tctaccctgc ggagatcacg ctgacctggc 2520 agcgggatgg ggaggaacag acccaggaca cagagcttgt ggagaccagg cctgcagggg 2580 atggaacctt ccagaagtgg gccgctgtgg tggtgccttc tggagaggaa cagagataca 2640 catgccatgt gcagcacgag gggctgcccc agcccctcat cctgagatgg ggtaaggagg 2700 gagatgggta aagaggggaa cgaggggtca tgtcttttct cagggaaagc aggagccctt 2760 ctggagctct tcagcagggt cagggctgag gcctggagat cagggcccct caccttccct 2820 tcctttccca gagcagtctc cccagcccac catccccatc gtgggcatcg ttgctggcct 2880 tgttgtcctt ggagctgtgg tcactggagc tgtggtcgct gctgtgatgt ggaggaagaa 2940 gagctcaggt aggaaggggt gaggagtgga gtctgagttt tcttgtccca ctgggggttg 3000 caagccccaa gtagaagtgt gccctgcctc attactggga agcaccatcc acactcatgg 3060 gtctacccag cctgggccct gtgtgccagc acctactcat ttgtaaagct cctgtgaaaa 3120 tgaaggacag attcttcact tcgatgatta tggtggtgat gggacctgat cccagcagtc 3180 acaaatcaca ggggaaggtc cctgctgatg acagacctca ggagggcagt tggtccagga 3240 cccacatctg ctttcttcat atttcttgat cctgccctgg atctacagtt acacttttct 3300 ggaaacttct ctgggatcaa agactagggg tttgctctag gaccttatgg ccctgcctcc 3360 tttctggcct ctcacaggac attttcttcc catagataga aacagaggga gctactctca 3420 ggctgcaggt aagatgaagg aggctgatcc ctgagattgt tgggatattg tggtcaggag 3480 cctatgaggg agctcaccca ccccacagtt cctctagcca catctgtggg ctctgaccag 3540 gtcctgtttt tgttctaccc caatcactga cagtgcccag ggctctgggg tgtctctcac 3600 agctaataaa ggtgacactc cagggcaggg gccctgatgt gagtggggtg ttggggggga 3660 acagagggga ctcagctgtg ctattgggtt tctttgactt ggatgtcttg agcatgaaat 3720 gggctattta gagtgttacc tctcactgtg actgatacga atttgttcat gaatattttc 3780 tctatagtgt gagacagctt ccttgtgtgg gactgagaag caagatatca atgtagcaga 3840 attgcacttg tgcctcacga acatacataa attttaaaaa taaagaataa aaatatatct 3900 ttttatagat acaggtagat atgtttttat agcatgcacg taaatgtgtg tgtgtgtgtg 3960 tgtgtgtgaa gagaaagagt gaatagagag attaagattc ttttaatggt gaaaagatat 4020 acatatattt ggaattagcc agcttgactc agtttaggtg atcccaattt tggtggcaac 4080 aaccaaagca tcgtagtcag gagccagtcg aacatatgcc ttcctctctc catcagactg 4140 aatcagagtg ttgactttgg ccacatcaat gtcacaaact tcttcacagc ctgtttgatc 4200 tggtgcttgt tggctttaac atccacagtg aacacaagta ggctgttgtt ttctatcttc 4260 ttcacagcct actcagtggt cagcggaaac ttgatgataa catggtggtc aagctt 4316 82 362 PRT Homo sapiens 82 Met Ala Pro Arg Ser Leu Leu Leu Leu Leu Ser Gly Ala Leu Ala Leu 1 5 10 15 Thr Asp Thr Trp Ala Gly Ser His Ser Leu Arg Tyr Phe Ser Thr Ala 20 25 30 Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Tyr Ile Ala Val Glu Tyr 35 40 45 Val Asp Asp Thr Gln Phe Leu Arg Phe Asp Ser Asp Ala Ala Ile Pro 50 55 60 Arg Met Glu Pro Arg Glu Pro Trp Val Glu Gln Glu Gly Pro Gln Tyr 65 70 75 80 Trp Glu Trp Thr Thr Gly Tyr Ala Lys Ala Asn Ala Gln Thr Asp Arg 85 90 95 Val Ala Leu Arg Asn Leu Leu Arg Arg Tyr Asn Gln Ser Glu Ala Gly 100 105 110 Ser His Thr Leu Gln Gly Met Asn Gly Cys Asp Met Gly Pro Asp Gly 115 120 125 Arg Leu Leu Arg Gly Tyr His Gln His Ala Tyr Asp Gly Lys Asp Tyr 130 135 140 Ile Ser Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Val 145 150 155 160 Ala Gln Ile Thr Gln Arg Phe Tyr Glu Ala Glu Glu Tyr Ala Glu Glu 165 170 175 Phe Arg Thr Tyr Leu Glu Gly Glu Cys Leu Glu Leu Leu Arg Arg Tyr 180 185 190 Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Ala 195 200 205 His Val Ala His His Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys 210 215 220 Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg 225 230 235 240 Asp Gly Glu Glu Gln Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro 245 250 255 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser 260 265 270 Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro 275 280 285 Gln Pro Leu Ile Leu Arg Trp Glu Gln Ser Pro Gln Pro Thr Ile Pro 290 295 300 Ile Val Gly Ile Val Ala Gly Leu Val Val Leu Gly Ala Val Val Thr 305 310 315 320 Gly Ala Val Val Ala Ala Val Met Trp Arg Lys Lys Ser Ser Asp Arg 325 330 335 Asn Arg Gly Ser Tyr Ser Gln Ala Ala Val Thr Asp Ser Ala Gln Gly 340 345 350 Ser Gly Val Ser Leu Thr Ala Asn Lys Val 355 360 83 10 DNA Homo sapiens 83 tcagacgcag 10 84 10 DNA Homo sapiens 84 ttatgggatc 10 85 10 DNA Homo sapiens 85 cccgcccccg 10 86 10 DNA Homo sapiens 86 gaggaagaag 10 87 10 DNA Homo sapiens 87 gaagctttgc 10 88 10 DNA Homo sapiens 88 taccagtgta 10 89 10 DNA Homo sapiens 89 tcttctccct 10 90 10 DNA Homo sapiens 90 ttggcttttc 10 91 10 DNA Homo sapiens 91 ggaagggagg 10 92 10 DNA Homo sapiens 92 aagccagccc 10 93 10 DNA Homo sapiens 93 tttcagattg 10 94 10 DNA Homo sapiens 94 gcataggctg 10 95 10 DNA Homo sapiens 95 tttgttaatt 10 96 10 DNA Homo sapiens 96 gagactcctg 10 97 10 DNA Homo sapiens 97 cctgtaattc 10 98 10 DNA Homo sapiens 98 gtggtgcgtg 10 99 10 DNA Homo sapiens 99 ttggacctgg 10 100 10 DNA Homo sapiens 100 cttaaggatt 10 101 10 DNA Homo sapiens 101 gtctgtgaga 10 102 10 DNA Homo sapiens 102 gaaactgaac 10 103 10 DNA Homo sapiens 103 gggcatctct 10 104 10 DNA Homo sapiens 104 tttgggccta 10 105 10 DNA Homo sapiens 105 atcgtggcgg 10 106 10 DNA Homo sapiens 106 tattatggta 10 107 10 DNA Homo sapiens 107 gcctacccga 10 108 10 DNA Homo sapiens 108 ctcgcgctgg 10 109 10 DNA Homo sapiens 109 ttgcttgcca 10 110 10 DNA Homo sapiens 110 cctgcttgtc 10 111 10 DNA Homo sapiens 111 agggaggggc 10 112 10 DNA Homo sapiens 112 tgtgggaaat 10 113 10 DNA Homo sapiens 113 cctgatctgc 10 114 10 DNA Homo sapiens 114 accattggat 10 115 10 DNA Homo sapiens 115 agtttgttag 10 116 10 DNA Homo sapiens 116 cctgggaagt 10 117 10 DNA Homo sapiens 117 caactaattc 10 118 10 DNA Homo sapiens 118 gcctgcagtc 10 119 10 DNA Homo sapiens 119 cgaccccacg 10 120 10 DNA Homo sapiens 120 ttctgtgctg 10 121 10 DNA Homo sapiens 121 cgccgacgat 10 122 10 DNA Homo sapiens 122 cccgcccccg 10 123 10 DNA Homo sapiens 123 gatcaggcca 10 124 10 DNA Homo sapiens 124 gtggaagacg 10 125 10 DNA Homo sapiens 125 gatgaggaga 10 126 10 DNA Homo sapiens 126 ttcccttctt 10 127 10 DNA Homo sapiens 127 ccccctgcag 10 128 10 DNA Homo sapiens 128 tgctgcctgt 10 129 10 DNA Homo sapiens 129 tgcagcacga 10 130 10 DNA Homo sapiens 130 ggttattttg 10 131 10 DNA Homo sapiens 131 tgtcatcaca 10 132 10 DNA Homo sapiens 132 aaaataaaca 10 133 10 DNA Homo sapiens 133 taaaaatgtt 10 134 10 DNA Homo sapiens 134 gagcttttga 10 135 10 DNA Homo sapiens 135 ggctgatgtg 10 136 10 DNA Homo sapiens 136 cgacgaggag 10 137 10 DNA Homo sapiens 137 gcccccaata 10 138 10 DNA Homo sapiens 138 gcaacttgga 10 139 408 PRT Homo sapiens 139 Met Pro Gly His Leu Gln Glu Gly Phe Gly Cys Val Val Thr Asn Arg 1 5 10 15 Phe Asp Gln Leu Phe Asp Asp Glu Ser Asp Pro Phe Glu Val Leu Lys 20 25 30 Ala Ala Glu Asn Lys Lys Lys Glu Ala Gly Gly Gly Gly Val Gly Gly 35 40 45 Pro Gly Ala Lys Ser Ala Ala Gln Ala Ala Ala Gln Thr Asn Ser Asn 50 55 60 Ala Ala Gly Lys Gln Leu Arg Lys Glu Ser Gln Lys Asp Arg Lys Asn 65 70 75 80 Pro Leu Pro Pro Ser Val Gly Val Val Asp Lys Lys Glu Glu Thr Gln 85 90 95 Pro Pro Val Ala Leu Lys Lys Glu Gly Ile Arg Arg Val Gly Arg Arg 100 105 110 Pro Asp Gln Gln Leu Gln Gly Glu Gly Lys Ile Ile Asp Arg Arg Pro 115 120 125 Glu Arg Arg Pro Pro Arg Glu Arg Arg Phe Glu Lys Pro Leu Glu Glu 130 135 140 Lys Gly Glu Gly Gly Glu Phe Ser Val Asp Arg Pro Ile Ile Asp Arg 145 150 155 160 Pro Ile Arg Gly Arg Gly Gly Leu Gly Arg Gly Arg Gly Gly Arg Gly 165 170 175 Arg Gly Met Gly Arg Gly Asp Gly Phe Asp Ser Arg Gly Lys Arg Glu 180 185 190 Phe Asp Arg His Ser Gly Ser Asp Arg Ser Ser Phe Ser His Tyr Ser 195 200 205 Gly Leu Lys His Glu Asp Lys Arg Gly Gly Ser Gly Ser His Asn Trp 210 215 220 Gly Thr Val Lys Asp Glu Leu Thr Glu Ser Pro Lys Tyr Ile Gln Lys 225 230 235 240 Gln Ile Ser Tyr Asn Tyr Ser Asp Leu Asp Gln Ser Asn Val Thr Glu 245 250 255 Glu Thr Pro Glu Gly Glu Glu His His Pro Val Ala Asp Thr Glu Asn 260 265 270 Lys Glu Asn Glu Val Glu Glu Val Lys Glu Glu Gly Pro Lys Glu Met 275 280 285 Thr Leu Asp Glu Trp Lys Ala Ile Gln Asn Lys Asp Arg Ala Lys Val 290 295 300 Glu Phe Asn Ile Arg Lys Pro Asn Glu Gly Ala Asp Gly Gln Trp Lys 305 310 315 320 Lys Gly Phe Val Leu His Lys Ser Lys Ser Glu Glu Ala His Ala Glu 325 330 335 Asp Ser Val Met Asp His His Phe Arg Lys Pro Ala Asn Asp Ile Thr 340 345 350 Ser Gln Leu Glu Ile Asn Phe Gly Asp Leu Gly Arg Pro Gly Arg Gly 355 360 365 Gly Arg Gly Gly Arg Gly Gly Arg Gly Arg Gly Gly Arg Pro Asn Arg 370 375 380 Gly Ser Arg Thr Asp Lys Ser Ser Ala Ser Ala Pro Asp Val Asp Asp 385 390 395 400 Pro Glu Ala Phe Pro Ala Leu Ala 405 140 10 DNA Homo sapiens 140 atgataatgg 10 141 1024 DNA Homo sapiens 141 ccccacccga aacacactca gcccttgcac tgacctgcct tctgattgga ggctggttgc 60 ttcggataat gacctccagg accccactgt tggttacagc ctgtttgtat tattcttact 120 gcaactcaag acacctgcag cagggcgtga gaaaaagtaa aagaccagta ttttcacatt 180 gccaggtacc agaaacacag aagactgaca cccgccactt aagtggggcc agggctggtg 240 tctgcccatg ttgccatcct gatgggctgc ttgccacaat gagggatctt cttcaataca 300 tcgcttgctt ctttgccttt ttctctgctg ggtttttgat tgtggccacc tggactgact 360 gttggatggt gaatgctgat gactctctgg aggtgagcac aaaatgccga ggcctctggt 420 gggaatgcgt cacaaatgct tttgatggga ttcgcacctg tgatgagtac gattccatac 480 ttgcggagca tcccttgaag ctggtggtaa ctcgagcgtt gatgattact gcagatattc 540 tagctgggtt tggatttctc accctgctcc ttggtcttga ctgcgtgaaa ttcctccctg 600 atgagccgta cattaaagtc cgcatctgct ttgttgctgg agccacgtta ctaatagcag 660 gtaccccagg aatcattggc tctgtgtggt atgctgttga tgtgtatgtg gaacgttcta 720 ctttggtttt gcacaatata tttcttggta tccaatataa atttggttgg tcctgttggc 780 tcggaatggc tgggtctctg ggttgctttt tggctggagc tgttctcacc tgctgcttat 840 atctttttaa agatgtggga cctgagaaaa ctagccttat cccttgagga aagcctattc 900 agccgcgagg tgtttccatg gccaagtcat actcagcccc tcgcacagag acggccaaaa 960 tgtatgctgt agacacaagg gtgtaaaatg cacgtttcag ggtgtgtttg catatgattt 1020 aatc 1024 142 294 PRT Homo sapiens 142 Pro Pro Glu Thr His Ser Ala Leu Ala Leu Thr Cys Leu Leu Ile Gly 1 5 10 15 Gly Trp Leu Leu Arg Ile Met Thr Ser Arg Thr Pro Leu Leu Val Thr 20 25 30 Ala Cys Leu Tyr Tyr Ser Tyr Cys Asn Ser Arg His Leu Gln Gln Gly 35 40 45 Val Arg Lys Ser Lys Arg Pro Val Phe Ser His Cys Gln Val Pro Glu 50 55 60 Thr Gln Lys Thr Asp Thr Arg His Leu Ser Gly Ala Arg Ala Gly Val 65 70 75 80 Cys Pro Cys Cys His Pro Asp Gly Leu Leu Ala Thr Met Arg Asp Leu 85 90 95 Leu Gln Tyr Ile Ala Cys Phe Phe Ala Phe Phe Ser Ala Gly Phe Leu 100 105 110 Ile Val Ala Thr Trp Thr Asp Cys Trp Met Val Asn Ala Asp Asp Ser 115 120 125 Leu Glu Val Ser Thr Lys Cys Arg Gly Leu Trp Trp Glu Cys Val Thr 130 135 140 Asn Ala Phe Asp Gly Ile Arg Thr Cys Asp Glu Tyr Asp Ser Ile Leu 145 150 155 160 Ala Glu His Pro Leu Lys Leu Val Val Thr Arg Ala Leu Met Ile Thr 165 170 175 Ala Asp Ile Leu Ala Gly Phe Gly Phe Leu Thr Leu Leu Leu Gly Leu 180 185 190 Asp Cys Val Lys Phe Leu Pro Asp Glu Pro Tyr Ile Lys Val Arg Ile 195 200 205 Cys Phe Val Ala Gly Ala Thr Leu Leu Ile Ala Gly Thr Pro Gly Ile 210 215 220 Ile Gly Ser Val Trp Tyr Ala Val Asp Val Tyr Val Glu Arg Ser Thr 225 230 235 240 Leu Val Leu His Asn Ile Phe Leu Gly Ile Gln Tyr Lys Phe Gly Trp 245 250 255 Ser Cys Trp Leu Gly Met Ala Gly Ser Leu Gly Cys Phe Leu Ala Gly 260 265 270 Ala Val Leu Thr Cys Cys Leu Tyr Leu Phe Lys Asp Val Gly Pro Glu 275 280 285 Lys Thr Ser Leu Ile Pro 290 143 10 DNA Homo sapiens 143 gtgggcacag 10 144 1851 DNA Homo sapiens 144 ggatatcgtc gacccagcgt ccggaccggg acagctcgcg gccccccgag agctctagcc 60 gtcgaggagc tgcctgggga cgtttccctg ggccccagcc tggcccgggt caccctggca 120 tgaggagatg ggcctgttgc tcctggtccc gttgctcctg ctgcccggct cctacggact 180 gcccttctac aacggcttct actactccaa cagcgccaac gaccagaacc taggcaacgg 240 tcatggcaaa gacctcctta atggagtgaa gctggtggtg gagacacccg aggagaccct 300 gttcacctac caaggggcca gtgtgatcct gccctgcgta ccgctacgag ccggccctgg 360 tctccccgcg gcgtgtgcgt gtcaaatggt ggaagctgtc ggagaacggg gccccagaga 420 aggacgtgct ggtggccatc gggctgaggc accgctcctt tgggactacc aaggccgcgt 480 gcactgcggc aggacaaaga gcatgagctc tcgctggaga tccagatctc gctggaggac 540 tatggggctt accgctgtga ggtcattgac gggctggagg atgaaagcgg tctggtggag 600 ctggagctgc ggggtgtggt ctttccttac cagtccccaa cgggcgctac cagttcaact 660 tccacgaggg ccagcaggtc tgtgcagagc aggctgcggt ggtggcctcc tttgagcagc 720 tcttccgggc ctgggaggag ggcctggact ggtgcaacgc gggctggctg caggatgcca 780 cggtgcagta ccccatcatg ttgccccggc agccctgcgg tggcccgggc ctggcacctg 840 gcgtgcgaag ctacggcccc cgccaccgcc gcctgcaccg ctatgatgta ttctcgttcg 900 ctactgccct caaggggcgg gtgtactacc tggagcaccc tgagaacgtg acgctgacag 960 aggcaaggga ggcctgccag gaagatgatg ccacgattgc caaggtggac agctctttgc 1020 cgcctggaag ttccatggcc tggaccgctg cgacgctggc tggctggcag atggcagcgt 1080 ccgctaccct gtggttcacc cgcatcctaa ctgtgggccc ccagagcctg gggtccgaag 1140 ctttggcttc cccgacccgc agagccgctt gtacggtgtt tactgtaccg ccagcactag 1200 gacctggggc cctcccctgc cgcattccct cactggctgt gtatttattg agtggttcgt 1260 tttcccttgt gggttggagc cattttaact gtttttatac ttctcaattt aaattttctt 1320 taaacatttt tttactattt tttgtaaagc aaacagaacc caatgcctcc ctttgctcct 1380 ggatgcccca ctccaggaat catgcttgct ccccgggctt ctggagggtt ccccgccatc 1440 caggctggtc tccctccctt aaggaggttg gtgcccagag tgggcggtgg cctgtctaga 1500 atgccgccgg gagtccgggc atggtgggca cagttctccc tgcccctcag cctgggggaa 1560 gaagagggcc tcgggggctc cggagctggg ctttgggcct ctcctgccca cctctacttc 1620 tctgtgaagc cgctgacccc agtctgccca ctgaggggct agggctggaa gccagttcta 1680 ggcttccagg cgaaagctga gggaaggaag aaactccctc cccgttcccc ttcccctctc 1740 ggttccaaag aatctgtttg ttgtcatttg tttctcctgt ttccctgtgt ggggaggggc 1800 cctcaggtgt gtgtactttg gacaataaat ggtgctatga ctgccttccg c 1851 145 10 DNA Homo sapiens 145 cctgccccgc 10 146 4111 DNA Homo sapiens 146 ctcacagccc agcacctgcg gagggagcgc tgaccatggc tccctggcct gaattgggag 60 atgcccagcc caaccccgat aagtacctcg aaggggccgc aggtcagcag cccactgccc 120 ctgataaaag caaagagacc aacaaaaata acactgaggc acctgtaacc aagattgaac 180 ttctgccgtc ctactccacg gctacactga tagatgagcc cactgaggtg gatgacccct 240 ggaacctacc cactcttcag gactcgggga tcaagtggtc agagagagac accaaaggga 300 agattctctg tttcttccaa gggattggga gattgatttt acttctcgga tttctctact 360 ttttcgtgtg ctccctggat attcttagta gcgccttcca gctggttgga ggaaaaatgg 420 caggacagtt cttcagcaac agctctatta tgtccaaccc tttgttgggg ctggtgatcg 480 gggtgctggt gaccgtcttg gtgcagagct ccagcacctc aacgtccatc gttgtcagca 540 tggtgtcctc ttcattgctc actgttcggg ctgccatccc cattatcatg ggggccaaca 600 ttggaacgtc aatcaccaac actattgttg cgctcatgca ggtgggagat cggagtgagt 660 tcagaagagc ttttgcagga gccactgtcc atgacttctt caactggctg tccctgttgg 720 tgctcttgcc cgtggaggtg gccacccatt acctcgagat cataacccag cttatagtgg 780 agagcttcca cttcaagaat ggagaagatg ccccagatct tctgaaagtc atcactaagc 840 ccttcacaaa gctcattgtc cagctggata aaaaagttat cagccaaatt gcaatgaacg 900 atgaaaaagc gaaaaacaag agtcttgtca agatttggtg caaaactttt accaacaaga 960 cccagattaa cgtcactgtt ccctcgactg ctaactgcac ctccccttcc ctctgttgga 1020 cggatggcat ccaaaactgg accatgaaga atgtgaccta caaggagaac atcgccaaat 1080 gccagcatat ctttgtgaat ttccacctcc cggatcttgc tgtgggcacc atcttgctca 1140 tactctccct gctggtcctc tgtggttgcc tgatcatgat tgtcaagatc ctgggctctg 1200 tgctcaaggg gcaggtcgcc actgtcatca agaagaccat caacactgat ttcccctttc 1260 cctttgcatg gttgactggc tacctggcca tcctcgtcgg ggcaggcatg accttcatcg 1320 tacagagcag ctctgtgttc acgtcggcct tgacccccct gattggaatc ggcgtgataa 1380 ccattgagag ggcttatcca ctcacgctgg gctccaacat cggcaccacc accaccgcca 1440 tcctggccgc cttagccagc cctggcaatg cattgaggag ttcactccag atcgccctgt 1500 gccacttttt cttcaacatc tccggcatct tgctgtggta cccgatcccg ttcactcgcc 1560 tgcccatccg catggccaag gggctgggca acatctctgc caagtatcgc tggttcgccg 1620 tcttctacct gatcatcttc ttcttcctga tcccgctgac ggtgtttggc ctctcgctgg 1680 ccggctggcg ggtgctggtt ggtgtcgggg ttcccgtcgt cttcatcatc atcctggtac 1740 tgtgcctccg actcctgcag tctcgctgcc cacgcgtcct gccgaagaaa ctccagaact 1800 ggaacttcct gccgctgtgg atgcgctcgc tgaagccctg ggatgccgtc gtctccaagt 1860 tcaccggctg cttccagatg cgctgctgct gctgctgccg cgtgtgctgc cgcgcgtgct 1920 gcttgctgtg tggctgcccc aagtgctgcc gctgcagcaa gtgctgcgag gacttggagg 1980 aggcgcagga ggggcaggat gtccctgtca aggctcctga gacctttgat aacataacca 2040 ttagcagaga ggctcagggt gaggtccctg cctcggactc aaagaccgaa tgcacggcct 2100 tgtaggggac gccccagatt gtcagggatg gggggatggt ccttgagttt tgcatgctct 2160 cctccctccc acttctgcac cctttcacca cctcgaggag atttgctccc cattagcgaa 2220 tgaaattgat gcagtcctac ctaactcgat tccctttggc ttggtgggta ggcctgcagg 2280 gcacttttat tccaacccct ggtcactcag taatctttta ctccaggaag gcacaggatg 2340 gtacctaaag agaattagag aatgaacctg gcgggacgga tgtctaatcc tgcacctagc 2400 tgggttggtc agtagaacct attttcagac tcaaaaacca tcttcagaaa gaaaaggccc 2460 agggaaggaa tgtatgagag gctctcccag atgaggaagt gtactctcta tgactatcaa 2520 gctcaggcct ctcccttttt ttaaaccaaa gtctggcaac caagagcagc agctccatgg 2580 cctccttgcc ccagatcagc ctgggtcagg ggacatagtg tcattgtttg gaaactgcag 2640 accacaaggt gtgggtctat cccacttcct agtgctcccc acattcccca tcagggcttc 2700 ctcacgtgga caggtgtgct agtccaggca gttcacttgc agtttccttg tcctcatgct 2760 tcggggatgg gagccacgcc tgaactagag ttcaggctgg atacatgtgc tcacctgctg 2820 ctcttgtctt cctaagagac agagagtggg gcagatggag gagaagaaag tgaggaatga 2880 gtagcatagc attctgccaa aagggcccca gattcttaat ttagcaaact aagaagccca 2940 attcaaaagc attgtggcta aagtctaacg ctcctctctt ggtcagataa caaaagccct 3000 ccctgttgga tcttttgaaa taaaacgtgc aagttatcca ggctcgtagc ctgcatgctg 3060 ccaccttgaa tcccagggag tatctgcacc tggaatagct ctccacccct ctctgcctcc 3120 ttactttctg tgcaagatga tttcctgggt taacttcctt ctttccatcc acccacccac 3180 tggaatctct ttccaaacat ttttccattt tcccacagat gggctttgat tagctgtcct 3240 ctctccatgc ctgcaaagct ccagattttt ggggaaagct gtacccaact ggactgccca 3300 gtgaactggg atcattgagt acagtcgagc acacgtgtgt gcatgggtca aaggggtgtg 3360 ttccttctca tcctagatgc cttctctgtg ccttccacag cctcctgcct gattacacca 3420 ctgcccccgc cccaccctca gccatcccaa ttcttcctgg ccagtgcgct ccagccttat 3480 ctaggaaagg aggagtgggt gtagccgtgc agcaagattg gggcctcccc catcccagct 3540 tctccaccat cccagcaagt caggatatca gacagtcctc ccctgaccct cccccttgta 3600 gatatcaatt cccaaacaga gccaaatact ctatatctat agtcacagcc ctgtacagca 3660 tttttcataa gttatatagt aaatggtctg catgatttgt gcttctagtg ctctcatttg 3720 gaaatgaggc aggcttcttc tatgaaatgt aaagaaagaa accactttgt atattttgta 3780 ataccacctc tgtggccatg cctgccccgc ccactctgta tatatgtaag ttaaacccgg 3840 gcaggggctg tggccgtctt tgtactctgg tgatttttaa aaattgaatc tttgtacttg 3900 cattgattgt ataataattt tgagaccagg tctcgctgtg ttgctcaggc tggtctcaaa 3960 ctcctgagat caagcaatcc gcccacctca gcctcccaaa gtgctgagat cacaggcgtg 4020 agccaccacc aggcctgatt gtaatttttt tttttttttt tactggttat gggaagggag 4080 aaataaaatc atcaaacccc aaaaaaaaaa a 4111 147 689 PRT Homo sapiens 147 Met Ala Pro Trp Pro Glu Leu Gly Asp Ala Gln Pro Asn Pro Asp Lys 1 5 10 15 Tyr Leu Glu Gly Ala Ala Gly Gln Gln Pro Thr Ala Pro Asp Lys Ser 20 25 30 Lys Glu Thr Asn Lys Asn Asn Thr Glu Ala Pro Val Thr Lys Ile Glu 35 40 45 Leu Leu Pro Ser Tyr Ser Thr Ala Thr Leu Ile Asp Glu Pro Thr Glu 50 55 60 Val Asp Asp Pro Trp Asn Leu Pro Thr Leu Gln Asp Ser Gly Ile Lys 65 70 75 80 Trp Ser Glu Arg Asp Thr Lys Gly Lys Ile Leu Cys Phe Phe Gln Gly 85 90 95 Ile Gly Arg Leu Ile Leu Leu Leu Gly Phe Leu Tyr Phe Phe Val Cys 100 105 110 Ser Leu Asp Ile Leu Ser Ser Ala Phe Gln Leu Val Gly Gly Lys Met 115 120 125 Ala Gly Gln Phe Phe Ser Asn Ser Ser Ile Met Ser Asn Pro Leu Leu 130 135 140 Gly Leu Val Ile Gly Val Leu Val Thr Val Leu Val Gln Ser Ser Ser 145 150 155 160 Thr Ser Thr Ser Ile Val Val Ser Met Val Ser Ser Ser Leu Leu Thr 165 170 175 Val Arg Ala Ala Ile Pro Ile Ile Met Gly Ala Asn Ile Gly Thr Ser 180 185 190 Ile Thr Asn Thr Ile Val Ala Leu Met Gln Val Gly Asp Arg Ser Glu 195 200 205 Phe Arg Arg Ala Phe Ala Gly Ala Thr Val His Asp Phe Phe Asn Trp 210 215 220 Leu Ser Leu Leu Val Leu Leu Pro Val Glu Val Ala Thr His Tyr Leu 225 230 235 240 Glu Ile Ile Thr Gln Leu Ile Val Glu Ser Phe His Phe Lys Asn Gly 245 250 255 Glu Asp Ala Pro Asp Leu Leu Lys Val Ile Thr Lys Pro Phe Thr Lys 260 265 270 Leu Ile Val Gln Leu Asp Lys Lys Val Ile Ser Gln Ile Ala Met Asn 275 280 285 Asp Glu Lys Ala Lys Asn Lys Ser Leu Val Lys Ile Trp Cys Lys Thr 290 295 300 Phe Thr Asn Lys Thr Gln Ile Asn Val Thr Val Pro Ser Thr Ala Asn 305 310 315 320 Cys Thr Ser Pro Ser Leu Cys Trp Thr Asp Gly Ile Gln Asn Trp Thr 325 330 335 Met Lys Asn Val Thr Tyr Lys Glu Asn Ile Ala Lys Cys Gln His Ile 340 345 350 Phe Val Asn Phe His Leu Pro Asp Leu Ala Val Gly Thr Ile Leu Leu 355 360 365 Ile Leu Ser Leu Leu Val Leu Cys Gly Cys Leu Ile Met Ile Val Lys 370 375 380 Ile Leu Gly Ser Val Leu Lys Gly Gln Val Ala Thr Val Ile Lys Lys 385 390 395 400 Thr Ile Asn Thr Asp Phe Pro Phe Pro Phe Ala Trp Leu Thr Gly Tyr 405 410 415 Leu Ala Ile Leu Val Gly Ala Gly Met Thr Phe Ile Val Gln Ser Ser 420 425 430 Ser Val Phe Thr Ser Ala Leu Thr Pro Leu Ile Gly Ile Gly Val Ile 435 440 445 Thr Ile Glu Arg Ala Tyr Pro Leu Thr Leu Gly Ser Asn Ile Gly Thr 450 455 460 Thr Thr Thr Ala Ile Leu Ala Ala Leu Ala Ser Pro Gly Asn Ala Leu 465 470 475 480 Arg Ser Ser Leu Gln Ile Ala Leu Cys His Phe Phe Phe Asn Ile Ser 485 490 495 Gly Ile Leu Leu Trp Tyr Pro Ile Pro Phe Thr Arg Leu Pro Ile Arg 500 505 510 Met Ala Lys Gly Leu Gly Asn Ile Ser Ala Lys Tyr Arg Trp Phe Ala 515 520 525 Val Phe Tyr Leu Ile Ile Phe Phe Phe Leu Ile Pro Leu Thr Val Phe 530 535 540 Gly Leu Ser Leu Ala Gly Trp Arg Val Leu Val Gly Val Gly Val Pro 545 550 555 560 Val Val Phe Ile Ile Ile Leu Val Leu Cys Leu Arg Leu Leu Gln Ser 565 570 575 Arg Cys Pro Arg Val Leu Pro Lys Lys Leu Gln Asn Trp Asn Phe Leu 580 585 590 Pro Leu Trp Met Arg Ser Leu Lys Pro Trp Asp Ala Val Val Ser Lys 595 600 605 Phe Thr Gly Cys Phe Gln Met Arg Cys Cys Cys Cys Cys Arg Val Cys 610 615 620 Cys Arg Ala Cys Cys Leu Leu Cys Gly Cys Pro Lys Cys Cys Arg Cys 625 630 635 640 Ser Lys Cys Cys Glu Asp Leu Glu Glu Ala Gln Glu Gly Gln Asp Val 645 650 655 Pro Val Lys Ala Pro Glu Thr Phe Asp Asn Ile Thr Ile Ser Arg Glu 660 665 670 Ala Gln Gly Glu Val Pro Ala Ser Asp Ser Lys Thr Glu Cys Thr Ala 675 680 685 Leu 

What is claimed is:
 1. A method of detecting an ovarian tumor in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not having an ovarian tumor, detects an ovarian tumor in said subject.
 2. A method of identifying a subject at increased risk for developing ovarian cancer, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not at increased risk for developing ovarian cancer, identifies an individual at increased risk for developing ovarian cancer.
 3. A method of determining the effectiveness of an ovarian cancer treatment in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject after treatment of said subject, wherein a modulation in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in said subject prior to said treatment, indicates an effective ovarian cancer treatment in said subject.
 4. The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined in said subject by measuring the expression level of said tumor marker gene in a sample from said subject.
 5. The method of claim 4, wherein said sample from said subject is selected from the group consisting of a tissue biopsy, ovarian epithelial cell scrapings, peritoneal fluid, blood, urine, and serum.
 6. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is measured in vivo in said subject.
 7. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is determined by measuring the level of ovarian tumor marker mRNA.
 8. The method of claim 7, wherein said level of ovarian tumor marker mRNA is measured using RT-PCR, Northern hybridization, dot-blotting, or in situ hybridization.
 9. The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined by measuring the level of ovarian tumor marker polypeptide encoded by said ovarian tumor marker gene.
 10. The method of claim 9, wherein said level of ovarian tumor marker polypeptide is measured by ELISA, immunoblotting, or immunohistochemistry.
 11. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is compared to the expression level of said tumor marker gene in a reference subject diagnosed with ovarian cancer.
 12. The method of claim 2, wherein said expression level of said ovarian tumor marker gene in said subject is compared to the expression level of said tumor marker gene in a reference subject that is identified as having an increased risk for developing ovarian cancer.
 13. A method of identifying a tumor as an ovarian tumor, said method comprising measuring the expression level of an ovarian tumor marker gene in a tumor cell from said tumor, wherein an increase in said expression level of said ovarian tumor marker gene in said tumor cell, relative to the expression level of said ovarian tumor marker gene in a noncancerous ovarian cell, identifies the tumor as an ovarian tumor.
 14. A method of treating or preventing an ovarian tumor in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in an ovarian epithelial cell in said subject.
 15. A method of inhibiting the growth or metastasis of an ovarian tumor cell in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in said ovarian tumor cell in said subject.
 16. A method of inhibiting the growth or metastasis of an ovarian tumor in a subject, said method comprising contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide encoded by an ovarian tumor marker gene, wherein the binding of said antibody to said ovarian tumor marker polypeptide inhibits the growth or metastasis of said ovarian tumor in said subject.
 17. The method of claim 16, wherein said ovarian tumor marker polypeptide is on the surface of said ovarian tumor cell.
 18. The method of claim 16, wherein said antibody is coupled to a radioisotope or a toxic compound.
 19. A method of diagnosing ovarian cancer in a subject, said method comprising measuring the amount of an ovarian tumor marker polypeptide in said subject, wherein an amount of ovarian tumor marker polypeptide that is greater than the amount of ovarian tumor marker polypeptide measured in a subject not having ovarian cancer diagnoses an ovarian cancer in the subject.
 20. The method of claim 19, wherein said ovarian tumor marker polypeptide is present at the surface of a cell.
 21. The method of claim 19, wherein said ovarian tumor marker polypeptide is in soluble form.
 22. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96)1; HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.
 23. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione perroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apoplipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.
 24. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-Iib).
 25. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.
 26. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.
 27. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or
 145. 28. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor is an epithelial ovarian tumor.
 29. The method of claim 28, wherein said epithelial ovarian tumor is selected from the group consisting of a serous cystadenoma, a borderline serous tumor, a serous cystadenocarcinoma, a mucinous cystadenoma, a borderline mucinous tumor, a mucinous cystadenocarcinoma, an endometrioid carcinoma, an undifferentiated carcinoma, a clear cell adenocarcinoma, a cystadenofibroma, an adenofibroma, and a Brenner tumor.
 30. A kit comprising an antibody for measuring the expression level of an ovarian tumor marker gene in a subject.
 31. A kit comprising a nucleic acid for measuring the expression level of an ovarian tumor marker gene in a subject.
 32. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96)1; HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.
 33. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione perroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apoplipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (13CAM); collagen type III, alpha-1; Mal CT cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.
 34. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-Iib).
 35. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.
 36. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.
 37. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or
 145. 